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 ABSTRACT 
 
Three novel, synthetic biarylheterocycles bearing imidazole terminal groups had 
previously been discovered with high cytotoxicity (IC50 16–640 nM) against a 
number of human tumour cell lines. Notably, this biological activity was 
independent of duplex DNA binding affinity. The compounds were tested in the 
NCI 60-cell line panel and COMPARE analysis suggests they have a novel 
mechanism of action, targeting the product of a „gene-like sequence‟ of 
unidentified function. 
 
The identity of likely protein targets was explored using a chemical proteomic 
strategy. Bespoke affinity matrices for chromatography were prepared in which 
test compounds were attached to a solid support through a biotin tag. A 
synthetic route to hit compounds containing a biotin moiety in place of one of 
the imidazole sidechains was developed. Chemosensitivity studies confirmed 
that the biotinylated compounds retained their activity showing IC50 = 6.25 µM in 
a susceptible cell line, compared with > 100 µM for an insensitive cell line.  
 
The biotinylated ligands were complexed to a streptavidin-activated affinity 
column and exposed to cell lysates from the susceptible cell lines. Bound 
proteins were eluted from the column and separated using SDS-PAGE. 
Proteins were characterised by MALDI MS and MS/MS and identified using 
Mascot database searches. Heterogeneous nuclear ribonuclear protein A2/B1 
was found to selectively bind to the affinity probes. 
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1.1  INTRODUCTION 
 
Cancer is a leading cause of death worldwide and in the UK the lifetime risk of 
developing cancer is more than one in three. In 2008, cancer was the cause of 
7.6 million deaths and it is estimated that globally there were 12.4 million newly-
diagnosed cancer cases. Considering the continued growth and age of the 
world‟s population, cancer mortality is predicted to keep rising, with an 
estimated 26.4 million incidences and 17.0 million cancer deaths by 2030.1  In 
conjunction with reducing incidence and early detection, the design and 
development of new and superior treatments for cancers is essential.  
 
Cancer treatment can take numerous approaches including surgery, 
radiotherapy, chemotherapy, immunotherapy and endocrine therapies. Surgery 
is the oldest and most frequently used treatment method and one of the few 
curative therapies. However, this type of treatment is only suitable for localised, 
solid tumours. Similarly radiation therapy can be used in place of surgery, as a 
less invasive approach, for localised cancers. However, both methods fail if 
cancer metastasises and spreads to secondary sites within the body.     
 
Cancer is characterised by increased rates of cellular proliferation and many 
current chemotherapeutic strategies target this. Conventional chemotherapeutic 
treatments have been successful since they were first implemented in the 
1940s, after toxicological studies of mustard nerve gas, and continue to extend 
many lives today. Nowadays chemotherapy refers to the use of cytotoxic drugs 
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to treat a cellular component, such as DNA, RNA or proteins, required for 
proliferation resulting in cell death.2  
 
Despite advances in the treatment of some cancers, the majority of cancers do 
not respond well to current chemotherapy, therefore treatments can be 
described as palliative rather than curative. As conventional chemotherapeutic 
agents are not specific to neoplastic cells, the treatments can lead to toxic side 
effects, such as bone marrow toxicity, neurotoxicity and carcinogenicity. 
Furthermore, this usually limits the dose of drug that can be administered. Also 
chemotherapeutic treatments may prove to be effective for defined periods of 
time; however, prolonged use can lead to acquired drug resistance.  
 
The problems with drug resistance and toxic side effects present significant 
limitations for the treatment of cancers with classic chemotherapeutic agents. 
Hence, a priority of current research is developing new and improved drugs 
which are specific to cancers and selective for antitumour targets.  These recent 
therapies are often referred to as „molecular cancer therapeutics‟ and attempt to 
target the precise molecular mechanisms responsible for cancer initiation and 
progression.3  
 
The first successful, small, synthetic molecular-targeted, cancer therapeutic was 
Glivec (Imatinib) and in many ways represents a prototype for drugs targeting 
oncogenic signal transduction pathways.4 In addition to small molecules, 
monoclonal antibodies (e.g. Avastin and Herceptin) can be used as oncogenic 
therapies. 
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1.2 THE DRUG DISCOVERY PROCESS 
 
Potential new anticancer agents originate from a number of sources, ranging 
from random screening of natural products and synthetic chemicals to rational 
drug discovery.5 Synthetic organic chemistry is considered the underpinning 
field6 and has historically driven the drug discovery process. However as the 
biological understanding of cancer progresses, the successful discovery and 
development of small-molecule anticancer drugs is becoming multidisciplinary 
and highly dependent on the creative interaction between the different areas.7  
 
Classical drug discovery (Figure 1.1) involves continual cycles of synthetic 
chemistry and biological evaluation, allowing refinement and optimisation of a 
target compound.7 Once optimised, the compound can enter preclinical in vivo 
evaluation generating efficacy and toxicological data. Before a compound can 
enter clinical trials, formulation is required.  
 
Figure 1.1.  The Drug Discovery Process 
 
Traditionally drug discovery was based on random screening of natural 
products, substrate analogues (antimetabolites) and small synthetic compounds 
in vitro and in vivo in the search for agents.8 Nowadays there are two main 
ways in which drugs are discovered, random drug screening and target 
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orientated drug discovery. A major programme runs at the NCI which screens 
many compounds arising from industry and academia allowing drugs to be 
discovered via an empirical drug discovery approach.   
 
1.2.1 THE NATIONAL CANCER INSTITUTE SCREENING PROGRAMME 
 
The National Cancer Institute (NCI), Bethesda, MD, USA, has been involved 
with drug discovery and development since its establishment in 1955. This was 
when it started a screening service for the large number of compounds arising 
from academia and industry9 – The Developmental Therapeutics Programme 
(DTP). The DTP allows selection of possible drug compounds as clinical 
candidates.10  
  
Initial screening models used by the NCI were based on three transplantable 
rodent tumour models in vivo (sarcoma 180, carcinoma 755 and leukemia 
L1210). In 1975, the scheme was changed and the NCI tested all potential 
anticancer agents against a P388 or L1210 murine leukaemia pre-screen before 
testing on a panel of tumours.10 The programme produced drugs that were 
effective in the treatment of many cancers, mostly childhood leukaemia. 
However, there was limited success in the treatment of the common adult solid 
tumours.11 Also, several compounds that failed to show activity in pre-screens 
showed activity in the second panel of tumour models and in clinical trials. In 
addition, the classes of anticancer drugs which were active against the rodent 
tumours were mainly cytotoxic alkylating agents and other DNA damaging 
agents and novel structures had not been discovered for over 20 years.12  
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Consequently the NCI changed its approach to large scale screening. In April 
1990 a novel programme began, part of the Rapid Access to NCI Discovery 
Resources (R·A·N·D) programme, which involves in vitro screening of potential 
anti-cancer drugs against numerous human tumour cell lines.13 This massive-
scale drug screening initiative is known as the „NCI-60 DTP Human Tumour 
Cell Line Screen‟. These primary pre-screens are followed by in vivo evaluation 
by hollow fibre assays14 and human tumour xenografts,12 if compounds prove to 
be potent and selective against a particular disease category.  
 
The screen has allowed vast number of compounds to be tested each year for 
potential anticancer activity. During the 1980s and 1990s the NCI were 
screening 10,000 compounds per year, however, screening throughput has now 
been reduced to approximately 3,000 compounds per year due to reductions in 
workforce.15  
 
The primary screening programme involves in vitro testing of potential 
anticancer agents against 60 well characterised human tumour cell lines, 
grouped into the nine major histological classes of malignancies (leukaemia, 
melanoma, lung, colon, prostate, breast, renal, ovarian and CNS cancer).16 It 
was intended that the screen would exploit unique features of each tumour type 
and therefore replace the need for the primary in vivo screening previously 
employed. However, the patterns of drug sensitivity and resistance generated 
with the NCI 60 screen were found to reflect the mechanisms of drug action with 
standard anticancer agents, therefore providing an unexpected dimension to the 
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screening model.17 This has produced a number of discoveries which have 
greatly contributed to the field of targeted anticancer therapy.15  
 
Data derived from the in vitro screening assay can be displayed and analysed in 
different ways. Dose response curves can be generated expressing percentage 
cell survival at varying concentrations of drug, relative to a drug-free control. 
From these curves LC50 values (the concentration of drug required to kill 50 % 
of the original cell population), GI50 values (the concentration of drug required to 
inhibit growth in 50 % of the cells) and TGI (the concentration of drug required 
to inhibit 100 % of cell growth) can be calculated15 (Figure 1.2). 
 
   
 
Figure 1.2. Dose-response curves showing the activity of a compound on three different 
NSC lung cancer cell lines. Linear interpolation gives the GI50, TGI and LC50. Adapted from 
Shoemaker 2006.
15
  
 
The data collected can also be expressed in the form of a „mean graph‟. This is 
derived from a typical horizontal bar graph of the logarithms of the GI50 (or TGI, 
or LC50) values. In a mean graph each bar is plotted along a centred vertical line 
which is representative of the mean value of the log GI50 for all cell lines. For 
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each cell line, the difference between the individual measured value and the 
mean, „delta‟, is plotted18 (Figure 1.3). 
 
 
 
Figure 1.3.  An example of a DTP mean graph showing GI50 data for three types of 
malignancy treated with the immunotoxin transforming growth factor α. Deltas projecting to the 
right have a GI50 greater than the mean. Adapted from Shoemaker 2006.
15
  
 
The mean graphs have deltas projecting to either the right or left of the mean 
depending on the sensitivity of a particular cell line to an experimental drug 
compared with the mean.19 The mean graphs are a compact method of 
representing the test data and afford a profile for each compound which 
emphasises the differential effects and provides a unique data set – a 
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„Chemosensitivity fingerprint‟. Comparison of the mean graphs generated 
provides an insight into the mechanism of action (MOA) of a drug. An 
automated method of comparison with large screening databases is also 
provided by the NCI – the „COMPARE‟ programme. 
 
1.2.1.1  COMPARE Programme 
 
COMPARE is a computerised, pattern-recognition algorithm which evaluates 
data generated by the NCI 60 screen.18 The programme calculates the linear 
correlation coefficient between the data of an investigational seed compound 
over the 60 cell lines against all the profiles of previously tested compounds 
within a certain database.20 Similarities between compounds are expressed as 
a quantitative figure – the Pearson correlation coefficient (PCC). Each 
COMPARE analysis affords a rank-ordered list of compounds. Compounds with 
comparable mean graphs, work by the same or similar mechanisms of action16, 
19  Therefore, compounds with low PCCs suggest novel MOA. The NCI 
databases available include:  
 
 The synthetic database, which is subdivided into the standard agent 
database and the „diversity set‟. The standard agents database contains 
175 FDA-approved anticancer drugs.20  122 of these compounds have 
well-established mechanisms of action21 and are present within the Anti-
cancer Agent Mechanism Database. The diversity set contains 1990 
compounds available from the NCI.20  
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 The molecular characterisation database, which is subdivided into the 
molecular targets database and the NCI 60 microarray panel. The latter 
contains DNA chip measurements for all of the cell lines.22, 23 All of the 60 
cell lines have been characterised for targets and potential targets, 
including protein levels, RNA measurements, mutation status and 
enzyme activity levels. The molecular targets database contains 
approximately 200 target levels and activity measurements.   
 The natural product extracts database, which contains data for 
approximately 15,000 natural products.20  
 All compounds previously tested at the NCI stored in a publicly available 
database. 
 
COMPARE is an information-intensive approach to drug discovery in cancer 
which can indicate novel chemical structural classes of compounds that exhibit 
a biochemical mechanism of action, in addition to compounds with novel 
mechanisms of action. The natural products database also allows crude 
extracts to be analysed for the identity of compounds possessing anticancer 
activity.18  
 
Compounds are taken forward a stage in development for in vivo testing if they 
present a preferential activity against a certain type of cancer. Also if they 
exhibit a unique mean-graph fingerprint, indicating a novel mechanism of action, 
and have correlation with specific molecular target expression.  
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1.2.1.2 Self-Organised Maps 
 
The extensive screening programme implemented by the NCI has generated 
great volumes of data relating to established anticancer drugs, diverse chemical 
compounds with unknown biological activity and molecular targets. Systematic 
investigations of the patterns of mean graph results, create a possibility of 
discovering new anticancer drugs and improving molecular taxonomy.24 
Computer algorithms have been developed to analyse these data patterns of 
log(GI50) measurements against the various tumour cell lines received from the 
60-cell line screens.  
 
The basis of this analysis relays the pairwise statistical correlations between the 
growth inhibition measurements for different drugs tested against the cell lines 
and establishes the similarities in mechanism of action, modes of resistance 
and molecular structure for all of the compounds tested.25 A method of 
determining the biological significance in cellular response, between the 
different cell lines, can lead to identification of tumour-selective agents, new 
molecular targets and new lead compounds.24  
 
The Data mining programme – 3D MIND (mining information for novel 
discoveries) – implemented by the NCI, provides tools for analysis of data which 
complements COMPARE results using clustering methods.15 The self-organised 
map (SOM) is a useful method for exploration of data via two-dimensional 
response maps.24 The SOM utilises iterative minimisation techniques to group 
multidimensional data into response vectors.25 SOMs have been used in 
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various analyses of large datasets that exhibit large amounts of random noise26 
and missing data, making it suitable for mining the data from the NCI screen.  
Although the raw data generated by the screening programme determine the 
potency of a compound for growth inhibition, the most useful data lie in the 
biological significance of the cellular response patterns. Therefore, raw data are 
normalised using Z-score conditioning to enhance the biological response 
signal.24 Hence, improving the quality of data by providing a common mean 
reference and scale which leads to the enhancement.  
 
The SOM method can be divided into two elements, clustering in high 
dimensional space and projections into a lower dimensional display space, thus 
providing a means of visual translation.24 Visualisations of the clustering results, 
are 2D hexagonal projections containing 1066 clusters25 (Figure 1.4). 
Compounds represented within each cluster have a unique pattern of growth 
inhibition.  
 
Projection of the cellular profiles in the molecular targets database and 
microarray subpanels onto the complete DTP SOM allows the clusters to be 
divided into regions corresponding to the apparent cellular activity. Regions 
have been defined on the map that group individual map nodes with the most 
similar response profiles and nine functional clusters have been defined. 
Namely, mitotic (M), nucleic acid metabolism (S), membrane function (N), 
metabolic stress and cell survival (Q) and phosphatases/kinases and oxidative 
stress (P). The four remaining clusters are uncharacterised and have been 
named R, F, J and V.27  
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.  
 
Figure 1.4.  Complete DTP SOM map for approx. 20,000 compounds (Feb 2003 version). 
Colour is used to represent the distance between clusters.
28
  
 
In addition to the complete DTP SOM, the NCI 3D MIND programme also 
provides a bit vector map. This SOM relays data from a group of chemical 
descriptors for approximately 20,000 small compounds which are also used in 
the complete DTP map. The vectors represent the chemical properties of a 
Far 
Close 
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given molecule, such as hydrogen bond donors, hydrogen bond acceptors, and 
aromatic rings. 
 
The data from the NCI 60 screen for each cluster can be viewed from the SOM 
cluster graphs as a data vector (Figure 1.5). This is a graphical representation 
of the variation in GI50 data across the cell lines. 
 
 
 
Figure 1.5.  A data vector for a cluster of the complete DTP map. The x-axis consists of the 
different cell lines and the y-axis the compounds present within the vector.
28
  
 
The NCI 3D MIND programme also provides a mechanism of action map which 
is a small subset of the complete DTP map (Figure 1.6). The data expressed 
within the map are a set of 362 compounds identified as having one of six 
classes of molecular action:  antimitotic agents, RNA/DNA antimetabolites, DNA 
antimetabolites, topoisomerase I inhibitors, topoisomerase II inhibitors, and 
alkylating agents. 
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Figure 1.6.  A SOM cluster map showing the expanded mechanism of action data set.
28
  
 
The tools provided by the NCI DTP programme have been responsible for the 
discovery and development of a number of anticancer agents including 
Phortress, Taxol and Halichondrin B.  
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1.2.2 PHORTRESS: AN EXAMPLE OF COMPOUND-DRIVEN DRUG 
DISCOVERY 
 
Phortress is a novel antitumour agent currently in Phase I clinical trials in the 
UK. It has a unique mechanism of action relating to the activation of cytochrome 
P450 1A1 (CYP1A1).  
 
The development of Phortress has taken many years and began with the 
synthesis of polyhydroxylated-2-phenyl benzothiazoles related to genistein and 
quercetin.29 
  
OHO
HO
O
OH
OHO
HO
O
OH
OH
OH
Genistein Quercetin
 
 
Biological evaluation of benzothiazole CJM 126 revealed selectivity towards 
MCF-7 ER+ breast carcinoma cells (GI50 < 1 mM). It was also noted that growth 
inhibition was associated with an unusual biphasic dose response.29  
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Structure-activity relationship studies found CJM 126 has a 10-fold increased 
activity compared with the benzoxazole and a 1000-fold increased activity 
compared with the benzimidazole analogue. The production of tertiary amine 
analogues pyrrolidin-1-yl, piperidin-1-yl or morpholin-4-yl groups showed 
increased growth inhibition (GI50 = 0.1µM – 1 µM).
30  
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Alkoxy or hydroxy groups substituted into the benzothiazole nucleus led to 
reduced biological responses. Also, replacement of the 2-(4-aminophenyl) 
group of CJM 126 with a 2-(pyridin-4-yl) or 2-(2-aminopyridin-5-yl) group 
showed activity with GI50 < 1 µM. 
 
Introduction of a bromo group to yield 2-(2-amino-3-bromopyridin-5-yl) 
benzothiazole enhanced activity by more than 100-fold compared with the 
unbrominated analogue. Replacement of the amino group by a nitro group in 3' 
substituted 2-(4-aminophenyl)benzothiazole analogues reduced cellular activity 
(GI50 < 1 µM).  
 
Introduction of a substituent to the 2' position of the aminophenyl group of CJM 
126 showed an increase in the GI50 values. However, potent activity was 
demonstrated with 3'-methyl (DF 203), 3'-ethyl, 3'-bromo (DF 209), 3'-iodo (DF 
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129) and 3'-chloro (DF 229) substituted analogues (GI50 < 0.1 nM). Although 3'-
cyano and 3'-hydroxy substituents showed a decrease in cellular response. 
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In 1994 the NCI DTP received the parent benzothiazole compound (DF 203) 
and its analogues.31 The NCI 60 tumour cell line screen demonstrated potent 
activity against breast, ovarian, renal, colon, melanoma and NSC lung cancer 
cell lines (GI50 < 10 nm).
29 The biphasic dose response previously seen was 
confirmed and the COMPARE programme demonstrated a unique fingerprint. 
The molecular target SMART screen confirmed the target to be of unknown 
function. Collectively these data suggested a novel MOA.  
 
Fluorination of a compound prevents undesirable hydroxylation of bioactive 
substrates. Therefore, a series of mono- and di-fluoro analogues of the 3'- 
substituted 2-(4-aminophenyl)benzothiazole compounds was synthesised. All 
analogues retained their potency and selectivity. Moreover, only the 5- and 7- 
substituted compounds showed a conventional dose response, i.e. the biphasic 
response was eradicated.30  
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In 1996 analogues of 5F 203 were presented to the Drug Development Group 
(DDG). However, the compounds were not accepted due to high lipophilicity 
and poor water solubility. Initially 2-(4-aminophenyl)benzothiazole sulfamate 
salts were synthesised but they were found to be sparingly soluble in aqueous 
medium and degraded rapidly to the free base under acidic conditions. Also 
they showed a decrease in in vitro activity. 
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Alanyl- and lysyl- amide hydrochloride salts showed higher degrees of water 
solubility and chemical stability. The prodrugs also rapidly reverted to their 
parent compounds in vitro. 
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Screening of the amino acid prodrugs in the NCI 60-cell line panel showed 
selectivity was retained with the same potency as the parent amine (Figure 
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1.7).30 In 1999 5F 203 lysylamide dihydrochloride salt was submitted to the NCI 
DDG and was approved for development as a clinical candidate in 2002. The 
DDG provided synthesis, formulation, pharmacokinetic and toxicity resources.  
 
In 2004, Pharminox acquired exclusive rights to develop and commercialise  
5F 203 lysylamide dihydrochloride salt under the name of Phortress.31  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7.  Comparison of the activities of 5F 203 (left) and its lysylamide dihydrochloride 
salt (Phortress, right).
30
 
 
The information generated by the NCI COMPARE programme has been 
effective in identifying Phortress has a novel mechanism of action, which has 
successfully advanced the drug to the clinic. 
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1.2.3 TARGET-ORIENTATED DRUG DISCOVERY 
 
The discovery of anticancer drugs today is taking a more rational approach, 
leading to more selective agents that act on targets specific to cancer (Figure 
1.8).  
 
Figure 1.8. Molecular-Targeted Drug Discovery.  
 
1.2.3.1 Target Identification 
 
Understanding the molecular mechanisms underpinning cancer development 
and progression unveils many potential new drug targets. Human cancers are 
known to evolve through a multistage process which extends over several 
years.32 The carcinogenesis process is driven by the accumulation of mutations 
and epigenetic alterations in gene expression with important biochemical 
roles.32, 33 Hanahan and Weinberg outlined six essential alterations between 
normal and cancer cells that dictate malignant growth termed „The Hallmarks of 
Cancer‟ (Figure 1.9).34 
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Figure 1.9.  Acquired Capabilities of Cancer.
34
  
 
The selection of a target is based on numerous factors including its role in the 
initiation and progression of cancer and its „druggability‟.3 Alterations in cancer 
cells can include mutated genes, such as p5335 or B-raf36, or amplification and 
over-expression of specific cancer gene products, such as HER-2, MDM2, 
EGFR and cyclin dependent kinases.37 Also, a normal gene product associated 
with cancer, such as telomerase which has been found at increased levels in  
85 % of tumour cells tested. 
 
A variety of different biotechnological techniques can be used to identify 
potential targets. Cancer gene discovery is predominantly carried out using 
genome-wide high-throughput systematic screening techniques which include 
gene copy number analysis, gene expression profiling and gene resequencing.3 
RNA interference technologies38 and proteomic techniques39 are also becoming 
more widely used to identify potential targets for drug development.  
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 1.2.3.2 Target Validation 
 
Genomics and proteomics have identified thousands of potential targets.40 
However, the new mechanism-based approach to drug discovery has led to a 
decrease in the number of agents approved for cancer treatment, with only one 
compound being approved in 2008.8 This high failure rate can be attributed to 
incorrect target selection.41 For example, reversal of only a few of the large 
numbers of abnormalities present in the cancer genome has a profound effect 
on tumour growth. This is described as oncogenic addiction.42  
 
Discovery and development of a drug towards a particular target costs time and 
money. Once a target enters the pipeline of a pharmaceutical company, it can 
take approximately 12 years to develop at a cost of $1 billion by the time it 
reaches the market.43 Therefore, once a target has been identified it is essential 
to prove that the target is involved in neoplastic development and also that 
modulating the target can have a therapeutic effect, hence be a suitable target 
for development of a new drug.  
 
A target may be validated, even so not all validated targets are deemed to be 
„druggable‟. The intrinsic pathway of apoptosis is blocked in many cancer cells, 
exposing many targets. Developing a drug towards these blocks appears 
attractive to induce programmed cell death. However, all the targets are 
„undruggable‟ protein-protein interactions, resulting in the majority of 
chemotherapeutic agents for these targets being antisense compounds, rather 
than synthetic small molecules.40  
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Target validation aims to prove that the knockdown of a target is associated 
with a phenotypic change.44 Many molecular tools are available for target 
validation, including RNA interference, transgenic mice and chemogenomics 
and chemoproteomics using high throughput screening of compound libraries.45  
 
 1.2.3.3 Hit Compound Identification 
 
Following target validation the process of hit compound identification is initiated. 
Hit compounds are ideally „drug-like‟, that is they have functional groups and 
similar properties to known drugs. Hit identification can be achieved by various 
methods. Large libraries of compounds, including small molecules and natural 
products, can be evaluated against targets in specific, high-throughput 
biochemical assays, such as the NCI‟s SMART screen, to allow a hit compound 
to be identified. This method has proved successful as it allows up to 10,000 
compounds to be investigated daily.46 Combinatorial chemistry has allowed the 
numbers of compounds in libraries to increase.  Fragment-based lead discovery 
follows the same approach, but uses low molecular weight compounds, instead 
of drug-like molecules. This technique has increased the hit rate of lead 
discovery and also increased the ability to take hits successfully through 
optimisation into drug candidates.47 Following screening of fragment libraries, 
combination of the fragments, can lead to a hit compound.48 Alternatively hits 
can arise from literature compounds, where analogues can be selected on the 
basis of medicinal chemistry experience, intuition and trial and error.49  
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Rational structure-based drug design can be employed to discover hit 
compounds. X-ray crystallography and NMR can provide detailed structural 
information to generate 3-D structures of targets, in addition to computational 
generation of models.50 If the location of the binding pocket of a target is known, 
ligands can be generated to fit the target with the aid of molecular modelling 
programmes. Docking methods and structure based in silico HTS can be used, 
with the advantage of calculating the local binding energy.51  
 
A hit compound is usually a small organic molecule with potent activity and 
selectivity. Good hit compounds are generally smaller, less lipophillic and 
contain less functionality than typical drugs.7 These features allow for 
modification during the lead optimisation stage in the drug discovery process. It 
has been shown that leads share many structural similarities to their 
corresponding drugs, therefore, hit identification along with lead optimisation are 
crucial steps in the drug discovery process.52  
 
1.2.3.4 Lead Compound Optimisation  
 
Hit compounds that are potent in in vitro studies often need optimising to 
improve the pharmacokinetics, selectivity and solubility. In addition to reduce 
toxicity effects whilst retaining potency.53 This stage of the drug discovery 
process is challenging and resource-intensive. 
 
Compound optimisation can be pursued using a combination of experimental 
and computational studies. Computational studies using the 3-D ligand-protein 
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structure can accurately predict the binding affinity of the complex. Compound 
optimisation is carried out on the basis that increased affinity leads to increased 
potency.54 Optimisation normally involves the synthesis of hundreds of 
analogues, however the combination of synthesis with informatics can lead to a 
significant reduction in time and cost.53  
 
Modifications in the structure of a lead, followed by in vitro screening, allow the 
generation of structure-activity relationship (SAR) information essential for 
developing a lead compound into a drug for clinical use.55 Analysis of drugs and 
their corresponding leads has shown that the structural core of the lead remains 
and that drugs are usually more complex.56 In addition leads are generally 
smaller, more polar, have higher solubility and are less flexible than drugs.57 
Scheme 1.1 outlines some of the modifications made to compounds 
progressing through the lead optimisation phase of drug discovery.7  
 
A study calculating the variations between drugs and leads found that common 
changes were made to leads during the optimisation stage of drug 
development.58  
 
 Increase in molecular weight. 
 Increase in lipophilicity. 
 Relatively small increase in the number of hydrogen bond acceptors. 
 Almost no change in the number of hydrogen bond donors. 
 Almost no change in the number of rings within the structure.  
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Scheme 1.1. Modifications made to small molecule leads during optimisation into drugs. (A) 
Nexavar is a kinase inhibitor. The hit was discovered during HTS against CRAF protein kinase. 
(i) Combintational modification generated a more potent analogue (IC50 = 0.23 µM compared 
with 17 µM). (ii) Studies to increase in vivo activity lead to Nexavar. (B) VER49009 is a HSP90 
inhibitor. The hit was identified using HTS against HSP90 ATPase and co-crystallised with the 
enzyme. (i) Structure based design was modified to give the potent inhibitor (IC50 = 25 nM 
compared with 9 µM).
7
   
 
Properties desirable for orally-available drugs have been outlined by Lipinski. 
His „rule of fives‟ assesses physical and structural features of compounds to 
determine whether they could become orally active drugs.59 These empirical 
rules predict information about the pharmacokinetics of a compound, 
specifically the Absorption, Distribution, Metabolism and Elimination (ADME), 
early in preclinical development.  
 
Lipinski‟s rule considers the molecular weight of a compound, as evidence 
shows poorer intestinal permeability with larger molecular weight compounds.60 
It relies on the ClogP, which is the logarithm of the calculated  
(A) 
(B) 
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n-octanol/water partition coefficient, a measure of the compound‟s lipophilicity, 
and hence relates to its aqueous solubility, which affects the uptake and 
distribution of a drug.  
 
Finally the rule includes the number of hydrogen bond donors and acceptors. 
Excessive numbers of hydrogen bond donors can reduce permeability across a 
cell membrane.59 Lipinski‟s rule of fives state that a drug should ideally have no 
more than 5 hydrogen bond donors and 10 hydrogen bond acceptors, ClogP ≤ 
5 and the compound should have a molecular mass < 500. 
 
In addition to the rule of fives, the rule of threes has emerged for fragments 
during fragment based HTS (Section 1.2.3.3). This rule is based on Lipinski‟s 
rule and states for a fragment to be built into an orally-available drug, it must 
have a molecular weight < 300, ClogP ≤ 3 and it should have no more than 3 
hydrogen bond acceptors and three hydrogen bond donors.61  
 
 
1.3  BIARYLHETEROCYCLIC HIT COMPOUNDS 
 
A series of biarylheterocyclic compounds bearing tertiary and cyclic amino 
groups was discovered by Victoria Phillips.62 This work was designed to 
develop and evaluate molecular twist ligands as a novel strategy for structure-
selective nucleic acid binding. Their DNA binding ability was assessed using 
thermal DNA „melting‟ assays and compounds showed strong DNA binding 
affinity with ∆Tm ranging between 10-15 °C.
63 During this work three novel 
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compounds (1, 2, 3) bearing an imidazol-1-ylpropyl side chain were 
synthesised.62  
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Unexpectedly, biophysical evaluation of these three novel compounds with DNA 
thermal melting assays revealed only modest duplex DNA binding  
(∆Tm ≤ 2.1 °C). Further biological evaluation of the three compounds in cell-
based chemosensitivity assays revealed potent activity against the drug-
resistant (MMC and EO9) colon carcinoma cell line BE64 (Table 1.1). It can 
therefore, be concluded that the observed potent activity is due to a different 
mechanism from DNA binding. Additional evaluation was carried out by the NCI.  
 
The NCI 60-cell line screen confirmed activity with nM concentrations against 
some of the high priority tumour cell lines, non-small cell lung cancer and 
leukaemia sub-panels (Figure 1.10).  
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Table 1.1.  DNA Binding and MTT Chemosensitivity Data
62
  
 
 
∆Tm / °C 
CT DNA 
Chemosensitivityc / µM 
A2780 BE H460 
1 2.1
a 0.079 0.644 15.2 
2 0.6
b 0.014 0.064 2.18 
3 1.0
 b 0.010 0.016 1.43 
 
a
50 µMbp DNA, 10 µM ligand, 10 µM Na2HPO4/Na2H2PO4, 1 mM Na2EDTA, pH = 7.00 ± 0.01. 
b
50 µMbp DNA, 20 µM ligand. 
c
IC50 96 h exposure. 
 
Standard COMPARE analysis utilising the GI50 data for each of the compounds 
as seed revealed some attractive properties of the hit compounds. These data 
demonstrated:   
 
 no correlation with 175 FDA-approved anti-cancer drugs (P ≤ 0.365);  
 correlation with gene-like sequences of currently unknown function (P ≤ 
0.77)22, 23 in the molecular target and microarray panels;   
 correlation with a complex marine natural product dehydrodidemnin 
(aplidine). 
 
These data provide evidence that the hit compounds work by a novel 
mechanism of action targeting a gene-like sequence of unknown function. 
Isolation and subsequent identification of the target could offer an insight 
into the mechanism of action and scope for optimisation of the novel ligands.  
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Figure 1.10. NCI GI50 Mean Graphs  and Results of COMPARE Analysis.   
a
Pearson 
correlation coefficient (P).  
b
30 compounds, diverse structures. 
c
GC11087, gene-like sequence 
of unknown function.  
d
Dehydrodidemnin (aplidine). 
 
 
Further investigation into the NCI data for compound 1 was conducted by 
Dawen Rong,65 who confirmed the correlation with aplidine, and unveiled new 
correlations (Table 1.2).  
 
 
                                       1                                2            3 
All Compoundsa      1.0b       0.748d       0.498 
Molecular Targets      0.77c       0.615       0.524 
Standard Agents     0.365       0.347        0.35  
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Table 1.2.  Compare data for compound 1. Adapted from Rong 2009.
65
  
 
Database 
NSC 
number 
Correlation Structure 
Standard 
Agent (TGI) 
325319 1.0 
Aplidine 
Mechanistic 
Set 
636084 0.824 
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Diversity Set 99671 0.825  
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Synthetic 
Compounds 
641873 0.932   
637579 0.927   
640586 0.913   
634772 0.913   
671133 0.878  
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All Public 
Data 
698068 0.803  
N N
NH
N
O
O
O
O
 
 
 
Chapter 1: Introduction 
32 
 
The compounds in the NCI databases showing correlation with compound 1 
were analysed with the NCI 3D MIND tools. Each compound was mapped onto 
the complete SOM (Figure 1.4) to identify the functional cluster each of the 
compounds belong. Compound NSC 698068 was mapped in the F-region 
(unknown) on the 2003 version of the DTP complete SOM and the P-region 
(phosphatase- and kinase- mediated cell cycle regulation) in the earlier 1999 
version. The similarities in structure suggest the hit compounds (1, 2, 3) may 
also cluster to this region due to a similar MOA, however, observation of the 
data vector for this compound suggested differences in chemosensitivity 
profiles. Compound 99671 was mapped to functional clusters J5 and J7. These 
cluster regions still have an unknown MOA. The data present within the cluster 
vectors showed similar chemosensitivity profiles. 
 
Rong also mapped compounds found in each cluster onto the bit map to find 
structures with similar chemical properties. He synthesised several different 
analogues incorporating some of the structural features found within the 3D 
MIND data, for example replacing the amide with a sulphonamide, inverting the 
amide and using a non-planar conjugated ring system. Although the potency of 
the compounds was not improved, useful SAR data were achieved.65  
 
In addition to the compounds synthesised following investigation into the NCI 
3D MIND and COMPARE research, Rong also synthesised compounds based 
around the common structure 4 (Figure 1.11). It was believed that the 
pharmacophore features of compounds 1, 2 and 3 were still present in the 
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minimal structure 4 and this minimal structure also better adhered to Lipinski‟s 
rule. 
N
H
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4 
 
Figure 1.11.  Pharmacophore features of compounds 1, 2 and 3 outlined in red.
65
  
 
The minimal compounds synthesised retained activity, however, they showed 
reduced potency against selected cell lines (IC50 = 0.9 µM, compared with 0.01-
0.079 µM for hit compounds 1, 2 and 3 against the A2780 cell line).65  
 
 
1.4    APLIDINE 
 
The NCI COMPARE data gave high correlations of hit compounds 1 (P=1.0), 2 
(P=0.748) and 3 (P=0.498) with aplidine. Aplidine (plitidepsin / dehydrodidemnin 
B) is a marine antitumour natural product currently in phase II clinical trials for 
solid and haematological cancers, such as multiple myeloma, renal cancer and 
aggressive lymphomas.66 The cyclic depsipeptide, originally isolated from the 
Mediterranean tunicate Aplidum albican and currently obtained by total 
synthesis,67 shares structural similarities with didemnin B and other didemnins 
harvested from the tunicate Trididemnum solidum.68 Aplidine has a cytotoxicity 
of < 10 nm against Ehrlich cells.69  
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Aplidine 
 
Aplidine has been described as a multifactor apoptosis inducer which has a low 
systemic toxicity and high specificity for tumour cells.66 The mechanism of 
action of aplidine is only partially understood. Many mechanisms of action have 
been reported for the natural product, including blocking tumour cell 
proliferation, inhibiting cell cycle progression and suppressing tumour 
associated angiogenesis.70  
 
It is understood that aplidine is a potent inducer of apoptosis in a p53-
independent and caspase-dependent manner.71, 72 One study suggests aplidine 
induces cellular oxidative stress producing ROS, increasing lipid and DNA 
oxidation, by GSH depletion. It also showed JNK activation is critical for 
aplidine-induced apoptosis. This is caused by two gene-expression independent 
mechanisms, Rac1 activation and MKP-1 down-regulation. Rac1 activation can 
be caused by GSH depletion.67  
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Other research has shown aplidine treatment up-regulates phosphorylation of 
EGFR by a mechanism partly dependent on Src activation and sustained 
activation of JNK and p38 MAPK, due to a decrease in GSH levels and Src 
kinase, in breast and renal cell lines.71 In addition, aplidine causes induction of 
the mitochondrial apoptopic pathway, including the release of cytochrome c, 
activation of the caspase cascade and proteolytic cleavage of PKCδ generating 
a positive feedback loop which amplifies the apoptotic cascade.73  
 
Investigations into the mechanism of action of aplidine in melanoma cells (SK-
MEL-28 and UACC-257) confirmed activation of Rac1 leading to JNK and p38 
MAPK activation. However, at low concentrations of the drug, aplidine has a 
potent anti-proliferative effect caused by G1 phase cell cycle arrest and G2/M 
blockade, which is not seen in breast, renal and cervical carcinomas. This is 
supported by the fact cyclin A and cyclin B are at reduced levels in cells treated 
with aplidine.74  
 
Aplidine down-regulates the flt-1 receptor for VEGF which is involved in 
angiogenesis. These data suggested the mechanism may involve blocking an 
autocrine loop relevant for cell growth and survival.75 It has also been shown 
that aplidine inhibits the expression of multiple angiogenic genes.76  
 
Mapping aplidine onto the DTP complete SOM revealed it clustered into several 
different areas (N7, P1, P2, M2, M3 and M5). The areas represented are mitotic 
(M), membrane function (N), and phosphatases/kinase and oxidative stress (P). 
COMPARE analysis and data mining carried out by Rong suggested that the hit 
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compounds, 1, 2, and 3 would map in the P region of the SOM.65 These 
combined results would imply that the MOA of the hit compounds may be 
related to protein kinase inhibition or oxidative stress.   
 
 
1.5  TARGET DECONVOLUTION 
 
A phenotypic approach to drug discovery is becoming more widely applied due 
to the limitations of target-orientated discovery. It involves HTS of large libraries 
of compounds against cell lines to identify a desired cellular response. 
Subsequently, the biological target(s) responsible for the change in phenotype 
is identified – target deconvolution. This approach extends beyond single target 
inhibition, which often leads to resistance, allowing signal transduction 
pathways to be explored.44  
 
There are many strategies which can lead to target deconvolution.77 Directly 
exploiting a compounds affinty for its biological target(s) can be achieved by 
classical affinity chromatography, to purify a biological target using the 
immobolised compound, or by screening protein microarrays using the 
compound as a probe. Alternatively, indirect approaches involve looking for 
compound-induced changes in the protein, metabolite and mRNA expression 
profiles.  
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 1.6 PROTEOMICS 
 
Proteomics is a relatively new enabling technology that is becoming an 
integrated part of the drug discovery process.78 It focuses primarily on 
understanding the structure, function, expression, cellular localisation, 
interacting partners and regulation of every protein produced from a whole 
genome.79, 80  
 
Proteomics seeks to profile every protein expressed in a target cell or tissue at 
any time. It has advantages over genomics as it is the proteins that directly 
assert the potential function of genes by means such as enzymatic catalysis, 
molecular signalling and physical interaction.81 In addition, a single gene may 
produce several different protein isoforms, each with different functions. Due to 
the differential splicing and translation of many genes in the genome, each 
human gene may encode multiple different proteins. Furthermore, proteomics 
can also identify the post-translational modifications of proteins78 which have 
profound effects on the biological function and their cellular localisation.82 
However, there is currently no equivalent to PCR for protein amplification, 
therefore detection of proteins in low abundance remains a problem.83 
 
Proteomic studies provide a wealth of information to aid understanding of 
biological processes, as proteins are involved in every biological pathway in 
living organisms.84 Recent advances in proteomic research have identified 
target proteins involved in these pathways, leading to a better understanding of 
how new therapeutic agents can be established.85 Cancers share a restricted 
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set of capabilities critical for their development and progression, „The Hallmarks 
of Cancer‟ (Figure 1.9).34 The protein expression pivotal to the hallmarks varies 
between patients with the disease and healthy individuals. These proteins can 
be considered as the key to finding new drug targets or biomarkers for detection 
and diagnosis of cancer.86  
 
During the early years of proteomics, protein profiling primarily relied on 2D 
Electrophoresis (2DE) to separate and detect proteins87 and Edman 
degradation was the standard procedure for identification of the proteins from 
their amino acid sequence.  Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) has become the standard technique for the 
separation of protein mixtures.88 The technique separates denatured proteins 
on the basis of their molecular weight. Two-dimensional polyacrylamide gel 
electrophoresis separates proteins according to their isoelectric point, by 
isoelectric focussing, and their molecular weight in the second dimension by 
SDS-PAGE.89 Edman degradation is the process of sequencing a protein or 
peptide from the amino terminus.90 This was the most common approach to 
protein identification due to its reliability and automation, however, sensitivity 
remained poor and the process was slow.84 Applications of mass spectrometry 
are now described as the „workhorse‟ methodology of proteomics, allowing 
large, complex mixtures of proteins and peptides to be investigated.91  
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1.6.1 MASS SPECTROMETRY 
 
Mass spectrometry is an analytical technique used to determine the structure, 
elemental composition and purity of a compound. The process relies on the 
formation of charged ions (positive or negative) in the gas phase which can be 
easily separated by their mass to charge ratio (m/z).92  
 
Early mass spectrometers were built to analyse small molecular weight 
compounds and used electron impact ionisation methods.93 The harsh 
conditions used prevented the mass spectrometric analysis of larger 
biomolecules. Complex biological molecules such as proteins cannot be 
transmitted into the gaseous state required for mass spectrometry without 
degradation of their structure.  Therefore, it was not until the introduction of soft 
ionisation techniques that biomolecules could be analysed using mass 
spectrometric techniques.92  
 
There are many different types of mass spectrometer, described by their 
ionisation method, mass analyser and detector. A mass spectrometer operates 
through three basic steps outlined in Figure 1.12.  
 
 
 
 
 
 
Figure 1.12.   The basic components of a mass spectrometer. 
Vacuum 
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A sample can enter a mass spectrometer by a variety of methods including 
HPLC, GC or direct injection. The first step then involves the formation of 
gaseous ions (positive or negative) within the ion source. There are several 
different ionisation methods available94 and Matrix-Assisted Laser Desorption 
Ionisation (MALDI) is currently the most widely applied ionisation method used 
in protein research.92 In addition to proteomics, MALDI has been used to study 
other biomolecules, such as lipids95 and DNA.96  
 
1.6.1.1 Matrix-Assisted Laser Desorption Ionisation 
 
MALDI was first described by Franz Hillenkamp and Michael Karas in 198897 
who demonstrated that alanine could be readily ionised using a laser beam of 
266 nm when it was combined with tryptophan. Following their discovery, Kochi 
Tanaka established MALDI for large molecular weight biomolecules using a 
matrix of ultrafine cobalt powder in glycerol.98 For this he was awarded the 
Nobel Prize for Chemistry in 2002. Many of the matrices that are used today are 
of an organic nature and these were first described by Karas and Hillenkamp 
who ionised proteins using a matrix of nicotinic acid.97, 99  
 
MALDI requires the sample to be mixed with a matrix prior to ionisation. The 
matrix strongly absorbs at a maximum wavelength matched to that of the laser 
used for the ionisation. α-Cyano-4-hydroxycinnamic acid (CHCA) is an organic 
compound commonly used as a matrix for MALDI.  
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α-cyano-4-hydroxy cinnamic acid 
λmax = 337 nm 
 
An aqueous solution of CHCA is applied to a metal target plate and allowed to 
dry. The sample is then loaded in a diluted organic solvent and more matrix is 
applied. The analyte molecules adhere to the matrix molecules by hydrophilic 
interactions.100 Upon evaporation of the solvent, the sample is concentrated 
onto the matrix to form a solid solution with isolated analyte molecules 
embedded within the matrix crystals.  
 
The target plate is inserted into a vacuum lock and transferred to the ion source. 
A pulsed laser beam is applied to the homogeneous solid solution on the target 
with the same frequency as the chromophore of the matrix (337 nm) leading to 
vibrational excitation of the CHCA molecules. Desorption of the matrix and co-
crystallised analyte puts them in the gas phase where the photo-excited matrix 
molecules (M) stabilise via proton transfer.  
 
M               M*    ;    M*               M•+  +  e-    ;    M•+  +  M               MH+  +  (M-H) • 
 
The charge on the matrix molecules is then transferred to the analyte molecules 
(A). 
MH+  +  A               (H+A) +  +  M 
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The analyte ions are accelerated using an electrostatic field to the mass 
spectrometer for analysis. The process is outlined in Figure 1.13. 
 
    
 
 
 
 
 
 
Figure 1.13.  The MALDI ionisation process. 
 
Once the gaseous ions have been formed the ions need to be separated based 
on their m/z ratio. A number of different mass analysers have been developed 
which can be used to separate the ions. All of the analysers work using static or 
dynamic electric and magnetic fields alone or in combination.94  
 
1.6.1.2 Time of Flight Mass Analysers 
 
Time-of Flight (TOF) mass analysers were first introduced in 1946 by 
Stephens101 and have a relatively simple underlying principle. A basic TOF 
mass spectrometer consists of: a short source extraction region, where ions are 
produced and accelerated to a constant kinetic energy using electric fields; a 
drift region, which is a field-free region with a bounded extraction grid at ground 
potential; and a detector. The principle is that the ions cross into the drift region 
with a velocity that is inversely proportional to the square root of its mass.  
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Therefore, lighter ions have a higher velocity and reach the detector in a faster 
time than heavier ions.102  
 
TOF-MS theoretically has no mass range limitations because the ions, however 
large, will still arrive at the detector in a particular time.103 The resolution of the 
data generated is dominated by the error in flight time and the difference in 
pulsed action and energy aberration of the laser. The introduction of MALDI with 
a TOF mass analyser has simplified the TOF design and has a great effect in 
eliminating error due to time and spatial distribution.102 MALDI produces 
gaseous ions using a pulsed laser, therefore leading to a time distribution 
(Figure 1.14A). Ions are extracted from the source using a high velocity pulse 
after a time delay, hence they are accelerated and enter the drift region at the 
same time,103 (Figure 1.14B). This is known as „time-lag focussing‟ and allows 
the ions within the source to rearrange their position with respect to their initial 
velocities. Therefore, ions with higher velocities travelling into the drift region will 
gain less energy from the extraction field when it is switched on,104 (Figure 
1.14).  
 
 
 
 
 
 
 
Chapter 1: Introduction 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14. Continuous and delayed pulse extraction mode in a TOF analyser. Blue ions of 
a certain mass have the correct kinetic energy. Red ions have the same mass, however a 
higher kinetic energy. Delayed pulse extraction corrects the energy dispersion.
94
  
 
Another improvement to the TOF mass analyser came with the development of 
an electrostatic reflector called the reflectron.105 This is basically an ion mirror 
which deflects the ions back through the flight tube.94 Once ions reach the 
reflector they are deflected by an electric field and continue towards the 
detector.103 This compensates for any difference in the initial energy and can 
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therefore separate ions with the same m/z with increased resolution.  This is 
because ions with the same m/z may have differences in their kinetic energy. 
The reflectron allows the ions with a higher kinetic energy to move more deeply 
into the reflector than ions with a lower energy, therefore correcting the time of 
flight (Figure 1.15). 
 
 
 
 
 
 
 
Figure 1.15. A reflectron. Blue and red ions have the same mass, however red ions have a 
kinetic energy which is too low and therefore enter the reflectron later but do not travel as 
deeply. Both ions leave the reflectron with the same kinetic energy as before and hence reach 
the detector at the same time.
94
 
  
Fragmentation of ions due to their high kinetic energy after acceleration may 
occur before leaving the source, known as in-source decay (ISD) fragments, or 
after leaving the source, which are known as post-source decay (PSD) 
fragments. ISD fragments can be separated from their parent ion on the basis of 
their m/z in the TOF analyser because they have the same kinetic energy and 
therefore different velocities on entering the drift tube. However, PSD fragments 
have the same velocity during their journey through the drift region and 
therefore, the same flight time in the absence of a field. The reflectron TOF MS 
Reflector Detector 
Reflectron 
Source 
Chapter 1: Introduction 
46 
 
has therefore, allowed distinction between parent and PSD fragments as the 
fragment ions will not move as deeply into the reflectron as their parent ions.94  
 
1.6.1.3 Tandem Mass Spectrometry 
 
Tandem mass spectrometry (MS/MS) incorporates multiple stages of mass 
analysis. This can be useful in peptide identification due to their fragmentation 
patterns which are representative of their amino acid sequence. A TOF 
reflectron mass analyser can be used to perform MS/MS. The best procedure 
combines a linear TOF and a reflectron TOF analyser.94 During MS/MS 
analysis, parent ions can be identified in the linear TOF, whereas fragments can 
be detected using the reflector TOF mass analyser. Collision induced 
dissociation (CID) is a process by which parent ions decay by collisions during 
passage through a cell filled with an unreactive gas, e.g. Ar.  In MS/MS, CID 
allows fragmentation of ions selected by the first mass analyser and the 
fragmentation products to be analysed by the second detector. CID leads to an 
increase in the number of ions that fragment and also increases the number of 
fragmentation pathways.94  
 
1.6.1.4 Instrumentation 
 
The Bruker Daltonics Ultraflex II is a MALDI tandem mass spectrometer which 
has been specifically designed for automated MS and MS/MS high throughput 
identification of proteins and peptides. The instrument uses a MALDI ionisation 
source and has two TOF mass analysers (Figure 1.16).106  
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Figure 1.16. The Bruker Daltonics Ultraflex II 
 
The instrument has an implemented „LIFT‟ device which allows full 
fragmentation spectra to be produced in the MS/MS mode. In MS mode, the 
LIFT feature is disabled and therefore only the parent ion is detected. In MS/MS 
mode the LIFT raises the kinetic energy of the parent and fragment ions 
allowing the detection of the fragments with the parent. Fragment ions have 
ground potential in comparison to the parent.  The „lift‟ in kinetic energy allows 
both parent and its fragment ions to travel down the flight tube with the same 
velocity. Upon entering the reflectron the ions with lower kinetic energy – 
fragments – do not travel as deep and are detected by the reflectron detector in 
a shorter flight time than the parent.  
 
Another feature of the instrument is that it has a precursor ion selector (PCIS) 
which enables selection a particular parent ion and its fragments, then 
separates them from other ions for MS/MS analysis. It consists of deflector 
plates which can be switched on and off to allow only ions with a certain velocity 
to pass through.  A second deflector, known as the post-lift metastable 
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suppressor (PLMS), deflects any remaining intact precursor ions, preventing 
undesired fragmentation which may occur following acceleration.107  
 
Protein identification is achieved by associating the isolated protein with a gene 
and hence a biochemical function based on its sequence identity revealed 
following mass spectrometric analysis.108  
 
1.6.2 PROTEIN IDENTIFICATION 
 
Protein identification is achieved through the analysis of peptides produced 
following enzymatic digestion of a protein into smaller peptides.85 Enzymatic 
digestion with trypsin exclusively hydrolyses the peptide bond formed at the C-
terminus of both arginine and lysine residues in a protein (provided the next 
amino acid in the sequence is not proline), resulting in a variety of shorter 
peptides.83 The peptides produced, therefore have two protonation sites, the N-
terminal amino group and the C-terminal lysine or arginine side chain. The 
peptide fragments produced each have a mass which is characteristic of their 
amino acid sequence and hence one particular protein which is known as the 
Peptide Mass Fingerprint (PMF).83, 109 The PMF produced can be compared 
against in silico digestion of protein sequences in databases to produce a list of 
likely matches.108 Protein sequence databases are constantly updated with 
amino acid sequences generated by the translation of nucleotide sequences in 
their correct reading frame.108 
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The PMF cannot always identify a protein, especially if the protein is part of a 
mixture,83 or there is an amino acid substitution or post-translational 
modification.108 Therefore further analysis using MS/MS can be conducted. 
Under CID conditions, peptides fragment to create patterns characteristic of the 
amino acid sequence. These fragmentation patterns are reproducible and 
predictable if a sequence is known.110  
 
Peptide CID spectra are generally more useful for protein identification than 
PMFs, as they provide information about the peptide sequence in addition to the 
peptide molecular mass.111 The amino acid sequence can be manually 
generated from the series of daughter ions identified in a MS/MS spectrum.112 
Manual interpretation and subsequent identification relies on identifying various 
daughter ions whose mass difference is equal to the exact mass of one amino 
acid residue.110  
 
Amino-acid specific fragment ions are primarily produced from the cleavage of 
amide bonds in the peptide backbone during MS/MS analysis. Depending on 
the basicity of the amino acids within the peptide, the charge can be retained 
upon the N-terminus giving a acylium ion, known as a „b‟ ion or by proton 
rearrangement be retained on C-terminus leading to „y‟ ions85, 110 Fragmentation 
can also occur at other points along the peptide backbone (Figure 1.17).  
 
The most frequently occurring ions are type a and b and these are generally 
seen when there is no basic amino acid or it is located near the N-terminus; y 
ions are observed if the basic amino acid is located at the C-terminus of the 
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peptide, as is the case of trypsin generated peptides. All three are generally 
observed with one or two dominating.113 The ions are thought to be produced 
following protonation of the amide nitrogen.114    
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Figure 1.17.  Fragmentation patterns of peptides showing: (A) the different cleavage 
positions in the peptide backbone; (B) the residual fragments produced following cleavage. 
 
Several algorithms and computer programmes have been designed to search 
protein sequence databases and identify proteins. „Mascot‟115 is a search 
engine which incorporates probability-based protein and peptide identification. It 
(A) 
(B) 
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is a development on the MOWSE molecular weight search engine,116 which was 
one of the first programmes for identifying proteins by PMF. Mascot can 
conduct three different types of searches, PMFs; sequence queries; and 
tandem MS ion searches. 
   
For protein identification, MOWSE calculates the sequence molecular weights 
of all proteins in the database (DMW) and calculates the molecular weights of 
the peptides produced following complete enzymatic digests (FMW). The 
peptide mass calculations are based on the linear sequence and use the 
average isotopic masses of amide bonded amino acid residues116 described in 
Equation 1. A hit is scored when the criterion from Equation 2 is met where 
tolerance is user selective.116 
 
 
 
DMW – tolerance – 1 < FMW < DMW + tolerance + 1 
 
The programme generates a ranked „hit‟ list of proteins and each protein 
identification is given a Mascot score, which is based on the absolute probability 
that the observed match is a random event. Specifically the scoring is based on 
the frequency of a fragment molecular weight being found in a protein of a given 
weight.  Scores are calculated as: -10 log10(p); where p is the absolute 
probability. Therefore a very low probability will give a high Mascot score. The 
match with the lowest probability is reported as the „best‟ match. Good matches 
1 
2 
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have a probability of p < 0.05. Mascot searches can also take into account post-
translational modifications and modifications due to chemical derivatisation.117  
 
Proteomics coupled to mass spectrometry and database searching can be used 
in drug discovery to indicate novel targets by comparing the proteomes from 
normal and neoplastic tissues. Differences in each of the proteomes could 
identify potential targets for drug discovery. In addition to large scale proteome 
screening, chemical proteomics can be used to identify, enrich and isolate 
targets as a more direct method to target deconvolution.  
   
1.6.3 CHEMICAL PROTEOMICS  
 
Chemical proteomics can take two different forms (Figure 1.18). The first is 
activity-based probe profiling (ABPP). This approach focuses on the enzymatic 
activity of a particular protein family. The second form is a compound-centric 
approach which aims to characterise the molecular mechanism of action of a 
small molecule inhibitor.118 
 
The compound-centric approach can be described as the classical drug affinity 
chromatography118 and has proven a successful approach to studying inhibitor 
function. It utilises small molecular derivatives which can be covalently 
immobilised onto beads for affinity purification of cellular target proteins.119 
Following direct immobilisation of a compound on to a solid support, a protein 
lysate can be incubated with the resin. Subsequent to the affinity capture and 
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several washing steps, the bound proteins can be eluted by denaturation or 
competitive elution using the free ligand for identification.39  
 
Brehmer et al.120 used a chemical proteomic strategy to identify any additional 
targets of the EGFR kinase inhibitor Gefitinib used in the treatment of NSC lung 
cancer. They synthesised an analogue of Gefitinib incorporating a free amine in 
place of a morpholino group for direct immobilisation to a solid support.  
 
The affinity matrices were incubated with total HeLa cell lysate. Non-binding 
proteins were removed from the column by washing and bound targets removed 
by competitive washing with free gefitinib and ATP. LC-MS/MS analysis of 
trypsin digested target proteins revealed more than twenty kinases and other 
cellular proteins.  
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Figure 1.18.  Comparison of activity-based probe profiling (ABPP) and compound-centric 
chemical proteomics (CCCP).
118
 ABPP forms a covalent bond between a warhead and a 
protein. The warhead can be an irreversible inhibitor attached by a linker to a reporter tag such 
as biotin. Bound proteins are then captured on an affinity matrix through the reporter tag using 
an affinity wash. CCCP uses a compound of interest bound to an inert matrix which is incubated 
with a biological sample for capturing proteins. Unbound proteins are washed from the matrix. 
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1.7 CONCLUSION 
 
The three hit compounds synthesised by Phillips62 have COMPARE profiles 
indicative of a novel mechanism of action. The target of compounds, 1, 2 and 3, 
is present in sensitive cell lines from the NCI 60-cell line screen, in particular 
leukaemia and NSC lung cancer subpanels. COMPARE analysis with the 
molecular targets database identified that the protein target is from a „gene-like‟ 
sequence of unknown function. Isolation and subsequent identification of the 
biological target, could present attractive possibilities for optimisation of the hit 
compounds and indicate a new molecular target for drug discovery. 
 
Isolating the target will be attempted using an affinity-based proteomic 
technique and subsequently identified using MALDI-TOF mass spectrometry 
and Mascot. Isolation requires affinity probes of the hit compounds.  Therefore, 
the hit compounds must be immobilised on a solid support. Immobilisation 
requires inclusion of an additional functional group into the hit compounds that 
can be used for reaction with the chromatography medium, or alternatively 
incorporating a moiety such as biotin, into the compounds for complexation with 
a streptavidin-based matrix. 
 
Any alteration to the structures of the compounds may affect their cytotoxicity. 
Therefore, all compounds must be tested before affinity chromatography is 
carried out. During the affinity chromatography procedure, compounds of similar 
structure demonstrating no potency will also be required to act as controls. This 
will eliminate non-specific binding of cellular proteins. 
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1.8 AIMS 
 
The aims of this work are: 
 
 To synthesise bespoke matrices of the three hit compounds for affinity 
chromatography. 
 To synthesise bespoke matrices of an „inactive‟ compound to act as a 
control. 
 To evaluate the biological responses of the modified hit compounds prior 
to attachment to a matrix. 
 To use a proteomics-mass spectrometry programme to isolate, identify 
and characterise target proteins. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
CHAPTER 2 
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2.1 INTRODUCTION 
 
The hit compounds previously identified in this laboratory62 possess common 
structural features only differing in the core heterocyclic ring. Figure 2.1 
highlights the differences (coloured) and similarities (black) between each of the 
structures. The similarities can also be described as the pharmacophore 
identified by Dawen Rong.65  
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Figure 2.1.  Superimposition of the three hit compounds 1 (red), 2 (green) and 3 (blue). The 
structure 4, common to all three ligands is shown in black.
62
  
 
The preliminary SAR for the compounds62 showed: 
 
 N-oxides of Ring A block cytotoxic activity; 
 Meta-substitution of ring B results in a decrease in activity and selectivity; 
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 Reduction in the length of linker D reduces activity in ligands; 
 Saturated rings in the place of ring C reduce cytotoxicity, dialkyl amines 
are inactive. 
 
These SAR data, in addition to the evidence that compound 4 is the minimal 
structure required for activity,65 reveal a number of accessible sites for 
attachment of the hit compounds to a matrix for use in affinity chromatography. 
As the compounds are symmetrical, a linker, containing a suitable functional 
group for attachment to a solid support, could be attached at various points 
within half of the compound, leaving the other half unchanged and accessible to 
the biological target. 
  
Evidence shows compound 4 to have a decreased potency compared with hit 
compound 1 (IC50 2.6 µM against the A2780 cell line for compound 4
65 
compared with 0.079 µM for hit compound 162), suggesting that the biaryl 
heterocyclic ring system, may be required for activity, or that the target has a 
symmetrical binding site. 
 
2.2     CHROMATOGRAPHY MEDIUM 
 
The hit compounds can be immobilised directly onto a chromatography medium 
by a suitable functional group, such as a carboxylic acid or an amine. Epoxy-
activated beads can be used to attach the hit compounds to the solid support by 
an amine (Scheme 2.1).  
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Scheme 2.1. Mechanism of a hit compound containing a primary amine reacting with epoxy-
activated chromatography media. 
 
Alternatively, instead of immobilising the hit compounds directly to the solid 
support, a more „universal‟ approach is to use streptavidin or avidin columns 
with biotin-derivatised compounds tethered to the resin.39 This strategy utilises 
the high affinity of biotin for (strept)avidin. However, a biotin tag could change 
the binding characteristics and directly affect the activity of the hit compounds. 
 
2.2.1 THE BIOTIN/STREPTAVIDIN BOND 
 
Streptavidin, isolated from Streptomyces avidinii, is a 159 residue, tetrameric 
protein with a molecular weight of 4 x 15,000.121 The protein is a dimer of 
dimers with 222 (d2) symmetry.122 It shares homology with the protein avidin 
which is isolated from egg white. Both proteins exhibit an exceptionally-high 
affinity for biotin (Kd ~ 10
15 M-1) which is the strongest non-covalent bond known 
in nature between a ligand and a protein.123 In the unbound state, the binding 
pocket is occupied by five water molecules, which abandon the binding site 
upon addition of biotin to the solution.122 Each subunit binds one biotin molecule 
and the binding energy is derived from several interactions between the protein 
and biotin. There are seven direct hydrogen bonds, five of which lie deep within 
the binding pocket, preventing competition from solvent. These include two to 
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the single ureido oxygen, one from each of the ureido nitrogens and one to the 
sulphur in the biotin molecule.124 In addition there are hydrophobic and Van der 
Waals contributions with tryptophan residues 79, 92, 108 and 120125 (Figure 
2.2). 
 
Each monomer of the streptavidin protein folds into an eight-stranded 
antiparallel β-barrel. Biotin binds into the open end of the twisted barrel and a 
surface loop folds over the binding site. This binding loop consists of 45-52 
residues.122 This could present a problem for utilising the biotin streptavidin 
bond in affinity chromatography, as biotin binds directly into the cleft of 
streptavidin. Therefore, the hit compounds must be designed to have the 
correct accessibility to the target during incubation steps.39  
 
 
 
Figure 2.2. The binding of biotin (white) to streptavidin. The binding loop (loop III) bends 
over the biotin molecule. (A) Tryptophan residues involved in binding; (B) The hydrogen 
bonding system between ligand and protein.
125
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Wang et al. employed a biotinylation approach to affinity capture to identify the 
binding protein of the antimitotic agent Diazonamide A.126  
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Cellular extracts of HeLa cells were probed with a biotinylated Diazonamide A 
and an inactive control. Mass spectrometry identified the cellular receptor that 
mediates the antimitotic effects as ornithine aminotransferase (OAT). Biotin is 
attached to the compound by a three carbon linker, therefore a linker of no less 
than three carbon atoms is essential for attaching the hit compounds, 1, 2 and 3 
to affinity matrices. 
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2.3   BESPOKE MATRICES FOR AFFINITY CHROMATOGRAPHY 
 
Synthesis of the bespoke matrices for affinity chromatography, following either 
of the methods described above, will involve addition of an extra functional 
group to the three hit compounds. However, the position of the functional group 
must be in such a place to ensure that the biological activity of the compounds 
is not compromised. 
 
Taking into account the SAR already established for this group of compounds 
(Section 2.1), there are several sites for an extra functional group to be 
positioned, these are identified in Figure 2.3.  
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Figure 2.3.  Compound 1, showing possible sites of incorporating an additional functional 
group. 
 
The central ring (Ring A) could include an additional functional group, such as 
an amine. For compound 1, illustrated above, the position which will be the 
most synthetically accessible and least affect the 3D structure would be the 
pyrimidine-2 position. An alternative for all three hit compounds would be to 
position the functional group within one of the side chains, therefore disrupting 
symmetry. This could be placed either in Linker D or in place of Ring C. Ring B 
could be modified to carry a functional group at either of the unsubstituted 
positions (2'/6' or 3'/5').  
 
The triaryl ring systems (ring A and rings B) of all three compounds are 
conjugated, but they do not adopt a rigid, planar structure. Instead they adopt a 
slightly rotated conformation (Figure 2.4C) due to steric hinderence effects 
between the hydrogen atoms ortho to the inter-annular bonds (Figure 2.4A). In 
contrast the bond between Ring A and Ring B cannot have a 90° torsion angle, 
as conjugation between the rings is lost due to a reduction in π-overlap (Figure 
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2.4B).62 SAR studies have shown the more planar the conjugated system, the 
higher the cytotoxicity of the compound.65  N-oxidation of the nitrogen atom of 
the heterocyclic ring A reduces potency (IC50 0.24 µM compared with 0.079 µM 
for hit compound 1)62 suggesting that the nitrogen atoms may be involved in the 
binding to the protein target. In view of the SAR data from Rong concerning the 
effect of the planarity of the conjugated system, it would imply the N atoms are 
required for a conformational effect related to the protein:ligand binding 
complex. Therefore, the nitrogen atoms must be free to act as either hydrogen 
bond acceptors or to govern the adopted conformation which may be required 
for binding. In addition the 2'/6' positions of Ring B and the pyrimidine-5 position 
must also be kept clear to prevent conformational changes of the 3D structure 
of the hit compounds. 
N NH
H
H
H
H H
H
H
H
H
N N
H
H
N N
45o
90o
 
 
Figure 2.4. 4,6-Diphenylpyrimidine: (A) in a planar conformation, red arrows indicate the 
steric clash; (B) with a 90° torsion angle of the inter-annular bond, π overlap is reduced; (C) in 
the minimum energy conformation, a compromise of π overlap and steric clash. 
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SAR data has shown that an increase in the length of Linker D, from a two 
carbon to a three carbon chain, causes a significant increase in potency of the 
compound series (IC50 > 100 µM
65 compared with 0.079 µM for hit compound 
162). Thus suggesting Linker D plays an important role in the binding of the hit 
compounds to the target. Therefore, at least one of the linker Ds must remain 
constant to ensure binding. In addition, the terminal imidazole group (Ring C) 
plays an essential role in the observed cytotoxic activity.62, 65 Replacing the 
imidazole groups with saturated heterocycles or alkyl amine groups resulted in 
a decrease in potency (IC50 = 0.079 µM for compound 1 compared with >100 
µM for the pyrrolidinyl and dimethylamino equivalents).62 Taking into account 
the chemosensitivity results for compound 4, it appears that only one of the 
imidazole groups is essential for binding to the biological target. Therefore, Ring 
C could be replaced with a nucleophilic group, such as a hydroxyl or primary 
amine group for attachment to biotin or directly to the epoxy spacer arm of the 
chromatography medium.  
 
The biological target of the hit compounds is unknown and hence the binding 
mode. Therefore, the position of an additional functional group, required for 
attachment to either a solid support or biotin, must be in such a place as to 
ensure the final affinity probes maintain as much structural similarity to the hit 
compounds as possible. Thus all hydrogen bond donors and acceptors should 
remain uninterrupted, in at least half of the compound. Reviewing the SAR 
studies, it appears the triaryl ring system (Ring A and Rings B) is required for 
maximum activity. However, if one of the imidazole groups (Ring C) is omitted, 
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activity remains. Therefore addition of a nucleophilic group in place of Ring C, 
ought to be the best site for attachment to all three hit compounds. 
 
 
2.4     ATTACHMENT LINKER  
 
Attachment of the hit compounds to either biotin or directly to a solid support, 
requires the addition of a functional group to the hit compounds. There must 
also be a relatively long spacer arm attached to the solid support before binding 
of the hit compounds (whether attachment is direct or indirect through 
streptavidin-biotin). This would ensure the prevention of interference with 
ligand-protein recognition and capture. Commercially-available solid supports 
contain a long spacer arm (12-18 atoms), however a linker region would have to 
be incorporated to attach the functional group to the spacer arm of the solid 
support or to a biotin molecule. A suitable linker is 1,3-diamino propane, 5. 
   
H2N NH2
5  
 
1,3-Diaminopropane, 5, is a bifunctional compound allowing both attachment to 
the hit compounds and to the chromatography medium or biotin (Scheme 2.2). 
Also, as the linker contains an aminopropyl group, it is possible to replace the 
whole of the side chain in one half of compounds preserving the original amide 
and carbon chain of Linker D.  
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Scheme 2.2.  Retrosynthetic analysis of the attachment of the linker to: (A) the spacer arm of 
the chromatography medium; (B) a biotin molecule. 
 
 
 
 
(A) 
(B) 
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2.5  PROTEOMIC STRATEGY 
 
The preparation of affinity probes of the hit compounds with different attachment 
points of the linker should prove useful in identifying the target protein through 
affinity chromatography techniques. Using different attachment points should 
ensure that at least one of the immobilised hit compounds will maintain its ability 
to bind the target protein effectively.  Also, compounds with free amines and 
compounds with biotin moieties will be synthesised to allow optimisation of 
methods for the chemoproteomics stage of the project.  
 
Furthermore, compounds which are inactive towards cell lines sensitive to the 
original hit compounds will be synthesised for use as controls during isolation of 
the biological target. Since saturated cyclic amines show reduced toxicity, 
compounds with a terminal pyrrolidine group will also be synthesised. 
 
The target compounds to be synthesised are shown in Figure 2.5. 
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Figure 2.5.  Target molecules for synthesis.  
  
 
 
 
 
 
CHAPTER 3 
SYNTHESIS 
 
 
 
 
 
 
 
 
 
Chapter 3: Synthesis 
 
70 
 
3.1     INTRODUCTION 
 
The target compounds for synthesis were defined in Chapter 2 and are 
summarised in Figure 2.5. The two main approaches to the target compounds 
are: 
 Breaking the symmetry of the hit compounds and replacing one of the 
side chains with the linker 1,3-diaminopropane, 5 (A-C); 
 Retaining the symmetry and attaching the linker at the pyrimidine-2 
position (D).  
 
The hit compounds, 1, 2 and 3, have previously been synthesised by a versatile 
three-step process outlined in Scheme 3.1.62 
 
Het
X X
X = Cl, Br or I
O
O
B
OH
OH
Y Y
Het
(i)
Y = CO2Me
Y = CO2H
H
N N N
O
(ii)
(iii)
Y =
 
Scheme 3.1.  Synthesis of hit compounds, 1, 2 and 3.
62
 Het = pyrimidine, pyridine or 
naphthyridine. 
Reagents and Conditions: (i) K2CO3, (Ph3P)4Pd, PhMe:MeOH (9:1), 72 h, ∆, 67-91%; (ii) 
NaOH (2 M), 12 h, ∆, then HCl, 90-100%;  (iii) PyBOP, Et3N, CH=NCH=CHN(CH2)3NH2, CH2Cl2, 
12 h, RT, 65-83%. 
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The three steps of the established synthesis are: 
 
 Formation of the biaryl heterocyclic ring system to afford an aryl 
dimethyl ester; 
 Hydrolysis of the esters; 
 Formation of amides by attaching the relevant side chains. 
 
Each of the synthetic steps has been applied successfully in synthesising a 
wide range of similarly-structured analogues which has generated data 
contributing to the SAR.62, 63, 65, 127 Adapting these established methods would 
provide access to the target compounds, 6-21.  
 
Incorporation of the 1,3-diaminopropane linker, for attachment to a solid support 
or to biotin, could theoretically be achieved at any one of the three steps of the 
established synthesis. Numerous routes of synthesis are possible following both 
approaches and many of these have been explored. Scheme 3.2 shows a 
retrosynthetic analysis of non-symmetrical compound 6, illustrating the different 
stages at which the symmetry of the compound can be broken. Route A 
involves breaking the symmetry during amide formation and Route B breaks the 
symmetry during hydrolysis. Both Route C and Route D involve breaking the 
symmetry in the first stage of the synthesis, formation of the biaryl heterocyclic 
ring system.  
 
Scheme 3.3 shows a retrosynthetic analysis of compound 33, again illustrating 
the steps at which the linker could be incorporated.  
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Scheme 3.3.  Retrosynthetic Analysis of compound 33 (Routes E and F) 
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3.2 ESTABLISHED SYNTHESIS 
 
3.2.1 STAGE 1 – FORMATION OF THE BIARYL HETEROCYCLIC RING 
SYSTEM  
 
Biarylpyrimidines have previously been prepared by aromatic nucleophilic 
substitution reactions with 1,3-diketones, 39, and formamide, 40,128 (Scheme 
3.4A) and by sequential aryllithium additions to pyrimidine129 (Scheme 3.4B). 
Previous work conducted in this laboratory has favoured Suzuki biaryl cross-
coupling reactions to synthesise the biarylheterocyclic ring system.62, 63, 65, 127 
(Scheme 3.4C). This reaction provides one of the most straightforward 
methodologies for various carbon–carbon bond formations.130  
 
3.2.1.1    The Suzuki Coupling Reaction 
 
The Suzuki coupling reaction is extremely versatile resulting in the formation of 
a carbon-carbon bond between an aryl or vinyl boronic acid and an aryl, vinyl or 
alkyl halide through a metal-catalysed reaction.130 The reaction was first 
described by Akira Suzuki‟s group in 1979.131 They reported that boranes react 
readily with 1-alkenyl halides in the presence of a catalytic amount of palladium 
and a base to give the corresponding conjugated dienes in good yields. More 
recently the Suzuki coupling reaction has had a huge number of applications, 
ranging from the synthesis of solar cells132 and carbon nanotubes133 to 
unnatural amino acids134 and versatile structural fragments for natural product 
synthesis.135  
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Scheme 3.4.  Formation of biarylpyrimidines.  
Reagents and Conditions: (A): 180-190 °C, 6 h, 62 %;
128
 (B) n-BuLi in hexanes, pyrimidine, 
DDQ, Et2O, -50 °C, 1.5 h, 40 %;
129
 (C) K2CO3, Pd(Ph3P)4, PhMe:MeOH (9:1), ∆, 72 h, 90 %.
62
. 
 
The mechanism of the Suzuki coupling is best viewed from the perspective of 
the palladium catalyst (Scheme 3.5) and involves oxidative addition, 
transmetalation, trans-cis isomerisation and reductive elimination. The catalyst 
used is palladium in its zerovalent state. Catalysts can be readily purchased 
containing palladium of this oxidation state, for example tetrakis(triphenyl 
phosphine) palladium (Pd(PPh3)4). Alternatively the catalyst can be added as a 
palladium (II) complex along with a ligand, such as palladium acetate with 
(A) 
(C) 
(B) 
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triphenylphosphine, which reduces readily in situ to the active palladium (0) 
species. Several intermediates of the Suzuki coupling reactions have been 
isolated and identified by electrospray mass spectrometry and are identified in 
Scheme 3.5.136  
 
Pd0L4
PdII
L
L
ArX
PdII
L
L
ArAr'
PdII
Ar
L
LAr'
XAr
Oxidative Addition
Transmetallation
B(OH)2Ar'
XB(OH)2
H2O
B(OH)3 + HX
Trans-Cis Isomerisation
Reductive Elimination
ArAr'
47
40
52
4856
55
54
49
50
53
PdIIL2
46
 
Scheme 3.5.  Catalytic cycle of the Suzuki Coupling Reaction.
136
  
 
Solid-supported palladium catalysts are often used, which enable them to be 
recovered and recycled. This has led to suggestions that the Suzuki coupling 
reaction works via a heterogeneous mechanism137 rather than the 
homogeneous mechanism more commonly described.138, 139  
 
Palladium is the most widely used transition metal in homogeneous catalysis 
and plays a major role in synthesis due to its electronegativity (2.2), which 
allows the formation of relatively strong Pd-C and Pd-H bonds and also 
polarised Pd-X bonds.140 Palladium chemistry is dominated by two oxidation 
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states, 0 and +II, although oxidation states +I, +III and +IV are possible but 
seldom mentioned in literature.140  
 
An ideal catalyst is a complex that is stable in the resting state for storage but it 
becomes activated in solution by dissociation of a ligand. The most stable 
transition metal complexes satisfy the 18 electron rule; they have 18 electrons 
in their valance shells, hence a noble gas configuration. This is achieved by 
combining the electrons of the metal with those donated by coordinating 
ligands.141  
 
Triphenylphosphine, as present in Pd(PPh3)4 57, is the most widely used 
coordinating ligand as it is relatively inexpensive and any contamination with 
phosphine oxide can be readily removed by recrystallisation from ethanol.142 
Pd(PPh3)4 is widely used to catalyse Suzuki reactions. The palladium (0) metal, 
with 10 valance electrons in its 4d orbital, is complexed to four PPh3 ligands, 
each donating 2 electrons from their lone pairs, leading to a palladium (0) four 
ligand complex, 57, containing 18 electrons in its valance shell (Figure 3.2).    
 
Pd(0)
Ph3P
Ph3P PPh3
PPh3
10 e's
2 e's
2 e's
2 e's
2 e's
57
 
 
Figure 3.1.  Pd(PPh3)4 complex, showing the number of electrons of the palladium (0) metal 
and its coordinating ligands.
141
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Each of the triphenylphosphine ligands, in Pd(PPh3)4, has a lone pair of 
electrons on the phosphine in a filled spn type orbital. This overlaps with a 
vacant dsp orbital of palladium. The result is the formation of a conventional 2 
electron σ-bond, leading to an increase in the electron density of the palladium 
atom. Ligands without a lone pair of electrons or a filled π-orbital interact with 
transition metals by breaking a σ-bond. This is known as oxidative addition as 
the palladium oxidation state is raised by two. This is the result of adding two 
extra ligands bearing a formal negative charge.141  
 
As a solid, Pd(PPh3)4, 57, is an unreactive, stable complex, however, in 
solution, Pd(PPh3)4 loses two ligands affording a 14 electron species, 46, which 
is very reactive. The oxidative addition stage of the Suzuki reaction is thought to 
take place on this coordinatively unsaturated species141 (Scheme 3.6).  
 
L
Pd
L
LL
L
Pd
L
L Pd
L
18 electrons
Unreactive
16 electrons
Stable
L L
Pd
L
XAr
ArX
14 electrons
Reactive
47
48
494658
 
 
Scheme 3.6.  Ligands dissociation from the Pd(0)(PPh3)4 complex, leading to oxidative 
addition to the aryl halide.
141
 (L = PPh3)  
 
Oxidative addition of the electrophilic aryl halide, 48, to a palladium (0) complex, 
46, affords a stable palladium (II) complex, 49.130 The palladium (0) complex 
has vacant coordination sites and acts as a nucleophile towards the aryl halide, 
48. This palladium complex undergoes oxidative addition via concerted insertion 
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into the aryl halide σ-bond.143 The result is a σ-bond between the halide and the 
metal and a σ-bond between the metal and the aryl group. As the electrons in 
these bonds are shared between the metal and the newly complexed ligands, 
the palladium is reduced to a Pd(II)L2RX, 49, complex where the palladium has 
16 electrons. 
 
This is often the rate determining step in the catalytic cycle. Aryl halides with 
electron-withdrawing groups are much more reactive towards the oxidative 
addition stage than those bearing electron donating groups.130 Alternatively the 
rate-determining step can be the transmetalation stage, this is dependent on the 
reaction conditions. A larger halide results in a slower transmetalation due to 
steric hindrance.144  
 
Following oxidative addition, transmetalation of an aryl group from boron, 50, to 
palladium, 49, affords a diaryl organopalladium species, 54 (Scheme 3.5). 
Transmetalation involves the exchange of ligands between two metal centres. 
In the Suzuki reaction exchange of the halide within the palladium complex, 49, 
and the aryl group from the boronic acid occurs, 50. Organoboranes do not 
undergo cross-coupling without the addition of a base due to the low 
nucleophilicity of the borane reagents.145 Matos et al. have carried out detailed 
mechanistic studies of the role of a hydroxide base in the coupling reaction of 
trialkyl borates and aryl halides and have suggested a more detailed 
mechanism than is normally depicted, incorporating the role of base145 (Scheme 
3.7). The organoborane compounds are predominantly present as their 
hydroxyborate complexes, 59, and it is this complex which reacts with 49 to 
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form a hydroxo-bridged intermediate, 60, which facilitates the transmetalation 
through transition state 64. 
 
B
HO
HO
ArRPdL2
R Ar
PdL2
B
O
PdL2Ar
R
OH
ArX
ArPdXL2
B
HO
X
R'
49
59
63
48
46
62
60
61
H
 
 
O
RL2Ar B
H
R'
64  
Scheme 3.7. (A) Suzuki coupling reaction incorporating the role of a base; (B) 
Transmetallation transition state.  Adapted from Matos et al.
145
 
 
During the oxidative addition stage, a trans isomer of the palladium (II) square 
planar complex, 49, is formed, through the addition of the palladium (0) catalyst, 
47, to the aryl halide, 48. This isomeric form is retained through the 
transmetalation stage, 54. For the reaction to proceed to the reductive 
elimination, trans-cis isomerism is required to give 55. The mechanism for this 
stage is uncertain, however it has been suggested that isomerisation occurs by 
at least four concurrent bimolecular pathways, two of which are autocatalytic 
and the other two are solvent assisted.143  
 
(A) 
(B) 
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Finally reductive elimination of the complex, 55, eliminates the aryl partners 
regenerating the reactive palladium (0) catalyst, 47, which can re-enter the 
catalytic cycle (Scheme 3.5).146 Reductive elimination is driven by the close 
proximity of the two aryl groups in the cis coordination sites of the metal. The 
aryl-aryl bond is stronger than the coordination with the metal, so the two aryl 
groups form a new carbon-carbon bond and are released from their 
coordination through a concerted reaction. This results in concurrent reduction 
of the palladium (II) complex, 46, and reassociation of the PPh3 ligands to the 
palladium (0), 47. 
 
3.2.1.1.1    Variants on the Suzuki Coupling Reaction 
 
There are several palladium-catalysed cross coupling reactions described for 
the formation of carbon-carbon bonds, summarised in Table 3.1. All of the 
couplings follow the same mechanism as that for the Suzuki reaction, oxidative 
addition, transmetalation, trans-cis isomerisation and reductive elimination.  
 
 
 
 
 
 
 
 
 
 
Chapter 3: Synthesis 
 
82 
 
Table 3.1.  Alternative palladium-catalysed cross coupling reactions. 
 
Reaction Scheme Halide Nucleophile 
Heck147 R X R' R'
R
Base
Pd0  
sp2 sp2 
Stille148 R X R' Sn(R')3 R R'
Pd0
 
sp2, sp3 sp, sp2, sp3 
Hiyama149 R X R' Si(R')3 R R'
F- or Base
Pd0
 
sp2, sp3 sp2 
Sonogashira150  
 
R X R'
Base
Pd0, Cu+
H R' R
 
sp2, sp3 sp 
Negishi151 
R X R' Zn R R'
Pd0
X'  
sp2, sp3 sp, sp2, sp3 
 
 
3.2.1.1.2    Suzuki Reactions Carried Out in This Project    
 
Suzuki reactions have been used in this project to synthesise the biaryl 
heterocyclic ring systems by coupling 4-methoxycarbonyl boronic acid, 27, with 
either 4,6-dichloropyrimidine, 26, 2,6-dibromopyridine, 65, or 2,7-
dichloronaphthyridine, 66, yielding the respective products in high purity 
(Scheme 3.8).  4,6-Dichloropyrimidine and 2,6-dibromopyridine were available 
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commercially and the 2,7-dichloronapthyridine, 66, was synthesised following 
the method from Newkome et al.152 Each of the reactions was carried out in a 
solvent system of toluene and methanol (9:1), to allow for a high reflux 
temperature and to increase the solubility of the potassium carbonate base. As 
the palladium catalyst used (Pd(PPh3) 4) is readily oxidised with air contact, the 
reactions were carried out under an inert atmosphere and the solvents were 
thoroughly degassed with either nitrogen or argon prior to use. Degassing with 
argon resulted in higher product yield due to the greater density compared with 
nitrogen.      
 
N N
Cl Cl
O
O
NN
NBr Br
O
O
O
O
N
O
O
79 %
76 %
N N ClCl
N N
O
O
O
O
65
26
67
25
6866
70 %
  
Scheme 3.8.   Suzuki reactions of symmetrical bis-4-methoxycarbonylheterocycles. 
Reagents and Conditions: 27, K2CO3, Pd(PPh3)4, PhMe:MeOH (9:1), ∆, 48 h.  
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3.2.2 STAGE 2 – HYDROLYSIS OF THE METHYL ESTERS 
 
Free acids of the symmetrical diesters, 25, 67 and 68, were prepared by basic 
hydrolysis of the methyl esters. The compounds were heated under reflux in  
2 M sodium hydroxide solution and then acidified with 4 M hydrochloric acid, 
affording products in up to 100 % yields (Scheme 3.9). 
 
HO
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NN
OH
O
HO
O
N
OH
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N N
OH
O
HO
O
67
25
69
24
70
68
100 %
95 %
99 %
 
 
Scheme 3.9.   Basic hydrolysis of symmetrical bis-4-methoxycarbonylheterocycles. 
Reagents and Conditions: NaOH (2 M), ∆, 24 h, then HCl (4 M).  
 
3.2.3    STAGE 3 – FORMATION OF AMIDE BONDS 
 
Amide condensations are equilibrium reactions. Direct reaction of amines and 
carboxylic acids results in an acid base reaction, leading to the formation of 
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stable salts (Scheme 3.10) which reduces the possibility of nucleophillic attack 
of the amine, although the reaction can proceed at very high temperatures.153  
 
RCOOH R'NH2 R'NH3 RCOO RCONHR' H2O
 
 
Scheme 3.10.  Reaction of carboxylic acids with amines 
 
Therefore, activation of the carboxylic acid is required, which converts the 
carboxylic acid into a reactive acylating agent, bearing a good leaving group, 
which can undergo a nucleophilic acylation reaction with the amine affording an 
amide. Carboxylic acids can be activated as acyl halides, acyl azides, 
anhydrides and esters. Activated esters can be formed through the reaction with 
alcohols and phenols containing an electron-withdrawing substituent, leading to 
an increased electrophilicity at the carbonyl centre. Examples of alcohols and 
phenols used to form activated esters are shown in Figure 3.3.   
 
N
N
N
OH
HOBt
HO
NO2
p-nitrophenol
F
F
F
F
F
HO
pentaf luorophenol  
 
Figure 3.2. Alcohols and phenols used in the synthesis of activated esters. 
 
Catalysts incorporating an electron withdrawing alcohol, can generate activated 
esters in situ. Benzotriazole-1-yl-oxytrispyrrolidinophosphoniumhexafluro- 
phosphate (PyBOP) contains HOBt and can activate a carboxylic acid providing 
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a good leaving group for nucleophillic acylating reactions with amines (Scheme 
3.11).  
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Scheme 3.11.  PyBOP mediated coupling.
154
 
 
PyBOP coupling is used widely for solid phase peptide synthesis and has been 
extensively used for the synthesis of compounds similar to the target 
compounds in high yields.62, 63 For reactions carried out in this project, the 
carboxylic acid was converted to the respective carboxylate anion with 
triethylamine prior to coupling, which also increased solubility in the dry DCM 
solvent. Completion of the reaction resulted in precipitation of the amides which 
were collected by filtration. 
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3.3 SYNTHESIS OF NON-SYMMETRICAL COMPOUNDS 
 
Non-symmetrical compounds can be produced using the routes shown in 
Scheme 3.2. Many of these routes have been explored with varying success. 
Prior to synthesis, the Boc-protected attachment linker 71 was synthesised. 
 
3.3.1  SYNTHESIS OF THE ATTACHMENT LINKER, 71 
 
Although, 1,3-diaminopropane, 5, provides an attractive linker for joining the hit 
compounds to biotin or a solid support, as it is a bifunctional compound, 
reactions could lead to the formation of polymers. Therefore, one of the amine 
groups was protected before use in synthesis. 
 
A Boc group provides good protecting group for one of the amines, as it is 
stable in the basic conditions required for each step of the established synthesis 
(Scheme 3.1), and can be easily removed with weak acid. N-Boc-1,3-
diaminopropane, 71, has been synthesised previously in very high yields (93 %) 
from di-tert-butyldicarbonate, 72, and the unprotected diamine, 5, in THF.155 
This synthesis has been repeated and produced high yields of product with only 
minor diprotected impurities, which were easily removed by distillation (160 °C, 
0.1 mm Hg). 
 
The Boc protecting group is introduced by reaction of the amine with di-tert-
butyl dicarbonate by a nucleophilic acyl substitution reaction and later removed 
by acidolysis (Scheme 3.12). 
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Scheme 3.12. Reaction mechanism of (A) Boc protection of a primary amine; (B) removal of a 
Boc protecting group using acid. 
 
3.3.2  ROUTE A – BREAKING SYMMETRY DURING AMIDE FORMATION 
 
Diacid 24 was synthesised using the established synthesis (Section, 3.2.1.1.2 
and 3.2.2). To break the symmetry during amide formation, a „one-pot‟ reaction 
approach was attempted to produce 22. One equivalent of PyBOP, Et3N and N-
Boc-1,3-diaminopropane, 71, were added and left to stir for 18 h. This was 
followed by the addition a further equivalent of PyBOP and Et3N with 1-(3-
aminopropyl)imidazole, 73 (Scheme 3.13). It was speculated that amide 
formation to one of the carboxylic acid groups would affect the pKa of the 
second acid due to the conjugation between the functional groups. Therefore, 
making initial reaction on another diacid molecule, 24 more favourable than a 
second reaction on a mono-amide 74.      
 
(A) 
(B) 
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Scheme 3.13.  One-pot synthesis of non-symmetrical amides. 
Reagents and Conditions: PyBOP, 1 eq. Et3N, dry DCM, RT, 18 h.  
 
The Boc protected side chain was added first as higher selectivity in coupling 
was observed. NMR data for the final product showed signs of the non-
symmetrical compound, 22, but the mass spectrum demonstrated that both 
possible dimers, 75 and 76, and the non-symmetrical product, 22, were present.  
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Attempts to separate the three compounds were made using flash 
chromatography, but the Rf values were too similar for separation. The solubility 
of all three compounds in various solvents was investigated, in the hope that 
this could lead to separation. However, all three compounds exhibited similar 
solubility in a wide range of solvents. Final attempts to separate the compounds 
involved the use of reverse phase HPLC, using a mobile phase of acetonitrile 
and water. The solute gradient was adjusted to try to achieve maximum 
separation, however, all attempts to separate the compounds failed.  
 
The unsuccessful separation of the non-symmetrical compound, 22, from the 
one-pot reaction mixture (Scheme 3.13) led to attempts to isolate the 4-(4-
carboxyphenyl)-6-(4-[3-N-Boc-aminopropyl]carboxyamidophenyl) pyrimidine, 
74, prior to a second amide coupling with a different side chain, 73 (Scheme 
3.14). Reaction was carried out using an excess of diacid, 24 (10 eq.). 
Unreacted starting material was recovered by trituration with hot methanol, 
leaving the product in solution. 
  
The preparation appeared successful on observation of the crude 1H NMR 
spectrum. Separation of the crude reaction mixture using flash chromatography, 
resulted in isolation of the side products HOBt, tris-(1-pyrrolidinyl)-phosphine 
oxide, Et3N and the disubstituted product, 75. However, the mono-substituted 
product, 74, failed to be collected in pure form due to very poor yields. However, 
mass spectra and 1H NMR indicated the presence of the desired compound.  
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Scheme 3.14.  Synthesis of 4-(4-carboxyphenyl)-6-(4-[3-N-Boc-aminopropyl]carboxyamido 
phenyl)pyrimidine, 74. 
Reagents and Conditions: 71, Et3N, PyBOP, dry DCM, RT, 18 h.  
 
 
3.3.3 ROUTE B – BREAKING SYMMETRY DURING ESTER HYDROLYSIS
  
Controlled partial hydrolysis of dimethyl esters, 25, 67, 68 was attempted using 
different bases and solvent systems. It was predicted that the use of a weak 
base would result in hydrolysis of one of the methyl esters. 
 
Partial hydrolysis of 2,6-bis-(4-methoxycarbonylphenyl) pyridine, 67,  was tried 
using the different bases and reaction conditions summarised in Table 3.2. The 
reactions were monitored by thin layer chromatography. 
 
The monohydrolysis of 2,6-bis-(4-methoxycarbonylphenyl) pyridine, 67, 
appeared to successful, using either 3 eq. of potassium carbonate as a base or 
30 eq. of sodium hydroxide. The 1H NMR spectrum (Figure 3.4) showed a 
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methyl peak of three hydrogens and non-equivalence of the two aromatic 
phenyl rings, which are seen a multiplet in the diester, 67 and two doublets in 
the diacid, 69. However, mass spectra showed these compounds to be mixtures 
of the starting material, 67, and the diacid, 69, in equimolar quantities. 
  
Table 3.2.  Reagents and conditions for the attempted partial hydrolysis of 2,6-bis-(4- 
methoxycarbonylphenyl) pyridine, 67. 
 
Base Equivalents Solvent Temperature Time Result 
NaOH 1.5 H2O 50°C 18 h 
Total recovery 
of starting 
material 
NaOH 30 
H2O:MeOH  
(9:1) 
50°C 24 h 
Mixture of the 
diacid and 
diester (1:1) 
NaOH 5 
H2O:MeOH 
(50:50) 
RT 18 h 
Total recovery 
of starting 
material 
KOH 4 
H2O:MeOH 
(9:1) 
50°C 24 h Diacid 
K2CO3 3 
H2O:MeOH 
(50:50) 
40°C 18 h 
Mixture of the 
diacid and 
diester (1:1) 
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Figure 3.3. 
1
H NMR spectrum in DMSO of the hydrolysis of 67 using K2CO3 as a base. 
 
 
3.3.4 ROUTE C AND ROUTE D – BREAKING SYMMETRY DURING 
FORMATION OF THE BIARYLHETEROCYLIC RING SYSTEM 
 
The previous two routes to synthesis of non-symmetrical compounds 
encountered problems. Therefore, breaking the symmetry during the formation 
of the heterocyclic ring system was explored. This route involved coupling 
boronic acid 27 with one equivalent of dihalide 26 followed by hydrolysis of the 
methyl ester. Two routes are possible following the hydrolysis, attachment of 
the first side chain, amide 73, prior to a second Suzuki coupling (Route C) or 
the second Suzuki coupling of 27 to monoacid 31 immediately (Route D).  
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3.3.4.1 Sequential Suzuki Coupling 
 
Routes C and D for the synthesis of target compounds 6-13, required sequential 
Suzuki couplings to be carried out, using heterocycles bearing more than one 
halide atom, to afford non-symmetrical products.   
 
Following the established conditions described for symmetrical compounds, 25, 
67 and 68 (Section 3.2.1.1.2) using one equivalent of 4-methoxyphenyl boronic 
acid, 27, with dichloropyrimidine was unsuccessful.  The reactions afforded 
mixtures of the starting material, monosubstituted, 32, and the disubstituted, 25, 
products (Scheme 3.15). The solvent volume and temperature were reduced in 
order to force precipitation of the product following the first coupling (Table 3.3). 
However, these conditions also yielded mixtures of products. 
 
O
O
NN
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O
N
O
O
N N
O
O
O
O
65
26
67
25
68
66
O
O
NN
Cl
O
O
N Br
N N Cl
O
O
78
77
32
2:3
5:7
2:3
Scheme 3.15.   Suzuki reactions of symmetrical bis-4-methoxycarbonylheterocycles. 
Reagents and Conditions: 27, K2CO3, Pd(PPh3)4, PhMe:MeOH (9:1), ∆, 48 h. 
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 Table 3.3.  Conditions for attempted sequential Suzuki coupling of 4,6-dichloropyrimidine, 
26, and 4-methoxycarbonylphenyl boronic acid, 27. 
a
Established conditions. 
 
Solvent 
Volume 
Temperature Result 
a200 ml a120 °C 
Mixture of mono and disubstituted 
ester (2:3) 
150 ml 90 °C 
Mixture of mono and disubstituted 
ester (2:3) 
100 ml 90 °C 
Mixture of mono and disubstituted 
ester (1:1) 
75 ml 90 °C 
Mixture of mono and disubstituted 
ester (8:7) 
 
 
The selectivity of arylation of 2,4,6-trichloropyrimidine, 38, via Suzuki coupling 
reactions has been reported by Schomaker et al.156 Substitution with one, two 
or three equivalents of an arylboronic acid led to the production of the mono-, 
di- and tri-substituted products respectively in very high yields (Scheme 3.16). 
This is rationalised as the consequence of regio-selectivity of the substrate 
coordinating with the catalyst and indicates an apparent order of reactivity, 
specifically position 4 > position 6 > position 2.  
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Scheme 3.16.  Sequential coupling of biarylpyrimidines.
156
   
Reagents and Conditions: PhB(OH)2, Na2CO3 (aq), Pd(OAc)2, PPh3, glyme, ∆, 18-24 h. 
 
 
The reaction conditions vary from those described in Section 3.2.1.1.2 for the 
disubstitution of the heterocyclic dihalides, in respect of the base (aqueous 
Na2CO3 instead of K2CO3), solvent (glyme instead of PhMe:MeOH) and catalyst 
(Pd(OAc)2 and PPh3 instead of Pd(PPh3)4).  The same group also investigated 
the coupling of substituted phenylboronic acids and trichloropyrimidines. The 
reactions proved very successful, selectively providing high yields of mono-, di- 
and tri-substituted products.157  
 
Synthesis of substituted non-symmetrical 4,6-dichloropyrimidines has been 
investigated by Zhou et al.158 The procedure involves nucleophilic displacement 
of one of the chlorine atoms for a methoxy group, allowing conventional Suzuki 
oxdative addition to the remaining carbon-chlorine bond of the heterocycle. The 
methoxy group can then be converted back to the chloride by the treatment with 
HBr-AcOH and POCl3. A second Suzuki coupling can introduce a different 
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substituted phenyl boronic acid yielding non-symmetrical compounds. (Scheme 
3.17).  
 
N N
Cl Cl
N N
Cl OMe
N N
OMe
N N
O
MeO
MeO
N N
Cl
MeO
N N
MeO
(i) (ii)
(v) (iv)
(iii)
 
 
Scheme 3.17. Synthesis of non-symmetrical 4,6-diaryl pyrimidines.
158
  
 
Reagents and Conditions: (i) 1 eq. NaOMe (25% w/w in MeOH), MeOH, RT, 10 min, 95%; (ii) 
1.4 eq. MeOC6H4B(OH)2, 0.1 eq. Pd(PPh3)4, 2 eq. Na2CO3, PhMe, 90 °C, 12 h; (iii) HBr-AcOH 
(1:3), 80 °C, then satd NaHCO3; (iv) POCl3, 30 min, 100 °C, then satd NaHCO3, 90%; (v) 1.4 eq. 
PhB(OH)2, 0.1 eq. Pd(PPh3)4, 2 eq. Na2CO3, PhMe, 90 °C, 12 h, 80%.   
 
Reactions were carried out following Delia‟s method as a one step synthesis 
was more attractive than Zhou‟s multi-step process. 4,6-Dichloropyrimidine, 26, 
and one equivalent of 4-methoxycarbonylphenyl boronic acid, 27, were reacted 
following the conditions defined in Scheme 3.16. This provided relatively high 
yields of product 32 (Scheme 3.18). 
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Scheme 3.18.  Selective arylation of dichloropyrimidine 
Reagents and Conditions: 27, aq. Na2CO3, Pd(OAc)2, PPh3, glyme, ∆, 18-24 h. 
 
Subsequent ester hydrolysis of the non-symmetrical compound 32 to afford the 
carboxylic acid 31, prior to a second Suzuki coupling with 27, was carried out 
using the reaction conditions previously described (Section 3.2.2). Mass spectra 
results revealed substitution of the chloride along with the hydrolysis of the 
methyl esters, 79 (Scheme 3.19). 
 
N N
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HN N
O
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7932
95 %
 
 
Scheme 3.19.  Hydrolysis of non-symmetrical ester 32. 
Reagents and Conditions: NaOH (2 M), ∆, 18 h, then HCl (4 M). 
 
 
Sequential Suzuki coupling reactions were performed using 4-carboxyphenyl 
boronic acid, 80, and 4,6-dichloropyrimidine, 26, to synthesise the carboxylic 
acid 31 directly. The reactions were unsuccessful possibly due to the boronic 
acid insolubility in the glyme:water solvent system. 
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To overcome the solubility problems, the couplings were carried out using 4-
carboxyphenyl boronic acid pinacol ester, 81, which is soluble in the solvent 
system required for sequential couplings. The desired mono- and di-
phenylcarboxylic compounds were recovered; however they were in equimolar 
quantities suggesting there was no selectivity.  
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Scheme 3.20.  Attempted synthesis of 4-chloro-6-(4-carboxyphenyl) pyrimidine, 31. 
Reagents and Conditions: aq. Na2CO3, Pd(OAc)2, PPh3, glyme, ∆, 18-24 h. 
 
Gong et al.159 have synthesised 4-chloro-6-(4-carboxyphenyl) pyrimidine, 31, 
from 4,6-dichloropyrimidine, 26, and 4-carboxyphenyl boronic acid, 80, via 
Suzuki couplings. The synthesis uses Pd(PPh3)4 as a catalyst, Na2CO3 as a 
base and a solvent system of 50 % aqueous acetonitrile (Scheme 3.21).159 
Reactions carried out following this method showed increased selectivity with 
only minor amounts of the dicarboxylic acid compound. Purification was 
achieved by washing the crude compound through a plug of silica with a 10 % 
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methanol in chloroform solution. The same method was used for the synthesis 
of 2-bromo-6-(4-carboxyphenyl) pyridine, 82.       
 
N N
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N N
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HO O
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NBr Br N Br
O
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31
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65
26
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Scheme 3.21. Synthesis of 4-chloro-6-(4-carboxyphenyl) pyrimidine, 31, and 2-bromo-6-(4-
carboxyphenyl) pyridine, 82. 
Reagents and Conditions: Na2CO3 (0.4M):MeCN (1:1), 0.1 eq. Pd(PPh3)4, 90 °C, Ar, 24 h.  
 
3.3.4.2 Route C 
 
Route C (Scheme 3.22) involved the addition of the side chain prior to a second 
Suzuki coupling. Attempts at amide formation were made using 31 and 73 
following the established PyBOP coupling method (Section 3.2.4). A crude 1H 
NMR spectrum of the reaction mixture showed only starting material. The 
reaction was left for 48 h, but coupling still did not occur.  As a second 
approach, 4-chloro-6-(4-methoxycarbonyl)pyrimidine 32 was heated in the 
presence of excess side chain, 73. The excess side chain was removed by 
evaporation at reduced pressure, however, 1H NMR spectroscopy revealed 
large quantities of 73 which could not be separated by flash chromatography or 
recrystallisation.  
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Scheme 3.22.  Attempted synthesis of 4-chloro-(4-[3-imidazol-1-ylpropyl]amidophenyl) 
pyrimidine, 29. 
Reagents and Conditions: (i) 73, PyBOP, Et3N, dry DCM, RT, 48 h; (ii) 73, ∆ 48 h.  
 
3.3.4.3 Route D 
 
Following synthesis of carboxylic acids 31 and 82, a second Suzuki coupling 
was performed, using one equivalent of 4-methoxyphenyl boronic acid, 27. The 
conditions described by Gong et al could not be followed as this would result in 
hydrolysis of the methyl esters. Therefore the reagents and conditions 
previously used for the symmetrical compounds62, 63 were used (Scheme 3.23). 
Reactions produced high yields of products, when left for long periods of time 
(72 h) and were degassed for one hour prior to addition of the catalyst. 
However, when the reactions were left for 18 hours and only degassed for short 
periods of time, large amounts of starting material remained. This is possibly 
due to the poor solubility of the carboxylic acid compounds within the solvent 
system. Solubility was improved by increasing the proportion of methanol within 
the solvent system to 20 % compared with toluene. Starting material which did 
remain was removed by trituration with hot methanol.   
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Scheme 3.23.   Synthesis of non-symmetrical biarylheterocycles 
Reagents and Conditions: 72, K2CO3, Pd(PPh3)4, PhMe:MeOH (8:2), ∆, 72 h. 
 
3.3.4.4 Acylation with Imidazole Side Chains 
 
Side chains were coupled to the non-symmetrical compounds 30 and 83, using 
the reaction conditions established in the synthesis of the hit compounds, 1, 2 
and 3. Reactions proved successful yielding pure product (Scheme 3.24). 
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Scheme 3.24. PyBop Couplings of non-symmetrical diarylheterocycles.    
Reagents and Conditions: 73, Et3N, PyBOP, dry DCM, RT, 18 h.  
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Hydrolysis of the methyl esters, following the conditions outlined in Section 
3.2.2, of compounds 28 and 84, led to the formation of the carboxylic acids, but 
the amide was also hydrolysed (Scheme 3.25). Using milder conditions of 10 
equivalents of NaOH at 50 °C for 2 h (compared with 2 M NaOH, ∆, 24 h) led to 
hydrolysis of the ester while retaining the amide at the pyridine compound 84, 
however, the pyrimidine compound 28, gave a mixture of products.  
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Scheme 3.25.  Hydrolysis of esters bearing amides. 
Reagents and Conditions: (i) NaOH (2M), ∆, 18 h; (ii) NaOH (10 eq), 50 °C, 2 h. 
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Attempts to couple the Boc protected side chain, 71, to 85 resulted in large 
quantities of starting material remaining. 
 
 
3.3.5 CONCLUSIONS 
 
Routes to non-symmetrical compounds displayed several difficulties, although 
Route D (Scheme 3.2) provided the most attractive way to synthesis. Scheme 
3.26 outlines the progress made during the synthesis.  
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3.4 SYNTHESIS OF NON-SYMMETRICAL BIOTINYLATED 
COMPOUNDS 
 
As discussed in Chapter 2, biotinylated compounds offer an attractive possibility 
for attachment to streptavidin activated sepharose beads. Due to the problems 
experienced with synthesising non-symmetrical compounds 22 and 86 bearing 
linker 5 following Route D (Scheme 3.2), it was speculated that synthesis of a 
biotinylated compound would prove more straight foreward.   
 
Biotin, 87 contains a carboxylic acid functional group and was attached to the 
Boc-protected linker, 71, described in Section 3.3.1, by PyBOP coupling 
(Scheme 3.27). The coupling produced high yields of N-Boc-1-amino-3-
biotinylamidopropane, 88, which could be easily deprotected using 
concentrated HBr in ethanol. Excess HBr was evaporated under reduced 
pressure yielding the ammonium hydrobromide salt, 89.  
H
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Scheme 3.27. Synthesis of biotinylated linker 89. 
Reagents and Conditions: (i) PyBOP, Et3N, DMF, RT, 18 h; (ii) HBr, EtOH. 
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The biotin side chain, 89, was directly coupled to 2-(4-methoxyphenyl)-6-(4-
carboxyphenyl) pyridine, 83, and 4-(4-methoxyphenyl)-6-(4-carboxyphenyl) 
pyrimidine, 30. The solvent used for these couplings was DMF in which all the 
starting materials were soluble, allowing shorter reaction times. Subsequent 
hydrolysis of compound 90 and 91, gave the corresponding carboxylic acid 92 
for the pyridine compound while the amide remained intact, however the 
pyrimidine compound led to a mixture of diacid 24 and the mono-amide 93 
(Scheme 3.28).   
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Scheme 3.28. Synthesis of non-symmetrical biotinylated compounds. 
Reagents and Conditions: (i) 89, PyBOP, Et3N, DMF, RT, 18 h; (ii) , NaOH (10 eq), 50 °C, 2 h. 
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1-(3-Aminopropyl)imidazole, 73, or 1-(3-aminopropyl)pyrrolidine, 94, were 
coupled to the non-symmetrical pyridine acid, 92, to give the final affinity probes 
16 and 17 (Scheme 3.29).  
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Scheme 3.29. Synthesis of non-symmetrical biotinylated affinity probes. 
Reagents and Conditions: PyBOP, Et3N, DMF, RT, 18 h. 
 
3.4.1  CONCLUSIONS 
 
Synthesis of biotinylated non-symmetrical compounds yielded two final 
products, 16 and 17, which could be used as affinity probes for chemical 
proteomics to identify the binding proteins. 
 
3.5     ATTACHMENT OF A LINKER TO THE PYRIMIDINE RING 
 
An alternative approach to bespoke matrices for use in affinity chromatography 
involves attachment of the linker at the pyrimidine-2 position of hit compound 1. 
Incorporation of linker 5, could be achieved prior to any of the stages of the 
established synthesis outlined in Scheme 3.1. A retrosynthetic analysis of 
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compound 33, is presented in Scheme 3.3, showing the different routes 
available (Routes E & F). 
 
3.5.1 FORMATION OF THE TRIARYL HETEROCYCLIC RING SYSTEM 
 
Sequential Suzuki coupling reactions following the Delia et al. method described 
in Section 3.3.4.1 successfully afforded product in high yields. The product 
precipitated from the glyme-water solvent system on completion of the reaction 
allowing straightforward purification by recrystallisation from ethanol. 
 
N N
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Cl Cl
Cl
37
38
79 %
 
 
Scheme 3.30.  Selective arylation of trichloropyrimidine 
Reagents and Conditions: 27, aq. Na2CO3, Pd(OAc)2, PPh3, glyme, ∆, 18-24 h. 
 
Attempted hydrolysis of 37 resulted in the substitution of the 2-chloro group of 
the compound along with the hydrolysis of the methyl esters as seen during the 
synthesis of non-symmetrical compound 79, Scheme 3.19 (Scheme 3.31). 
Therefore, attempts to attach the linker after the Suzuki coupling prior to 
hydrolysis of the methyl esters were made. 
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Scheme 3.31.  Hydrolysis of 37.  
Reagents and Conditions: NaOH (2 M), ∆, 18 h. 
 
3.5.2 ATTACHMENT OF THE LINKER  
 
Copper-catalysed coupling reactions of aryl halides and primary amines can 
occur using L-proline as a promoter in Ullmann type coupling reactions.160 The 
mechanism of the Ullmann reactions has been extensively studied and many 
mechanisms have been proposed. One of these includes the oxidative addition 
and reductive elimination cycle seen with palladium catalysed cross-
couplings.161 However, this mechanism seems unlikely as copper (III) 
complexes are rarely seen. Research by Paine et al proved that the catalytic 
species is the cuprous ion.162  
 
Two different reaction mechanisms have been proposed by Zhang and co-
workers.160 (Scheme 3.32). The first (Scheme 3.32A) suggests that as Cu (I) 
complexes with the amino acid promoter, 96, it becomes more reactive towards 
oxidative addition and stabilises the intermediate 97. This catalytic cycle can 
explain the order of I > Br > Cl with respect to the ease of halogen displacement 
and the increased reactivity of electron deficient aryl halides.  
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Scheme 3.32.  Two proposed mechanisms for the copper-catalysed coupling reactions of aryl 
halides and primary amines.
160
  
 
The second catalytic scheme (Scheme 3.32B) suggests that the Cu(I) makes 
the aromatic ring of the π complex 99 more electron deficient which could lead 
(A) 
(B) 
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to nucleophilic attack of the arylamines. This scheme could explain the 
substituent effect of the aryl halides.   
 
The reaction provided an attractive route for attachment of the linker, 71, to the 
hit compounds. The reaction was piloted using compound 37 and benzylamine, 
102. The reaction produced pure product, 103, after extraction and 
recrystallisation in relatively good yields (64 %). Due to the success of the 
reaction it was carried out with N-Boc-1,3-diaminopropane, 71, which also 
produced pure compound, 104, in a yield of 63 %. 
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Scheme 3.33.  Attachment of the linker to a pyrimidine ring. 
Reagents and Conditions: K2CO3, CuI, L-Pro, DMSO, 80 °C, 12 h.  
 
Compounds 103 and 104 were hydrolysed as described in Section 3.2.2. The 
benzylamino compound, 103, was successfully hydrolysed, precipitating out of 
solution affording pure product in 75 % yield. 1H NMR spectral data of the ester 
hydrolysis of compound 104 indicated that hydrolysis was successful, but the 
Boc-group was lost during the extraction process. Slow neutralisation of the 
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product with dilute acetic acid still led to premature removal of the Boc group, 
106.  
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Scheme 3.34.  Hydrolysis of diesters 103 and 104. 
Reagents and Conditions: NaOH (2M), ∆, 24 h, then HCl (4 M). 
 
Ester hydrolysis of compound 104 was repeated using 3 equivalents of sodium 
hydroxide in water. The water was evaporated under reduced pressure to leave 
the sodium salt, 107. Peptide coupling of 107 with 73 was carried out following 
the method outlined in Scheme 3.24. However, the couplings did not proceed, 
leaving large quantities of starting material, even when left for long periods of 
time. The hydrolysis was repeated using potassium hydroxide as a base for 
isolation of the potassium salt, however, the same difficulties occurred during 
coupling.  
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Scheme 3.35.  Attempted synthesis of 33. 
Reagents and Conditions: (i) NaOH (2M), ∆, 24 h; (ii) 73, PyBOP, Et3N, DMF, RT, 48 h. 
 
Sequential Suzuki coupling reactions were performed using 4-carboxyphenyl 
boronic acid pinacol ester, 81, and 2,4,6-trichloropyrimidine, 38, to synthesise 
the dicarboxylic acid, 36, directly prior to attachment of the linker (Scheme 
3.36). The reactions afforded the product in high yields (72 %). Attachment of 
the linker was attempted using the conditions described in Scheme 3.33, but the 
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product 34 could not be isolated from the DMSO solvent. The reaction was 
attempted using DMF, but did not proceed, leaving large quantities of starting 
material. 
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Scheme 3.36.  Attempted synthesis of 34. 
Reagents and Conditions: (i) 81, aq. Na2CO3, Pd(OAc)2, PPh3, glyme, ∆, 18-24 h; (ii) 71, 
K2CO3, CuI, L-Pro, DMSO, 80 °C, 12 h.   
 
 
Following Route F attempts to couple 36 to 73 were made. Observation of the 
1H NMR spectrum revealed peaks representing the starting materials, 
suggesting that coupling had not occured. 
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N N
H
N
O O
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N
36
(i)
N N
HO
O O
OH
Cl
35
Cl
N
N
N
N
 
 
Scheme 3.37.  Attempted synthesis of 35. 
Reagents and Conditions: (i) 73, PyBOP, Et3N, DMF, RT, 48 h. 
 
3.5.3    CONCLUSION 
 
Routes to synthesis of compounds with the linker attached at the pyrimidine-2 
position have progressed. However, attachment of linker 5 using the Ullman 
reaction160 has led to problems during separation due to the DMSO solvent 
required. Using a different catalyst to couple the linker may lead to the formation 
of compound 33. Scheme 3.37 summarises the reactions carried out during the 
attempted synthesis of compounds with the linker attached at the pyrimidine-2 
position.  
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3.6     CONCLUSION 
 
Several routes of synthesis have been explored for the development of affinity 
probes for use in chemical proteomics. The two compounds taken forward for 
use in affinity chromatography were biotinylated compounds 16 and 17. 
Compound 16 is predicted to be active against the sensitive human ovarian 
carcinoma A2780 cell line but not against the human colon adenocarcinoma 
HT29. Compound 17 is predicted to be inactive against both of the above cell 
lines. 
 
N
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N
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N N
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N
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N
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17
 
 
Figure 3.4. Affinity probes ready for chemical proteomics. 
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4.1 INTRODUCTION 
 
The two affinity probes, 16 and 17, that progressed to use in chemical 
proteomics are shown in Figure 4.1. 
 
N
H
N
O
H
N
O
H
N N
O
S
N
NHHN
O
N
H
N
O
H
N
O
H
N N
O
S
NHHN
O
16
17
 
 
Figure 4.1. Affinity probes used for chemical proteomics.  
 
Prior to the proteomics stage, the in vitro chemosensitivity of both affinity probes 
was measured to ensure that the distinction between the „active‟,  16, and 
„inactive‟, 17, analogues was retained.  
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4.2 IN VITRO CHEMOSENSITIVITY 
 
The biotinylated compounds 16 and 17, along with controls of biotin and hit 
compound 2, were tested against the sensitive A2780 human ovarian 
adenocarcinoma cell line and the insensitive HT29 colorectal adenocarcinoma 
cell line.  The chemosensitivity data are presented in Table 4.1.  
 
Table 4.1. IC50 values for compounds 2, 4, 16 and 17 against two cell lines.  
 
Compound 
IC50 (μM) 
A2780 HT29 
N
H
N
O
H
N
O
N N N
2
N
 
0.006  0.001 35.0  0.1 
N
H
N
O
N
4
N
 
2.6 0.2 47.8  0.1 
N
H
N
O
H
N
O
H
N N N
16Biotin
 
6.25  0.09 >100  
N
H
N
O
H
N
O
H
N N
17Biotin
 
35.0  0.2 6.25 0.16 
OH
O
87
S
NHHN
O
 
>100 >100 
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Compound 16 showed a thousand-fold decrease in activity compared with the 
corresponding hit compound 2. However, compared with the half compound 4 
there was only a 2.4 fold decrease, suggesting that the full structure, including 
both imidazole rings, is required for potent activity. Biotin possesses no 
cytotoxicity and as such ought not to affect the activity observed for biotinylated 
compounds. The 2.4 fold decrease in activity between the half compound 4 and 
compound 16 could be explained by the ability of biotinylated compounds to 
enter the cells. The activity observed against the A2780 cell line was not seen 
with the insensitive HT29 cell line (IC50 > 100 µM), supporting the NCI 
COMPARE data (Figure 1.10).  
 
Biotinylated compound 17 showed a 5.6 fold increase in IC50 compared with its 
imidazole equivalent 16, supporting the SAR data that a saturated heterocyclic 
ring (such as pyrrolidine) is less active than an unsaturated ring.62 Surprisingly, 
the control probe 17 showed relatively potent activity with the „insensitive‟ cell 
line HT29, which conflicts with the previous SAR data. It could be rationalised 
that the control compound has a different biological target leading to a different 
mechanism of action, or that biotinylation has resulted in a more potent 
compound still binding the same target.    
 
Compound 16 has shown the expected distinction in chemosensitivity against 
the two cell lines, activity against the sensitive A2780 cell line (IC50 = 6.25 µM) 
and no activity against the insensitive HT29 cell line (IC50 > 100 µM). Therefore 
the compound is suitable for use as an affinity probe in chemical proteomic 
analysis. Control compound 17 has shown unexpected cytotoxicity against the 
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insensitive cell line HT29 (IC50 = 6.25 µM). However, potency is decreased, as 
expected, against the sensitive A2780 cell line when compared with compound 
16. 
 
 4.3  PROTEOMICS 
 
The compound-centric approach to chemical proteomics, often referred to as 
classical affinity chromatography118 (Section 1.3.3), involves „fishing‟ for a 
cellular target protein from an entire cell lysate or tissue extract.163 Affinity 
capture with probes 16 and 17, utilises the strong affinity of biotin for 
streptavidin. This allows for a simple isolation of the biological target following 
incubation of the probes with cell lysates. 
   
Prior to affinity capture, large numbers of cells (1.5 x 107 – 6.1 x 108) were 
cultured to ensure that low abundance proteins were represented at detectable 
levels in the cell lysates. Cells were sub-cultured regularly to ensure they were 
kept in the exponential growth phase and were trypsinised, pelleted and stored 
at -80 °C until there was sufficient for affinity chromatography. 
 
As the abundance of the biological target and its affinity for the biotinylated 
compound 16 were unknown, four different methods were explored to capture 
binding proteins, defined in Figure 4.2. 
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Figure 4.2. Affinity chromatography procedure. Method 1 (red), Method 2 (blue), Method 3 
(green) and Method 4 (purple).  
 
 
Cell Pellets washed with PBS (3 x 1 ml) & Resuspended in Tris-
HCl with 4% CHAPS & PIC 
(Resuspended in PBS with 1% Triton X 100 & PIC and 2
nd
 
solubilisation in PBS with 1% C7BzO , 4% CHAPS and PIC) 
 
Cell pellets sonicated & DNA extruded 
 
Cell lysates incubated with affinity 
probes @ RT 
(2 h, 20 µM & 24 h, 100 µM) 
Streptavidin beads incubated with 
affinity probes  
(2 h, 100 µM, RT & 4 h, 1 mM, 4 °C ) 
 
Method 1 & Method 2 Method 3 & Method 4 
 
Cell lysates desalted with a NAP-5 
column & incubated with streptavidin 
beads @ RT for 4 h 
 
Cell lysate was incubated with 
streptavidin-affinity probe complex  
(24 h, RT & 24 h, 4 °C) 
 
Unbound proteins washed away with PBS and bound proteins 
eluted with 8M Urea in ambic (25 mM) 
(Bound proteins eluted with 2 mM 2 in PBS) 
 
SDS-PAGE analysis, MS and MS/MS following trypsin digestion of 
the elutions and streptavidin beads 
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4.3.1 METHOD 1 
 
Cells lysis can be achieved by mechanical or chemical techniques. The 
mechanical method sonication was chosen as it is less likely to result in 
denaturation of cellular proteins. The cells were suspended in Tris-HCl buffer 
containing 4 % 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) detergent (to ensure solubilisation of membrane proteins) and 
complete protease inhibitor cocktail (PIC, to prevent proteolysis) prior to 
sonication. The DNA present in the samples was extruded using a fine needle.  
 
The protein solution was split in two and one of the affinity probes (16 or 17,  
20 µM) was added to each batch and incubated for 2 h. Samples were then 
desalted using a NAP-5 column to remove any affinity probe not bound to a 
protein (therefore purifying the probe-protein complex) and to change the buffer 
to PBS. The protein-probe samples were incubated with streptavidin beads for  
4 h at room temperature. Unbound proteins were removed, by washing with 
PBS and bound proteins eluted with 8 M urea in ammonium bicarbonate  
(25 mM). 
 
The urea elutants and streptavidin beads from each experiment were analysed 
by SDS-PAGE (Figure 4.3). Visualisation of the proteins using an instant blue 
stain revealed only the presence of a band at ~ 13 kDa in lanes 5 and 9, 
corresponding to a streptavidin monomer from the streptavidin beads. The urea 
elutions did not contain any proteins. Silver staining of the gel confirmed the 
Chapter 4: Biological Evaluation and Proteomics 
125 
 
presence of streptavidin, however, it still did not show any further bands which 
would suggest the presence of a bound target protein.  
 
   1      2      3      4      5      6      7      8      9      10 
 
 
 
 
Figure 4.3.  SDS-PAGE Analysis. (A) Stained with Instant Blue stain; (B) Silver Stained. 
Lane 1, Molecular weight marker; Lane 2 and Lane 6, SDS buffer; Lane 3, total protein content 
prior to incubation with affinity probes; Lane 4, 16 unbound proteins; Lane 5, 16 streptavidin 
beads; Lane 7, 16 urea elution; Lane 8, 17 unbound proteins; Lane 9, 17 streptavidin beads; 
Lane 10, 17 urea elution.   
 
The same samples were trypsin digested and the peptides subjected to manual 
MALDI mass spectrometric analysis. MS analysis of the urea extracts showed 
only low mass peaks for experiments using both affinity probes, suggesting 
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contamination with detergents. Mascot protein searches did not identify any 
proteins from the peptide mass fingerprint (PMF) (Figure 4.4). 
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Figure 4.4.  Mass spectra for urea elutions. (A) 16; (B) 17.  
 
MS analysis of the streptavidin beads following incubation with the affinity 
probes revealed similar PMFs with only very few unique peaks, suggesting that 
proteins had failed to bind to the streptavidin-affinity probe complex (Figure 4.5).  
 
(B) 
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Figure 4.5.  MS spectra for streptavidin beads. (A) 16; (B) 17.  
 
Mascot searching identified one protein on the beads incubated with probe 17 - 
porphobilinogen deaminase from the species Chlorobium limicola (Mascot 
score 81, number of peptides 13). The peptides have a relatively high sequence 
coverage (53 %) and the matched peptides are shown in Table 4.2. However, 
the result can be considered a false positive as most of the peptides identified 
have one or more missed cleavages by trypsin digestion, several modifications 
and variable ppm differences in molecular weight. In addition, contamination 
with proteins of Chlorobium to either the streptavidin beads or the cell line used 
for protein extraction seems unlikely. 
(B) 
(A) 
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Table 4.2. Protein hit from the PMF of streptavidin beads incubated with affinity probe 
17. (A) Sequence coverage identified by peptides highlighted in red. (B) Matched peptides. 
 
     1 MKKQLIIGTR SSPLALWQAE FTKAELSRHF PELDITLKLV KTTGDVLLDS  
    51 PLSKIGDMGL FTKDIEKHLI AKEIDLAVHS LKDVPTSTPE GLIITSFTER  
   101 EDTRDVIISK GGAKLADLPL NAKVATSSLR RMSQLKSLRP DFEICDIRGN  
   151 LNTRFKKFDE GEFDAMMLAY AGVFRLNFSD RISEILPHEI MLPAVGQGAL  
   201 GIETRVDDEQ TREIVRILNH SNTEYCCKAE RALLRHLQGG CQIPIGAYAS  
   251 FKNGTLKLLA FVGSVDGTVG INNEITRSGL TSPDQAEEAG IALAEELLKQ  
   301 GADKILSEIR KTR 
 
   Search Parameters: All species; Database – Swissprot; Enzyme – Trypsin; Mass Tolerance 
– 100 ppm; Variable modifications – oxidation (M) & carboxyamidomethyl (C); Partials – 2.   
Amino 
Acids 
ppm Miss Sequence 
4 - 28 -91 2 K.QLIIGTRSSPLALWQAEFTKAELSR.H 
11 - 28 -8 1 R.SSPLALWQAEFTKAELSR.H 
55 - 67 -10 1 
K.IGDMGLFTKDIEK.H 
Oxidation (M) 
64 - 82 -63 2 K.DIEKHLIAKEIDLAVHSLK.D 
83 - 100 -39 0 K.DVPTSTPEGLIITSFTER.E 
137 - 154 -37 1 
K.SLRPDFEICDIRGNLNTR.F 
Carbamidomethyl (C) 
157 - 175 15 1 K.KFDEGEFDAMMLAYAGVFR.L 
157 - 175 40 1 
K.KFDEGEFDAMMLAYAGVFR.L 
2 Oxidation (M) 
158 - 181 -6 1 K.FDEGEFDAMMLAYAGVFRLNFSDR.I 
176 - 181 99 0 R.LNFSDR.I 
176 - 212 -37 2 
R.LNFSDRISEILPHEIMLPAVGQGALGIETRVDDEQTR.E 
Oxidation (M) 
213 - 228 -8 1 
R.EIVRILNHSNTEYCCK.A 
Carbamidomethyl (C) 
305 - 310 -28 0 K.ILSEIR.K 
(A) 
(B) 
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4.3.2 METHOD 2 
 
Method 1 did not result in the identification of any proteins that bound to either 
affinity probe. This may have been due to the low amount of protein present in 
the cell lysates. Method 2 followed the same procedure with an increased 
number of cells used (3.0 x 107, instead of 1.5 x 107) and higher concentration 
of affinity probes in the protein solution (100 µM instead of 20 µM).    
 
With this method, SDS-PAGE analysis failed to visualise any proteins in the 
urea elutions or on the streptavidin beads after incubation using either affinity 
probe 16 and 17. MS analysis of the urea elutions did not lead to the 
identification of proteins present in the samples from the PMFs. The most 
intense peptide peaks were subject to MS/MS analysis. The MS/MS spectra of 
two of the peptide peaks did not generate any hits with Mascot searching and 
the samples were too weak to allow good MS/MS spectra to be produced from 
less intense peaks. One peptide (m/z = 944.4450) was identified as Histone 
H2A type 1A (Mascot score 28) (Figure 4.6). Although this was a positive result, 
a protein identification from one peptide is not sufficient to confirm this as a 
specific binding protein of the affinity probe 17.    
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Figure 4.6. MS/MS spectrum of peptide m/z = 944.4450 from the MS of the urea elution 
with affinity probe 16, highlighting the matched peptide fragments.  
Search Parameters: All species; Database – Swissprot; Enzyme – Trypsin; Peptide Tolerance 
– 100 ppm; MS/MS Tolerance – 0.7 Da; Variable modifications – oxidation (M) & 
carboxyamidomethyl (C); Partials – 2.   
 
4.3.3 METHOD 3 
 
Method 3 followed a different approach to affinity capture. It was considered 
that desalting with a NAP-5 column, to remove excess affinity probe, before 
capture of the probe-protein complex with the streptavidin beads, may disrupt 
the binding equilibrium of the target with the affinity probe. This would result in a 
reduced amount of protein (P) binding to affinity probe (L).  
 
P L PL  
 
Therefore, incubation of the affinity probes with the streptavidin beads was 
carried out prior to exposure to the cellular lysates. This would immobilise the 
affinity probes onto the column preventing loss by desalting and hence 
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increasing the amount of protein captured. The conditions of each stage 
remained the same as those used in Method 2. 
 
Six parallel affinity experiments were carried out incorporating a sensitive 
(A2780) and an insensitive cell line (HT29), an active (16) and an inactive (17) 
affinity probe and a probe-free control (Table 4.3).  
 
Table 4.3.  Experiments carried out following Method 3 
 
Experiment Affinity Probe Cell Line 
1 16 A2780 
2 17 A2780 
3 No Compound A2780 
4 16 HT29 
5 17 HT29 
6 No Compound HT29 
 
 
SDS-PAGE analysis of the urea elutions from each experiment did not reveal 
the presence of proteins using instant blue staining (Figure 4.7A). Silver staining 
of the gels showed the presence of protein bands in lanes containing samples 
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from incubation of both affinity probes with the insensitive cell line HT29 
(experiments 4 and 5). This contradicts the chemosensitivity data, therefore the 
bands may represent specific binding of proteins that do not have a direct 
involvement with the mechanism of action of the hit compounds. The absence 
of bands in other samples was most likely due to the low quantity of proteins 
captured.  
 
1       2      3      4      5      6      7      8       9      10 
 
 
 
Figure 4.7.  SDS-PAGE Analysis of Urea Extracts. (A) Stained with Instant Blue stain;  
(B) Silver Stained.  
Lane 1, Molecular weight marker; Lane 2, total protein content from A2780 cell line prior to 
incubation with affinity probes; Lane 3, total protein content from HT29 cell line prior to 
incubation with affinity probes; Lane 4, SDS buffer; Lane 5, experiment 1; Lane 6, experiment 
2; Lane 7, experiment 3; Lane 8, experiment 4; Lane 9, experiment 5; Lane 10, experiment 6.   
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The urea elutions from each experiment were subject to MS analysis. 
Comparing the spectra from experiments 1 and 3 eliminated peptides from non-
specific binding proteins revealing peptides from proteins binding to 16. 
However, as the samples were weak, identification of only one peptide  
(m/z = 944.51) was possible – Histone H2A type 1-B/E (Mascot score = 48). 
SDS-PAGE of the streptavidin bead samples from each experiment only 
showed bands due to streptavidin (Figure 4.8).  
 
Comparisons of MS spectra for each sample allowed elimination of non-specific 
binding proteins in the same way as for the urea elutions. The peptide peaks 
present in these samples were more intense than those observed in the urea 
elutions suggesting that urea may not be eluting bound proteins from the affinity 
probe-streptavidin complex. The unique peptides were subject to MS/MS and 
the associated proteins identified using Mascot (Table 4.4).  
 
Proteins from the Histone H2A family have been identified in three different 
samples (streptavidin beads, Method 3 and urea elutions, Methods 2 and 3). 
However, the identification has arisen from the same peptide (m/z = 944). The 
evidence is therefore not strong enough to confirm a hit. The other proteins 
identified from the streptavidin bead samples also have only one identified 
peptide and the Mascot scores of each were lower than the threshold of 
significance (p<0.05), preventing confirmation of a hit. 
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1       2      3      4      5      6      7      8      9      10 
 
  
 
Figure 4.8.  SDS-PAGE Analysis of Streptavidin beads. (A) Stained with Instant Blue stain;  
(B) Silver Stained.  
Lane 1, Molecular weight marker; Lane 2, SDS buffer; Lane 3, total protein content from A2780 
cell line prior to incubation with affinity probes; Lane 4, total protein content from HT29 cell line 
prior to incubation with affinity probes; Lane 5, experiment 1; Lane 6, experiment 2; Lane 7, 
experiment 3; Lane 8, experiment 4; Lane 9, experiment 5; Lane 10, experiment 6.   
 
De novo sequencing was carried out from the MS/MS of two of the observed 
peptides, 1640.7730 and 3075.5880 as a hit was not confirmed using Mascot 
searching. This involved manually determining mass differences between 
fragments equal to one amino acid in weight (Figure 4.9). The sequences found 
were searched using the ExPASy proteomics server BLAST search engine and 
both were identified as streptavidin.   
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Figure 4.9. De novo sequencing of peptide m/z 3057.635. 
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SDS-PAGE and MS analysis for each method showed that the streptavidin 
protein is dominating the bead samples, with other proteins being less 
concentrated. A C18 ziptip was used to concentrate peptides which may belong 
to other proteins. Samples were eluted from the ziptip using increasing 
concentrations of acetonitrile in water. Although peptides were concentrated, 
MS and MS/MS analysis of each fraction did not identify any proteins in Mascot 
searching (Figure 4.10).  
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Figure 4.10. Mass spectra for peptides eluted with increasing concentrations of MeCN in 
H2O. (A) 20 % MeCN; (B) 30 % MeCN; (C) 40 % MeCN; (D) 80 % MeCN. 
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Method 3 has resulted in more concentrated protein samples following affinity 
chromatography. Therefore, the method appears to be a more efficient 
approach to capturing binding proteins compared with Methods 1 and 2.  
 
4.3.4  METHOD 4 
 
Method 4 followed the same path as Method 3, but was carried out on a larger 
scale. The volume of streptavidin beads (100 µl) used remained constant, 
however, the number of cells (6.1 x 108) and the concentration of the affinity 
probes (1 mM) was increased. Incubation periods were also increased (24 h) 
and carried out at 4 °C instead of room temperature.  
 
It was considered that the target protein may not be soluble in the Tris-HCl 
buffer containing 4 % CHAPS or that Tris was interfering with probe-protein 
interaction. Therefore, this method incorporated two solublisations of the cell 
lysate prior to affinity capture. The first solubilisation used a PBS buffer 
containing 1 % Triton X and PIC and the second used PBS containing 1 % 
C7BzO, 4 % CHAPS and PIC. The experiments carried out are summarised in 
Table 4.5. 
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Table 4.5.  Experiments performed using Method 4. 
 
Experiment Affinity Probe Cell Line Deteregent 
1 16 A2780 Triton X 
2 17 A2780 Triton X 
3 No compound A2780 Triton X 
4 16 HT29 Triton X 
5 17 HT29 Triton X 
6 No compound HT29 Triton X 
7 16 A2780 C7BzO + CHAPS 
8 17 A2780 C7BzO + CHAPS 
9 No compound A2780 C7BzO + CHAPS 
10 16 HT29 C7BzO + CHAPS 
11 17 HT29 C7BzO + CHAPS 
12 No compound HT29 C7BzO + CHAPS 
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Bound proteins were eluted by competitive elution with hit compound 2 (2 mM, 
24 h) instead of 8 M urea as urea elutions in the previous three methods did not 
lead to high concentrations of proteins. SDS-PAGE of the competition elutions 
(Figure 4.11) revealed proteins in experiments 1-3 (Figure 4.11A), representing 
incubation with A2780 cell lysates solubilised with Triton X. However, as these 
protein bands appear in control experiment 3, they were considered to have 
non-specific binding affinity. The gels from the remaining experiments failed to 
show the elution of any proteins.   
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1       2       3       4       5       6       7       8        9       10 
 
 
 
Figure 4.11.  SDS-PAGE Analysis stained with Instant Blue stain of Competition washes with 
2 from (A) The 1
st
 solubilisation stage of cell lysates from the A2780 cell line; (B) The 1
st
 
solubilisation stage of cell lysates from the HT29 cell line; (C) The 2
nd
 solubilisation stage of cell 
lysates from the A2780 cell line; (D) The 2
nd
 solubilisation stage of cell lysates from the HT29 
cell line.  
Lane 1, SDS buffer; Lane 2, Molecular weight marker; Lane 3, total protein content prior to 
incubation with affinity probes; Lane 4, unbound proteins after incubation with 16; Lane 5, 
bound proteins after incubation with 16; Lane 6, unbound proteins after incubation with 17; 
Lane 7, bound proteins after incubation with 17; Lane 8, experiment 4; Lane 9, unbound 
proteins after incubation with no compound; Lane 10, bound proteins after incubation with no 
compound.   
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MS of the competition washes with hit compound 2 identified proteins based on 
their PMF (Table 4.6). 
 
Table 4.6. Protein hits from the PMF of the hit compound 2 competition washes for each 
experiment.  
 
Experiment Protein Score 
Sequence 
Coverage 
1 None identified   
2 
Retinoid-inducible serine 
carboxypeptidase 
38 15 % 
3 
Retinoid-inducible serine 
carboxypeptidase 
44 22 % 
4 None identified   
5 Histone H2A type 1-J 28 27 % 
6 Epidermal growth factor-like protein 6 58 10 % 
7 Alpha-enolase 45 9 % 
8 RING finger protein 222 62 15 % 
9 None identified   
10 None identified   
11 Epidermal growth factor-like protein 6 58 10 % 
12 None identified 
  
 
Search Parameters: Homo sapiens; Database – Swissprot; Enzyme – Trypsin; Mass 
Tolerance – 100 ppm; Variable modifications – oxidation (M) & carboxyamidomethyl (C); 
Partials – 2.   
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Retinoid-inducible serine carboxypeptidase was identified in both experiment 2 
and control experiment 3, therefore this result can be discarded as a non-
specific binding protein. The same can be applied to the epidermal growth 
factor-like protein 6 seen in experiments 6 and 11. Experiment 5 identified 
another protein from the Histone H2A family. This result could now be 
considered as significant as it was identified from a PMF rather than MS/MS of 
the peptide found at m/z = 944. The sequence coverage for each of the 
identified proteins was relatively low and there was no protein identified from 
experiment 1, which would be expected if the target protein was captured.  
  
The competitive elutions did not reveal any significant specific binding proteins, 
so it was presumed the target was still bound to the affinity column. This is 
possibly a result of the concentration of the hit compound 2 eluting solution 
being too low.  Direct SDS-PAGE analysis of the streptavidin beads was 
therefore carried out (Figure 4.12). 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Biological Evaluation and Proteomics 
144 
 
1       2       3       4       5       6       7       8        9       10 
 
 
 
Figure 4.12.  SDS-PAGE Analysis stained with Instant Blue stain of streptavidin beads from 
(A) The 1
st
 solubilisation stage of cell lysates from both cell lines; (B) The 2
nd
 solubilisation stage 
of cell lysates from both cell lines.  
Lane 1, 3 & Lane 10, SDS buffer; Lane 2, Molecular weight marker; Lane 4, A2780 cell lysate 
incubated with 16; Lane 5, A2780 cell lysate incubated with 17; Lane 6, A2780 cell lysate 
incubated with no compound; Lane 7, HT29 cell lysate incubated with 16; Lane 8, HT29 cell 
lysate incubated with 17; Lane 9, HT29 cell lysate incubated with no compound.   
 
Instant blue staining of the gels revealed of several bands. Instead of direct 
trypsin digestion of the streptavidin bead samples, in-gel trypsin digestion of the 
protein bands allowed separation from the streptavidin peptides which had 
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dominated the MS analysis during the previous three methods. The gels were 
silver stained to enable better visualisation of the proteins allowing for easier 
selection of bands to excise (Figure 4.13 and Figure 4.14). Once the bands had 
been identified, the SDS-PAGE was repeated and the bands indicated in Figure 
4.13 and 4.14 were excised for digestion with trypsin.     
 
The gels in Figure 4.13 and 4.14 showed a marked concentration of streptavidin 
in the control experiments compared with experiments which incorporated 
incubation with an affinity probe. This may be because on binding of biotin to 
streptavidin, a suface loop of the streptavidin protein folds over the binding 
site.122 The complex is more stable, preventing denaturation and dissociation 
from the agarose beads during SDS-PAGE sample preparation. This visual 
marker could act as an indicator that the affinity probes have bound to the 
streptavidin beads in future experiments.  
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The excised bands were trypsin digested and subject to MS analysis. The 
peptides shown in each spectrum were compared and unique peptides (those 
which were not present in lane 10) identified. The unique peptide lists were 
searched using the PMF feature of the Mascot database and identified proteins 
are summarised in Tables 4.7 and 4.8. 
 
Comparisons of the PMF showed the highest numbers of unique peptides were 
present in band D of the gel from the first solubilisation (Figure 4.11A) and 
bands E and F of the gel from the second solubilisation (Figure 4.11B). The 
higher peptide numbers resulted in confirmed hits during database searching. 
Heterogeneous nuclear ribonuclear protein A2/B1 (hnRNP A2/B1) was 
identified in all of the bands outlined above. This result strongly suggests that 
the protein is binding to the affinity probes, 16 and 17.  In addition the sequence 
molecular weights of the proteins correspond to the molecular weights of the 
bands.  
 
Cytoskeletal keratin type 1 was identified in band A lane 7 of the gel 
representing the second solubilisation (Figure 4.11B). Keratins are common 
contaminants in proteomic analysis and are probably not binding specifically to 
the affinity probe. The other proteins identified from each gel were below the 
threshold of protein confirmation (p<0.05) due to their low Mascot scores and 
the theoretical molecular weights of the proteins identified did not correspond to 
the molecular weights of the bands in the SDS-PAGE gel. Therefore these 
identified proteins were ignored. 
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Table 4.7.  Highest ranking protein identifications from unique bands in the PMF of bands 
excised from gel shown in Figure 4.11A.  Blank rows indicate too few unique peptides to 
generate a hit. Red proteins scored a hit above the threshold. In brackets: number of peptides, 
sequence coverage and Mascot score. In blue, the theoretical molecular weight of the identified 
protein. 
 
 4 
(16, A2780) 
5 
(17, A2780) 
7 
(16, HT29) 
8 
(17, HT29) 
A None identified None identified None identified None identified 
B None identified None identified None identified None identified 
C None identified None identified None identified None identified 
D 
Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1  
(3, 16%, 32) B1 = 
36,006 Da, A1 = 
37,430 Da 
Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1  
(3, 16%, 32) B1 = 
36,006 Da, A1 = 
37,430 Da 
Heterogeneous 
nuclear 
ribonucleoproteins 
A2/B1  
(5, 28%, 56), B1 = 
36,006 Da, A1 = 
37,430 Da 
None identified 
E None identified None identified 
Abhydrolase 
domain-containing 
protein 12B  
(4, 16%,43)  
40,776 Da 
Aspartyl-tRNA 
synthetase, 
mitochondrial 
(4, 6%, 37)  
73,563 Da 
F 
N-acetyl-beta-
glucosaminyl-
glycoprotein 4-beta-
N-
acetylgalactosamin
yltransferase (6, 
7%, 38) 
114,975 Da 
None identified None identified None identified 
G 
Putative 3-
phosphoinositide-
dependent protein 
kinase (5, 16%, 38) 
44,765 Da 
AAH06133  
(3, 15 %, 14) 
113,678 Da  
None identified None identified 
 
Search Parameters: Homo sapiens; Database – Swissprot; Enzyme – Trypsin; Mass 
Tolerance – 100 ppm; Variable modifications – none; Partials – 2.   
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Table 4.8.  Highest ranking protein identifications from unique bands in the PMF of bands 
excised from gel shown in Figure 4.11B.  Blank rows indicate too few unique peptides to 
generate a hit. Red proteins scored a hit above the threshold. In brackets: number of peptides, 
sequence coverage and Mascot score. In blue, the theoretical molecular weight of the identified 
protein. 
 4 
(16, A2780) 
7 
(16, HT29) 
8 
(17, HT29) 
A 
Growth/differentiation factor 
2 (5, 14%, 36) 
47,320 Da 
Keratin, type I cytoskeletal 
16 (12, 26%, 89), 51,268 
Da 
Butyrophilin-like protein 9 
(4, 10%, 36) 59,716 Da 
B 
Toll-like receptor 9 (8, 13%, 
31), 115,860 Da 
Protein APCDD1 (5, 13%, 
41) 58,797 Da 
Junctophilin-3 (10, 14%, 43) 
81,469 Da 
C 
Probable N-
acetyltransferase 8 
(3, 22%, 57), 25,619 Da 
 
Protein S100-A8 (2, 44%, 
28) 10,835 Da 
D None identified 
Cysteine and glycine-rich 
protein 3 (4, 30%, 39) 
20,969 Da 
Zinc finger protein 174 (5, 
13%, 36) 46,455 Da  
E None identified 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(8, 39%, 79) B1 = 36,006 
Da, A1 = 37,430 Da 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(5,22%,48) B1 = 36,006 Da, 
A1 = 37,430 Da 
F 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(7, 32%, 86) B1 = 36,006 
Da, A1 = 37,430 Da 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(12, 45%, 103) B1 = 36,006 
Da, A1 = 37,430 Da 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
(13, 47%, 113) B1 = 36,006 
Da, A1 = 37,430 Da 
G None identified 
Protein LZIC (3, 20%, 22) 
21,495 Da 
PDZ domain-containing 
protein 7 (12, 14, 34)  
55,677 Da 
H None identified None identified 
Protein PAT1 homolog 1 (5, 
5%, 39) 86,850 Da 
 
Search Parameters: Homo sapiens; Database – Swissprot; Enzyme – Trypsin; Mass 
Tolerance – 100 ppm; Variable modifications – none; Partials – 2.   
 
The strongest unique peptide signals, for each band were subject to MS/MS. 
Table 4.9 and Table 4.10 show the peptides with a Mascot score above 25.  
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4.3.5 HETEROGENEOUS NUCLEAR RIBONUCLEAR PROTEIN A2/B1 
 
Heterogeneous nuclear ribonuclear proteins (hnRNPs) are a family of proteins 
which share common structural motifs. They are some of the most abundant 
nuclear proteins with a vast array of functions.164 These multi-tasking proteins 
play a central role in RNA metabolism, however they have also been reported to 
have roles in telomere biogenesis, cell signalling and regulation of gene 
expression at transcription and translational levels, although they lack any direct 
enzymatic activity.165  
 
hnRNP A2 and its spliced isoform B1 are major components of the 40S 
particles that package RNA. They have roles in addition to packaging hnRNA 
including alternative RNA splicing, mRNA export from the nucleus and 
cytoplasmic trafficking, stability and translation.166 hnRNP A2/B1 are increased 
at many types of cancer – lung, breast, pancreatic, stomach – hnRNP B1 is 
increased in oral and oesophagus cancers along with leukaemia and 
lymphoma.165 These increases can be linked to their role in telomere regulation 
and also in cell proliferation. 
 
Levels of hnRNP A2/B1 have been determined at different stages of the cell 
cycle showing that they peak during the G1 and S phase and decline during the 
G2 and M phase. This has a direct effect on cell cycle regulators, decreasing 
expression of BRAC1 and increasing p21, as a result it has been suggested 
that the proteins may be classed as oncogenic development proteins. hnRNP 
A1/B2 bind to the single-stranded telomeric repeat sequence. SiRNAi 
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experiments to reduce the protein expression in HeLa cells led to a change in 
the distribution in the lengths of the telomere G-tails. However, the functional 
significance of this binding on regulation and maintenance of telomere structure 
has not been reported.166  
 
As hnRNP A2/B1 form large complexes with many proteins, it is uncertain 
whether these are the unique protein targets for the hit compounds 1, 2 and 3, 
or that they are masking the binding of another protein. Figure 4.15 shows the 
proteins associated with hnRNP A2/B1 in the ribonucleosome using the 
STRING database.167  
 
 
 
 
Figure 4.15. STRING network display of hnRNP A2/B1, showing proteins which have a 
known association. 
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4.3.6 CONCLUSIONS 
 
The proteomic approach to target identification was successful in identifying 
proteins using affinity probes 16 and 17. Methods 1-3 failed to capture any 
binding proteins, possibly due to the scale of the procedure. Histone H2A 
proteins were identified from MS/MS spectra from different sources, however, 
the peptide (m/z = 944) was the same in each identification.   
 
Method 4 captured many proteins, the majority of which were successfully 
identified as heterogeneous nuclear ribonuclear protein A2/B1. This may be 
attributed to the change of detergent used to solubilise the proteins from the cell 
lysate and the larger scale of the method. Most of the peptides were present in 
samples from affinity experiments using a detergent of C7BzO and CHAPS 
instead of CHAPS alone, which was used in previous methods.  
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5.1 CONCLUSIONS 
 
Non-symmetrical biarylheterocycles containing a biotin group were designed, 
synthesised and used as affinity probes in chemical proteomics. Many synthetic 
routes were explored and the final synthesis of affinity probes 16 and 17 is 
shown in Scheme 5.1. 
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Scheme 5.1.  Synthesis of affinity probes 16 and 17. 
Reagents and Conditions: (i) Na2CO3 (0.4 M (aq)):MeCN (1:1), Pd(PPh3)4, 90 °C, N2, 24 h (93 
%); (ii) K2CO3,  Pd(PPh3)4, PhMe:MeOH (9:1), ∆, 48 h (86 %); (iii) 88, PyBOP, Et3N, DMF, RT, 
18 h (90 %); (iv) NaOH (10 eq), 50 °C, 2 h (46 %); (vi) PyBOP, Et3N,  DMF, RT, 18 h (70-89 %).   
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A method of affinity capture has been established and successful in capturing a 
number proteins, identified from Mascot searches of PMFs and MS/MS ion 
searches. Most proteins had Mascot scores below the threshold (p<0.05) and 
no correlation with the calculated molecular weights of the identified proteins, 
however, one significant protein was identified. This protein was identified as 
heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) which bound to 
both affinity probes 16 and 17. The identifications are from Mascot searching of 
PMFs and MS/MS ion searches, leading to strong evidence that hnRNP A2/B1 
is selectively binding to the affinity probes and not binding non-specifically to the 
streptavidin beads. 
 
The potency of affinity probe 16 was reduced by bearing a single imidazole 
group, suggesting that both imidazole rings are required for binding. The half 
compound 4 shows the same selectivity as the hit compounds 1-3 but with 
reduced potency, implying that the target could contain a symmetrical binding 
site. Although there is not a complete 3D structure of the hnRNP A2/B1 protein 
available, the primary sequence information confirms that there are two RNA 
recognition motifs.168 Each of these could bind to half of the hit compound or be 
binding two different RNAs which in turn are complexed to the hnRNP A2/B1. In 
addition, the amount of protein captured using affinity probes cannot be directly 
related to chemosensitivity data. 
 
The distinction in activity observed between the two different cell lines, A2780 
and HT29, with compound 16 was also lost during affinity capture and the 
protein was identified in both of the cell lines. It is possible that the target protein 
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only has a direct relation to the mechanism of cancerous growth in the A2780 
cell line, as the chemosensitivity assay showed a contrast for the affinity probe 
16 between the A2780 (IC50 = 6.25 µM) and HT29 (IC50  > 100 µM) cell lines. 
hnRNP A2/B1 is present in normal cells but found at increased levels in 
cancerous cells, suggesting that the presence of the protein may not be directly 
related to activity. 
 
Although there is strong evidence to relate hnRNP A2/B1, or a protein 
complexed to hnRNP A2/B1, with binding to the affinity probes, the loss of 
potency in comparison to the hit compounds and the loss of contrast between 
the „active‟ and the control affinity probe, has lead to uncertainty whether 
hnRNP A2/B1 is the target protein responsible for the potent activity of the hit 
compounds 1-3. Further work is required to confirm and validate the target 
protein. Also, development of affinity probes with biotin attached to alternative 
sites of the hit compounds must be investigated. 
 
5.2 TARGET VALIDATION 
 
The NCI COMPARE data showed the H522 NSC lung cancer cell was the most 
sensitive to the hit compounds. Therefore, affinity chromatography using the 
affinity probes should be carried out using this cell line to confirm hnRNP A2/B1 
as the biological target. In addition, western blotting can be used to determine 
the levels of hnRNP A2/B1 in the two tested cell lines, A2780 and HT29. 
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As another method of validation, affinity chromatography should be carried out 
in the presence of hit compound 2. If the binding proteins are hnRNP A2/B1, the 
incubation of the total cell lysate with compound 2 prior to affinity capture with 
the affinity probes complexed to streptavidin, would result in none of the protein 
becoming captured.  
 
 
5.3 SYNTHESIS OF ALTERNATIVE AFFINITY PROBES 
 
Due to the loss of potency of the affinity probes, synthesis of compounds with 
an alternative attachment site must be explored. Progress has been made in 
the synthesis of pyrimidine compounds with the linker at the pyrimidine-2 
position. However, the Ullmann copper-catalysed reactions only proceeded 
using a solvent of DMSO which led to purification problems for carboxylic acids 
36. Synthesis of compounds with the linker at the pyrimidine-2 position could be 
formed using palladium catalysed Buchwald-Hartwig amination reactions which 
proceed in organic solvents which can be easily removed.169  
 
Also, hydrolysis of esters containing the Boc protected linker led to premature 
removal of the protecting group. Attaching the biotinylated linker, 88, in place of 
the Boc-protected linker, 71, to afford compound 20, would overcome this 
problem. (Scheme 5.2).  
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Scheme 5.2. Possible synthesis of biotinylated affinity probe 20.  
Reagents and Conditions: (i) Na2CO3, Pd(OAc)2, PPh3, glyme, ∆, 18-24 h; (ii) 77, Pd(OAC)2, 
XPhos, t-BuONa, PhMe, 90 °C, 4 h; (iii) NaOH (2M), ∆, 24 h, then HCl (4 M); (iv) 62, PyBOP, 
Et3N, DCM, RT, 18 h. 
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The contrast between the control compound 17 and the „active‟ affinity probe 16 
was lost. Therefore, a less potent control compound is required. The SAR 
carried out by Phillips has shown that replacing the imidazole ring with an 
aliphatic or free amine results in no activity. Therefore, the control affinity 
probes should be 109 and 110 for non-symmetrical compound 16, and 111 and 
112 for compounds with the biotin linker at the pyrimidine-2 position, 20. 
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EXPERIMENTAL DETAILS FOR CHAPTER 3: SYNTHESIS 
 
REAGENTS  
 
Boronic acids were purchased from Frontier Scientific, Europe Ltd., Carnforth, 
Lancashire, UK, other reagents were purchased from Sigma-Aldrich, 
Gillingham, UK or Lancaster, Morecambe, UK.  Solvents were purchased from 
Riedel-de Haën.   
 
INSTRUMENTATION 
 
TLC was performed on highly purified silica gel plates with UV indicator (silica 
gel 60 F254), manufactured by Merck and visualised under UV light (254 or  
366 nm). Flash chromatography was performed using Silica gel (particle size 
40-63 m), purchased from Merck and followed the methodology described by 
Still et al.170 Melting points were determined using an Electrothermal IA9200 
digital melting point apparatus.  Infrared data were obtained as KBr discs on a 
Perkin Elmer (Paragon 1000) FT-IR spectrophotometer or as an ATR on a 
Perkin Elmer (Spectrum 100) FT-IR spectrophotometer. Nuclear magnetic 
resonance spectra were acquired on a Bruker DMX400 spectrometer 
(observing 1H at 400.13 MHz and 13C at 100.62 MHz) or a Jeol ECA600 
spectrometer (observing 1H at 600.17 MHz and 13C at 150.91 MHz). 13C 
assignments were made with the aid of the DEPT135 experiment.  Mass 
spectra were obtained from the University of Bradford Analytical Centre, UK. 
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Elemental analysis was performed by the Advanced Chemical and Materials 
Analysis Unit at the University of Newcastle upon Tyne, UK. 
 
EXPERIMENTAL DETAILS FOR SECTION 3.2 
 
Synthesis of 2,7-dichloronaphthyridine 
 
2-Amino-7-hydroxy-1,8-naphthyridine152  
 
NH2N
1
2
3
4 5
6
N OH
7
8
1a
4a
 
 
2,6-Diaminopyridine (3.3 g. 30.2 mmol) and malic acid (4.5, 33.3 g) were 
ground to a fine powder and cooled in an ice bath. Concentrated sulphuric acid 
(15 ml) was added dropwise over 10 min and the mixture heated at 110 °C for  
5 h. The reaction mixture was poured over ice and basified with ammonia 
solution. The precipitate was filtered to yield pure product (4.86 g, 100 %). m.p. 
decomp > 300 °C (lit. m.p > 350 °C); 1H NMR (DMSO) δ 11.82 (br s, 1H, OH), 
7.66 (d, J = 8.8 Hz, 2H, 4-H, 5-H), 7.00 (s, 2H, NH2), 6.35 (d, J = 8.8 Hz, 1 H,  
6-H), 6.12 (d, J = 8.8 Hz, 1H, 3-H); 13C NMR (DMSO) δ 164.2 (C-7), 161.0  
(C-2), 150.6 (C-1a), 140.2 (C-4 or C-5), 137.8 (C-4 or C-5), 115.3 (C-6), 105.6 
(C-3), C-4a not observed. 
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2,7-Dihydroxy-1,8-naphthyridine152  
 
NHO
1
2
3
4 5
6
N OH
7
8
1a
4a
 
 
2-Amino-7-hydroxy-1,8-napthyridine (4.70 g, 29.2 mmol) was added to 
concentrated sulphuric acid (40 ml). Sodium nitrite (2.4 g) was added and the 
mixture was poured over ice. The solution was neutralised with sodium 
carbonate and the acidified with glacial acetic acid to pH 3. The resultant 
precipitate was collected by filtration (3.01 g, 64 %). m.p. decomp > 300 °C (lit. 
m.p 321-323 °C); 1H NMR (DMSO) δ 11.59 (br s, 2H, OH), 7.82 (d, J = 8.8 Hz, 
2H, 4-H, 5-H), 6.35 (d, J = 8.8 Hz, 2H, 3-H, 6-H); 13C NMR (DMSO) 163.8 (C-2, 
C-7),139.9 (C-4, C-5), 120.6 (C-3, C-6), C-1a and C-4a not observed. 
 
2,7-Dichloro-1,8-naphthyridine, 66152  
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2,7-Dihydroxy-1,8-naphthyridine (2.5 g, 15.4 mmol), phosphorus pentachloride 
(6.45 g, 30.8 mmol) and phosphoryl chloride (4.72, 30.8 mmol) were heated 
under reflux for 2 h. Ice was added to the solution and basified to pH 8 with 
sodium carbonate. The resultant precipitate was collected by filtration and 
recrystallised from acetone to yield pure 66 (2.49 g, 81 %). m.p. decomp  
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256.6 – 257.3 °C (lit. sublimation point 258 °C); 1H NMR (DMSO) δ 8.63 (d,  
J = 8.6 Hz, 2H, 4-H, 5-H), 7.80 (d, J = 8.6 Hz, 2H, 3-H, 6-H); 13C NMR (DMSO) 
δ 154.2 (C-2, C-7), 141.7 (C-4, C-5), 124.6 (C-3, C-6), C-1a and C-4a not 
observed. 
 
 
General Method 1: The Suzuki coupling Reaction 
 
4,6- Bis-(4-methoxcarbonylyphenyl) pyrimidine, 2562  
 
4,6-Dichloropyrimidine, 26, (3.00 g, 20.14 mmol), 4-methoxycarbonylphenyl 
boronic acid, 27, (6.12 g, 40.27 mmol) and finely powdered potassium 
carbonate (8.35 g, 60.41 mmol) were stirred at 60 °C in a solution of 
toluene:methanol (9:1, 450 ml) for 1 h with thorough degassing with nitrogen. 
Pd(PPh3)4 (0.10 g) was added to the reaction and it was heated at 120 °C under 
reflux for 48 h. The solvents were evaporated and the residue partitioned 
between chloroform (3 x 200 ml) and water (250 ml). The organic layers were 
combined and dried over MgSO4. The solids were removed by filtration through 
a celite pad. The solvent was evaporated and the residue recrystallised from 
ethyl acteate to give a crystalline solid 25 (4.68 g, 79%); m.p. 248.2 – 248.6 °C 
(Lit. 223.5 – 225.0 °C); 1H NMR (CDCl3) δ 9.37 (s, 1H, 2-H), 8.21 (m, 8H, 2'-H, 
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3'-H, 5'-H, 6'-H), 8.14 (s, 1H, 5-H), 3.96 (s, 6H, OMe); 13C NMR (CDCl3) δ 166.6 
(C=O), 164.0 (C-4, C-6), 159.4 (C-2), 140.9 (C-4'), 132.4 (C-1'), 130.4 (C-3', 
C-5'), 127.3 (C-2', C-6'), 123.7 (C-5), 52.5 (OMe). 
 
2,6-Bis-(4-methoxycarbonylphenyl) pyridine, 6762  
Prepared according to general method 1 from 2,6-dibromopyridine, 65, (1.00 g,  
4.22 mmol) and 4-methoxycarbonylphenyl boronic acid, 27, (1.52 g,  
8.44 mmol). Recrystallisation from ethyl acetate afforded crystalline solid 67 
(1.12 g, 76 %); m.p. 212.9 – 213.5 °C (Lit. 194.5 – 195.5°C); 1H NMR (CDCl3) δ 
8.20 (½ AB, J = 8.4 Hz, 4H, 2'-H, 6'-H), 8.15 (½ AB, J = 8.4 Hz, 4H,3'-H, 5'-H), 
7.86 (t, J = 8.4 Hz, 1H, 4-H), 7.77 (d, J = 8.4 Hz, 2H, 3-H, 5-H), 3.95 (s, 6H, 
OMe); 13C NMR (CDCl3) δ 167.0 (C=O), 160.0 (C-2, C-6), 143.4 (C-4'), 137.9 
(C-4), 130.6 (C-1'), 130.1 (C-3', C-5'), 127.0 (C-2', C-6'), 120.0 (C-3, C-5), 52.3 
(OMe).  
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2,7-Bis-(4-methoxycarbonylphenyl) naphthyridine, 6862  
Prepared according to general method 1 from 2,7-dichloronaphthyridine, 66, 
(1.00 g, 5.02 mmol) and 4-methoxycarbonylphenyl boronic acid, 27, (1.68 g, 
11.1 mmol). Recrystallisation from ethyl acetate afforded a crystalline solid 68 
(1.39 g, 70 %); m.p. 267.2–267.8 °C (Lit. 268.0 – 268.5 °C); 1H NMR (CDCl3) δ 
8.35 (½ AB, J = 9.5 Hz, 4H, 2'-H, 6'-H), 8.31 (½ AB, J = 9.5 Hz, 2H, 4-H, 5-H), 
8.19 (½ AB, J = 9.5 Hz, 4H, 4-H), 8.03 (½ AB, J = 9.5 Hz, 4H, 3-H, 5-H), 3.95 
(s, 6H, OMe); 13C NMR (CDCl3) δ 167.1 (C=O), 160.0 (C-2, C-7), 143.3 (C-4'), 
138.0 (C-4, C-5), 131.6 (C-1'), 130.1 (C-3', C-5'), 128.1 (C-2', C-6'), 120.1 (C-3, 
C-6), 52.3 (OMe). C1a and C4a not observed.  
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General Method 2 – Hydrolysis of esters 
 
4,6-Bis-(4-carboxyphenyl) pyrimidine, 2462  
4,6-Bis-(4-methoxycarbonylphenyl) pyrimidine, 25, (0.50 g, 1.44 mmol) was 
added to a solution of sodium hydroxide (2 M, 50 ml) which was heated under 
reflux for 24 h. The reaction mixture was cooled and acidified to pH 5 with HCl 
(4 M). The precipitate was collected by filtration and washed with water and 
ether to yield a white powder 24 (0.45 g, 100 %); m.p. decomp. >300 °C (Lit. 
Decomp. >300 °C);΄1Η ΝΜR (DΜSΟ) δ 9.45 (s, 1Η, 2-Η), 8.74 (s, 1Η, 5-Η), 8.46 
(½ ΑΒ, J = 8.0 Ηz, 4Η, 2‟-Η, 6‟-Η), 8.09 (½ ΑΒ, Ξ = 8.2 Ηz, 4Η, 3‟-Η, 5‟-Η);΄13C 
ΝΜR (DΜSΟ) δ 167.4 (C=Ο), 163.5 (C-4, C-6), 159.6 (C-2), 140.5 (C-4‟), 133.5 
(C-1‟), 130.3 (C-3‟, C-5‟), 128.1 (C-2‟, C-6‟), 114.3 (C-5). 
 
2,6-Bis-(4-carboxyphenyl) pyridine, 6962  
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Prepare according to general method 2 from 2,6-bis-(4-methoxycarbonyl) 
pyridine, 67, (1.0 g, 2.87 mmol) yielding a white solid 69 (0.91 g, 99 %) m.p. 
decomp > 300 °C (lit. m.p. 321 – 323 °C); 1H NMR (DMSO) δ 8.38 (½ AB,  
J = 8.4 Hz, 4H, 2'-H, 6'-H), 7.92 (m, 5H, 3'-H, 5'-H, 4-H), 7.88 (d, J = 8.4 Hz, 2H, 
3-H, 5-H); 13C NMR (DMSO) δ 167.8 (C=O), 155.3 (C-2, C-6), 143.0 (C-4'), 
139.4 (C-4), 131.9 (C-1'), 130.5 (C-3', C-5'), 127.4 (C-2', C-6'), 121.0 (C-3, C-5). 
  
2,7-Bis-(4-carboxyphenyl) napthyridine, 7062  
 
Prepare according to general method 2 from 2,7-bis-(4-methoxycarbonyl) 
naphthyridine, 68, (0.5 g, 1.25 mmol) yielding a yellow solid 70 (0.44 g, 95 %) 
m.p. decomp > 300 °C (lit. m.p 321-323 °C); 1H NMR (DMSO) δ 8.67 (½ AB,  
J = 8.6 Hz, 2H, 4-H, 5-H), 8.51 (½ AB, J = 8.3 Hz, 4H, 2'-H, 6'-H), 8.39 (½ AB,  
J = 8.6 Hz, 2H, 3-H, 6-H), 8.16 (½ AB, J = 8.3 Hz, 4H, 3'-H, 5'-H); 13C NMR 
(DMSO) δ 167.8 (C=O), 159.3 (C-2, C-7), 139.6 (C-4, C-5), 138.7 (C-4'), 131.5 
(C-1'), 130.0 (C-3', C-5'), 128.8 (C-2', C-6'), 120.3 (C-3, C-6), C1a and C4a not 
observed.  
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EXPERIMENTAL DETAILS FOR SECTION 3.3 
 
N-Boc-1,3-diaminopropane, 71155  
 
H
NO
O
NH2
 
 
Di-tert-butyl dicarbonate, 72, (10.00 g, 45.8 mmol) in THF (50 ml) was added 
dropwise to a solution of 1,3-diaminopropane, 5, (11.20 g, 152.6 mmol) in THF 
(150 ml) at 0 °C. Once added, the solution was stirred at 0 °C for 30 min, and 
then left to stir at room temperature for 12 h. The solvents were evaporated and 
the residue dissolved in ethyl acetate (200 ml). The ethyl acetate layer was 
washed with brine (20 % w/v, 3 x 100 ml). The organic layer was collected, 
dried over MgSO4, filtered through a celite pad and evaporated to leave an oil. 
The oil was purified by distillation (160-170 °C at 0.1 mmHg) to give a 
colourless oil 71 (7.81 g, 98 %) Lit. b.p. not given; 1H NMR (CDCl3) δ 5.06 (br s, 
1H, CONH), 3.14 (q, 2H, J = 5.8 Hz, CH2NHCO), 2.70 (t, 2H, J = 5.8 Hz, 
CH2NH2), 1.57 (quint., 2H, J = 5.8 Hz, H2NCH2CH2), 1.40 (br s, 2H, NH2), 1.36 
(s, 9H, But); 13C NMR (CDCl3) δ 156.3 (C=O), 77.4 (CMe3), 39.3 (CH2NH2), 38.3 
(CH2NH), 32.9 (H2NCH2CH2), 28.5 (CCH3); NMR peaks correspond to literature.       
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Attempted synthesis of 4-(4-(3-[imidazol-1-yl]propyl)carboxamido phenyl)-
6-(4-[3-N-Boc-aminopropyl] carboxyamidophenyl) pyrimidine, 22 
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4,6-Bis-(4-carboxyphenyl)pyrimidine, 24, (0.10 g, 0.31 mmol), PyBOP (0.16 g,  
0.31 mmol) and Et3N (0.03 g, 0.31 mmol) was stirred in a solution of dry DCM 
(10 ml) at RT for 1 h. N-Boc-1,3-diaminopropane, 71, (0.05 g, 0.31 mmol) was 
added to the mixture which was left to stir at RT for 15 h. PyBOP (0.16 g,  
0.31 mmol) and Et3N (0.03 g, 0.31 mmol) was added and left at RT for 1 h. 1-(3-
Propyl)imidazole, 73, was added and the reaction stirred at RT for 18 h. The 
resultant precipitate was collected by filtration and washed with ether. The solid 
was recrystallised from methanol to give a mixture of products 22, 75 and 76 as 
a white powder (0.11 g). 1H NMR (DMSO) δ 9.28 (s, 1H, 2-H), 8.73-8.66 (m, 
3H, 5-H, NCHN, NH), 8.54 (t, J = 5.5 Hz, 1H, NH) 8.42 (m, 4H, 2'-H, 6'-H, 2''-H, 
6''-H), 7.95 (m, 4H, 3'-H, 5'-H, 3''-H, 5''-H), 7.62 and 7.41 (2 x s, 1H, NCHCHN), 
6.76 (t, J = 5.5 Hz, 1H, NH), 4.18 (t, J = 6.5 Hz, 2H, CH2-imidazole), 3.23-3.19 
(m, 4H, CH2CH2CH2-imidazole, CH2CH2CH2NHBoc), 2.90 (q, J = 6.5 Hz, 2H, 
CH2NHBoc), 1.99 (quint., J = 6.5 Hz, 2H, CH2CH2-imidazole), 1.55 (quint.,  
J = 6.5 Hz, 2H, CH2CH2NHBoc), 1.28 (s, 9H, CMe3); MS (ESI+): m/z (M+H)
+· 
633.5 (5 %), 584.4 (5 %), 535.4 (5 %).  
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Attempted synthesis of 4-(4-carboxyphenyl)-6-(4-[3-N-Boc-aminopropyl] 
carboxyamidophenyl) pyrimidine, 74, leading to 4,6-Bis-(4-[3-N-Boc-amino 
propyl]carboxyamidophenyl) pyrimidine, 75  
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4,6-Bis-(4-carboxyphenyl)pyrimidine, 24, (1.00 g, 3.12 mmol), PyBOP (1.62 g, 
3.12 mmol) and Et3N (0.32 g, 3.12 mmol) were stirred at room temperature in 
dry DCM (50 ml). N-Boc-1,3-diaminopropane, 71, (0.54 g, 3.12 mmol) was 
added to the mixture which was left to stir at room temperature for 15 h. The 
precipitate was collected by filtration and washed with ether. The solid was 
triturated with hot methanol to remove excess starting material. The filtrate was 
concentrated and purified by flash chromatography on silca gel eluting with 
chloroform: methanol (98:2 to 50:50) to yield white solid 75 (0.32 g, 16 %); m.p. 
220.9 – 221.7 °C; 1H NMR (DMSO) δ 9.36 (s, 1H, 2-H), 8.76 (s, 1H, 5-H), 8.63 
(t, J = 5.7 Hz, 2H, NHCOPh), 8.47 (½ AB, J = 8.4 Hz, 4H, 2'-H, 6'-H), 8.02  
(½ AB, J = 8.4 Hz, 4H, 3'-H, 5'-H), 6.85 (t, 1H, J = 5.7 Hz, NHBoc), 3.29 (q,   
J = 6.5 Hz, 4H, CH2NHCOPh), 2.98 (q, J = 6.5 Hz, 4H, CH2NHBoc), 1.65 (m,  
J = 6.5 Hz, 4H, NHCH2CH2), 1.37 (s, 9H, CCH3); 
13C NMR (DMSO) δ 166.4 
(C=OPh), 163.4 (C-4, C-6), 159.3 (C-2), 156.2 (COOBut), 139.1 (C-4'), 137.3 
(C-1'), 128.3 (C-3', C-5'), 127.8 (C-2', C-6'), 113.8 (C-5), 78.0 (CMe3), 38.2 and 
37.3 (NHCH2CH2CH2NH), 30.1 (CH2CH2NH), 28.8 (CH3); IR (KBr): 3350s  
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(N-H),  2950m (Ar C-H), 2350m (C-H), 1700s (C=O), 1600s (Ar C-C), 1550s  
(N-H), 1550s (C-H2), 1450m (C=C), 1375s (C-N), 1150m (C-O); MS (ESI+): m/z  
633 (98 %) (M+H)+•, 613 (4 %) (M-H3O)
+•, 595 (13 %), 577 (10 %) (M-But)+•, 566 
(4 %), 533 (8 %) (M-Boc)+•, 518 (4 %) (M-NBoc) +•, 486 (8 %), 477 (5 %) 
(M- CH2CH2CH2NHBoc)
+•, 381 (4 %), 347 (2 %), 339 (18 %), 309 (5 %), 300  
(27 %), 278 (95 %), 250 (32 %), 239 (12 %) 217 (100 %) (M-2(Boc)-NH)+•, 209 
(44 %), 200 (40 %) (NH(CH2)3NHBoc)
+•, 181 (24 %), 163 (13 %), 149  
(34 %),131 (18 %), 117 (36 %) (BocNH2)
+•.  
Elemental analysis found C, 64.19; H, 6.89; N, 13.32 %. 
C34H44N6O6 requires: C, 64.54; H, 7.01; N, 13.32 %.    
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4,6-Bis-(4-[3-aminopropyl]carboxyamidophenyl)-6-(4-hydroxycarbonyl 
phenyl) pyrimidine hydrobromide salt  
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4-(4-[3-Boc-aminopropyl]carboxyamidophenyl)-6-(4-hydroxycarbonylphenyl) 
pyrimidine, 75, (0.10 g, 0.16 mmol) was taken up in conc. HBr and evaporated 
to dryness to yield the hydrobromide salt (0.07 g, 85 %);  m.p. decomp.  
> 250°C; 1H NMR (DMSO) δ 9.36 (s, 1H, 2-H), 8.84 (br s, 2H, NH), 8.78 (s, 1H, 
5-H), 8.49 (½ AB, J = 7.2 Hz, 4H, 2'-H, 6'-H), 8.06 (½ AB, J = 7.2 Hz, 4H, 3'-H, 
5'-H), 7.75 (br s, 6H, +NH3), 3.36 (br, 4H, CH2NHCOPh), 2.87 (br, 4H, 
CH2
+NH3), 1.88 (br, 4H NHCH2CH2);  
13C NMR (DMSO) δ 166.5 (C=O), 163.6 
(C-4, C-6), 159.6 (C-2), 139.2 (C-1') 136.9 (C-4'), 128.4 (C-3', C-5'), 127.9 (C-2', 
C-6'), 113.9 (C-5), 37.8 and  37.3 (CH2NH, CH2
+NH3), 28.0 (CH2CH2NH); IR 
(KBr): 3400s (N-H), 3000 br (N-H), 2900m (Ar C-H), 2350m (C-H), 1550s (Ar  
C-C), 1525s (C=O), 1550s (N-H), 1475s (Ar C-C), 1450m (C-H2), 1425m (C=C), 
1250s (C-N), 1150m (C-O);  MS (ESI+): m/z 433 (22%) (M+H)+ •, 416 (M-NH3)
+·, 
399 (4 %) (M-2NH3)
+•, 359 (45 %) (M-H2NCH2CH2CH2NH)
+•, 342 (3 %)  
(M-[H2NCH2CH2CH2NH]-NH3)
+•, 274 (7 %), 256 (5 %), 229 (3 %)  
(M-2[H2NCH2CH2CH2NHCO])
+•, 203 (5 %), 175 (5 %), 135 (4 %), 122 (6 %), 
111 (14 %), 98 (15 %), 87 (18 %), 75 (25 %) (H2NCH2CH2CH2NH)
+•, 56  
(100 %). Elemental analysis found C, 64.19; H, 6.89; N, 13.32 % 
C34H44N6O2·3.75HBr·0.2H2O requires: C, 38.98; H, 4.38; N, 11.36 %. 
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4-chloro-6-(4-methoxycarbonylphenyl) pyrimidine, 32  
4,6-dichloropyrimidine, 26, (0.50 g, 3.36 mmol), 4-methoxyphenylboronic acid, 
27, (0.60 g, 3.36 mmol) and aqueous (1 ml)  sodium carbonate (1.10 g, 10.07 
mmol) were stirred in a solution of glyme (50 ml) at room temperature with 
thorough degassing with N2 for 1 h. Pd(OAc)2 (0.04 g, 2.50 mmol%) and PPh3 
(0.09 g, 5.00 mmol%) were added to the reaction mixture and it was heated at 
100 °C under N2 reflux for 18 h. The solvents were removed by evaporation and 
the residue separated between water (200 ml) and chloroform (150 ml, 2 x 50 
ml). The organic layers were combined and dried over MgSO4. The solids were 
removed by filtration through a celite pad and the solvents evaporated. 
Recrystallisation from IPA afforded a pink solid 32 (0.68 g, 79 %); m.p. 165.0 – 
166.3 °C; 1H NMR (DMSO) δ 9.22 (s, 1H, 2-H), 8.50 (s, 1H, 5-H), 8.46 (½ AB,  
J = 8.4 Hz, 2H, 2'-H, 6'-H), 8.18 (½ AB, J = 8.4 Hz, 2H, 3'-H, 5'-H), 3.96 (s, 3H, 
OMe); 13C NMR (DMSO) δ 166.2 (C=O), 164.3 (C-6), 162.1 (C-4), 159.6 (C-2), 
139.5 (C-4'), 132.7 (C-1'), 130.3 (C-3', C-5'), 128.4  (C-2', C-6'), 118.8 (C-5), 
53.0 (CH3); IR (KBr): 2350s, 1735s (C=O), 1575s (Ar C-C), 1460s (Ar C-C), 
1450 (C-H3), 1120 (C-O), 800s (C-Cl) cm
-1. MS (ESI+): m/z 251.1 (25 %) 
(M+H)+•(37Cl), 249.1 (100 %) (M+H)+•(35Cl), 239.2 (5 %), 205.1 (5 %);   
Elemental analysis found C, 55.69; H, 3.72; N, 10.54 %  
C12H24N2O2Cl•0.5H2O requires: C, 55.94; H, 3.91; N, 10.87 %. 
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4-Chloro-6-(4-carboxyphenyl) pyrimidine, 31159  
4-Carboxyphenylboronic acid, 80, (2.78 g, 16.75 mmol) was stirred in a solution 
sodium carbonate (0.4 M, 150 ml) with thorough degassing with Ar for 30 min. 
This solution was added dropwise to a solution of acetonitrile (150 ml) 
containing 4,6-dichloropyrimidine (5.00 g, 33.56 mmol) and Pd(PPh3)4 (0.01 g) 
also thoroughly degassed with Ar. The combined reaction mixture was heated 
under Ar at reflux at 90 °C for 18 h. The mixture was cooled and washed with 
DCM (200 ml). The solution was acidified with conc. HCl and the precipitate 
was collected by filtration, washing with water and ether. The solid was loaded 
onto a plug of silica and washed through with 10% methanol in chloroform 
solution. The solvents were evaporated to yield white solid 31 (2.50 g, 64 %); 
m.p. 248.0 – 248.9 °C (lit m.p. not given); 1H NMR (DMSO) δ 9.14 (s, 1H, 2-H), 
8.42 (s, 1H, 5-H), 8.36 (½ AB, J = 8.3 Hz, 2H, 2'-H, 6'-H), 8.09 (½ AB,  
J = 8.3 Hz, 2H, 3'-H, 5'-H); 13C NMR (DMSO) δ 167.3 (C=O), 164.4 (C-6), 162.1 
(C-4), 159.6 (C-2), 140.6 (C-4'), 139.2 (C-1'), 130.4 (C-2', C-6'), 128.2 (C-3',  
C-5'), 118.6 (C-5). NMR peaks correspond to literature.  
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2-Bromo-6-(4-carboxyphenyl) pyridine, 82171  
4-Carboxyphenylboronic acid, 80, (1.00 g, 6.03 mmol) was stirred in a solution 
sodium carbonate (0.4 M, 50 ml) with thorough degassing with Ar for 30 min. 
This solution was added dropwise to a solution of acetonitrile (75 ml) containing 
2,6-dibromopyridine, 65, (2.86 g, 12.05 mmol) and Pd(PPh3)4 (0.01 g) also 
thoroughly degassed with Ar. The combined reaction mixture was heated under 
reflux at 90 °C for 18 h, then cooled and washed with DCM (150 ml). The 
solution was acidified with conc. HCl and the precipitate was collected by 
filtration, washing with water and ether. The solid was loaded onto a plug of 
silica and washed through with a 10 % methanol in chloroform solution. The 
solvents were evaporated to leave a white solid 82 (1.56 g, 93 %) m.p. 278.3 – 
278.9  °C (Lit m.p. not given); 1H NMR (DMSO) δ 13.11 (br s, 1H, OH), 8.18  
(½ AB, J = 8.6 Hz, 2H, 2'-H, 6'-H), 8.12 (d, J = 7.6 Hz, 1H, 3-H), 8.06 (½ AB,   
J = 8.6 Hz, 2H, 3'-H, 5'-H), 7.89 (t, J = 7.6 Hz, 1H, 4-H), 7.67 (d, J = 7.6 Hz, 1H,  
5-H); 13C NMR (DMSO) δ 167.4 (C=O), 156.7 (C-6), 141.9 (C-4'), 141.2 (C-4), 
141.1 (C-2), 132.2 (C-1'), 130.3 (C-3', C-5'),128.0 (C-3), 127.2 (C-2', C-6'), 
120.8 (C-5). NMR peaks correspond to literature. 
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4-(4-methoxycarbonylphenyl)-6-(4-carboxyphenyl) pyrimidine, 30        
4-Chloro-6-(4-methoxycarbonylphenyl)pyrimidine, 31, (0.15 g, 0.64 mmol), 4-
methoxycarbonyl phenyl boronic acid, 27, (0.19 g, 1.28 mmol) and potassium 
carbonate (0.27 g, 1.92 mmol) were stirred with thorough degassing with Ar in a 
solution of toluene:methanol (8:2, 50 ml). After 2 h Pd(PPh3)4 (0.01 g) was 
added and the reaction mixture was heated under Ar at reflux at 120 °C for  
48 h. The solvents were evaporated and the residue partitioned between 
chloroform (50 ml) and water (50 ml). The water layer was collected and 
acidified with conc. HCl. The precipitate was collected by filtration to give a 
white solid 30 (0.28 g, 55 %); m.p. decomp > 250 °C; 1H NMR (DMSO) δ 9.38 
(s, 1H, 2-H), 8.78 (s, 1H, 5-H), 8.48-8.52  (m, 4H, 2'-H, 6'-H, 2''-H, 6''-H), 8.15 
(m, 4H, 3'-H, 5'-H, 3''-H, 5''-H), 3.90 (s, 3H, OMe); 13C NMR (DMSO) δ 167.4 
(COOH), 166.4 (COOMe), 163.6 and 163.4 (C-4, C-6), 159.6 (C-2), 140.9 and 
140.5 (C-4', C-4''), 133.5 and 132.3 (C-1', C-1''), 130.4 and 130.2 (C-3', C-5',  
C-3'', C-5''), 128.2 and 128.1 (C-2', C-6', C-2'', C-6''), 114.4 (C-5), 52.9 (OMe); 
IR (KBR): 3000m (Ar C-H), 2750s (O-H), 1725 (C=O(OMe)), 1700s (C=O(OH)), 
1600 (Ar C-C), 1475s (Ar C-C), 1450s (C-H3), 1375m (C-H3), 1115s (C-O) cm
-1. 
ΜS (ΕSΙ-): m/z 333.0 (100%) (Μ-Η)-•, 289.2 (10%) (Μ-CΟ2Μe)
-•, 212.2 (5%)  
(Μ-PhCΟ2Me)
-•, 145.1 (10%), 81.3 (5%), 59.2 (57%), (ΜeΟ2)
-•. 
Elemental analysis found C, 56.88; H, 3.57; N,6.88.  
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C19H14N2O4•½HCl•½CHCl3 requires: C, 56.81; H, 3.67; N, 6.80 %. 
 
 
2-(4-Methoxycarbonylphenyl)-6-(4-carboxyphenyl) pyrimidine, 83        
2-Bromo-6-(4-methoxycarbonylphenyl)pyridine, 82, (1.00 g, 3.60 mmol), 4-
methoxycarbonyl phenyl boronic acid, 27, (0.60 g, 3.96 mmol) and potassium 
carbonate (0.99 g, 7.19 mmol) were stirred with thorough degassing with Ar in a 
solution of toluene:methanol (8:2, 150 ml). After 1 h Pd(PPh3)4 (0.01 g) was 
added and the reaction mixture was heated under reflux at 120 °C for 72 h. The 
solvents were evaporated and the residue partitioned between chloroform (50 
ml) and water (50 ml). The water layer was collected and acidified with conc. 
HCl. The precipitate was collected by filtration to give a white solid 83 (1.12 g,  
74 %); m.p. decomp >300 °C; 1H NMR (DMSO) δ 8.38 (½ AB, J = 8.4 Hz, 2H, 
2''-H, 6''-H), 8.12 (½ AB, J = 8.4 Hz, 2H, 2'-H, 6'-H), 8.10 (½ AB, J = 8.4 Hz, 2H, 
3'-H, 5'-H), 8.0 (m, 3H, 3-H, 4-H, 5-H), 7.96 (½ AB, J = 8.4 Hz, 2H, 3''-H, 5''-H), 
3.91 (s, 3H, OMe); 13C NMR (DMSO) δ 168.4 (C=O), 168.0 (C=O), 155.6 and 
155.4 (C-2, C-6), 143.4 and 143.3 (C-1', C-1''), 139.0 (C-4), 130.8 and 130.6  
(C-4', C-4''), 130.3 and 129.9 (C-3', C-5', C-3'', C-5''), 127.5 and 126.0 (C-2',  
C-6', C-2'', C-6''), 120.3 and 120.0 (C-3, C-5), 52.8 (OMe); IR (ATR): 3295  
(O-H), 3000s (Ar C-H), 1712s (C=O(OMe)), 1699s (C=O(OH)), 1607 (Ar  
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C-C),1475s (Ar C-C), 1441m (C-H3), 1375m (C-H3), 1016 (C-O)  cm
-1. MS 
(ESI+): m/z 334.1 (100 %) (M+H)+•, 279.0 (2 %), 269.0 (5 %), 232.0 (15 %)  
(M-CO2-CO2Me)
+•, 214.2 (10 %), 187.0 (10 %), 121.1 (5 %), 105.2 (15 %) 
(PhCO2)
+•, 102.4 (3 %), 55.5 (5 %). 
Elemental analysis found C, 56.47; H, 4.44; N, 3.31 %  
C20H15NO4·2HCl·1H2O requires: C, 56.62; H, 4.51; N, 3.30 %. 
 
4-(4-[3-Imidazol-1-ylpropylcarboxyamido]phenyl)-6-(4-methoxycarbonyl 
phenyl)pyrimidine, 28  
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4-(4-Methoxycarbonylphenyl)-6-(4-carboxyphenyl)pyrimidine, 30, (0.5 g, 1.50 
mmol), PyBOP (0.87 g, 1.65 mmol) and Et3N (0.17 g, 1.65 mmol) were stirred in 
DCM (50 ml) at RT for 1 h. 1-(3-Aminopropyl)imidazole, 73, (0.21 g, 1.65 mmol) 
was added to the reaction mixture and it was left at RT for 18 h. The precipitate 
was collected by filtration to leave a white solid 28 (0.45 g, 48 %); m.p. 182.4 – 
183.5 °C; 1Η ΝΜR (DΜSΟ) δ 9.38 (s, 1H, 2-H), 8.78 (s, 1H, 5-H), 8.71 (t,  
J = 5.7 Hz, 1H, NH), 8.52 (½ ΑΒ, J = 8.4 Ηz, 2Η, 2'-Η, 6'-Η), 8.48 (½ ΑΒ, J = 8.4 
Ηz, 2Η,2''-Η, 6''-Η), 8.14 (½ ΑΒ, J = 8.4 Ηz, 2Η, 3'-Η, 5'-Η), 8.04 (½ ΑΒ, J = 8.4 
Ηz, 2Η, 3''-Η, 5''-Η), 7.99 (s, 1H NCHN), 7.36 and 7.07 (2 x s, 1H, NCHCHN), 
4.09 (t , J = 6.6 Hz, 2Η, CONHCH2CH2CH2), 3.89 (s, 3H, OMe), 3.28 (q, J = 6.6 
Hz, 2Η, CONHCH2CH2CH2), 2.01 (quint., J = 6.6 Hz, 2Η, CONHCH2CH2CH2); 
13C ΝΜR (DΜSΟ) δ 166.4 (C=O), 166.3 (C=O), 163.7 and 163.3 (C-4, C-6), 
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159.6 (C-2), 141.0 (C-4''), 139.0 (C-4'), 137.5 and 137.2 (C-1', C-1''), 132.2 
(NCHN), 130.2 (C-3'', C-5''), 128.4 (C-3', C-5'), 128.3 (C-2', C-6'), 127.8 (C-2'', 
C-6''), 127.1 and 120.5 (NCH2CH2N), 114.2 (C-5), 52.6 (OMe), 44.9 
(CONHCH2CH2CH2), 37.1 (CONHCH2), 31.0 (CONHCH2CH2); ΙR (ΚΒr): 3100m 
(Ar C-H), 1725s (C=O(OH)), 1650s (C=O(NH)), 1625s (N-H), 1500m (C-Η2), 
1450m (C-Η3), 1300s (C-Ν), 1100m (C-Ο) cm
-1.  MS (ESI+): m/z 442.1 (100 %) 
(M+H)+•, 374.1 (25 %) (M-C3H4N2)
+•, 257.0 (2 %), 86.0 (2 %), 69.1 (2 %) 
(C3H5N2)
 +•.  
Elemental analysis found C, 61.72; H, 4.56; N,14.29 %.  
C25H23N5O3•⅔CH2Cl2 requires: C, 61.86; H, 4.92; N, 14.05 %. 
 
2-(4-[3-Imidazol-1-ylpropylcarboxyamido]phenyl)-6-(4-methoxycarbonyl 
phenyl) pyridine, 84  
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2-(4-Methoxycarbonylphenyl)-6-(4-carboxyphenyl)pyridine, 83, (0.5 g, 1.38 
mmol), PyBOP (0.79 g, 1.52 mmol) and Et3N (0.28 g, 2.77 mmol) were stirred in 
a solution of DCM (50 ml) at RT for 1 h. 1-(3-Aminopropyl)imidazole, 73,  
(0.19 g, 1.52 mmol) was added and the mixture stirred for 18 h at RT. The 
precipitate was collected by filtration to leave a white solid 84 (0.61 g, 100 %); 
m.p. 183.2 – 183.6 °C; 1Η ΝΜR (DΜSΟ) δ 8.54 (t, J = 5.5 Hz, 1H, NH); 8.26 (½ 
ΑΒ, J = 8.4 Ηz, 2Η, 2'-Η, 6'-Η), 8.20 (½ ΑΒ, J = 8.4 Ηz, 2Η, 2''-Η, 6''-Η), 8.00 (½ 
ΑΒ, J = 8.4 Ηz, 2Η, 3''-Η, 5''-Η), 7.97-7.94 (m, 3H, 3-H, 4-H, 5-H), 7.89 (½ ΑΒ,  
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J = 8.4 Ηz, 2Η, 3'-Η, 5'-Η), 7.56 (s, 1H NCHN), 7.11 and 6.78 (2 x s, 1H, 
NCHCHN), 3.93 (t , J = 6.7 Hz, 2Η, CONHCH2CH2CH2), 3.78 (s, 3H, OMe), 
3.16 (q, J = 6.7 Hz, 2Η, CONHCH2), 1.87 (quint., J = 6.7 Hz, 2Η, 
CONHCH2CH2);  
13C ΝΜR (DΜSΟ) δ 166.6 (C=O), 166.3 (C=O), 155.6 and 
151.0 (C-2, C-6), 143.5, (C-4''), 141.4 (C-4'), 139.3 (C-4), 137.9 (NCHN), 130.6 
and 130.5 (C-1', C-1''), 130.3 (C-3'', C-5''), 129.0 (C-3', C-5') 128.4 (C-2', C-6'), 
127.5 (C-2'', C-6''), 127.1 (NCHCHN or NCHCHN), 120.9 and 120.7 (C-3, C-5), 
119.9 (NCHCHN or NCHCHN), 52.9 (OMe), 44.4 (CONHCH2CH2CH2), 37.2 
(CONHCH2), 31.3 (CONHCH2CH2); ΙR (ATR): 3054m (Ar C-H), 1713s 
(C=O(OMe)), 1645s (C=O(NH)), 1609s (Ar C-C), 1558 (N-H), 1509m (C-Η2), 
1438m (C-Η3), 1279s (C-Ν) cm
-1;  MS (ESI+): m/z 441.1 (100 %) (M+H)+•, 373.1 
(20 %) (M-imidazole)+•, 152.2 (5 %) (CO(CH2)3(CH)3N2)
+•,150.2 (15 %), 86.4 
(42 %), 58.5 (COOMe)+•. 
Elemental analysis found C, 70.62; H, 5.19; N,12.95 %  
C26H24N4O3 requires: C, 70.89; H, 5.49; N, 12.72 %. 
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4-(4-[3-Imidazol-1-ylpropylcarboxyamido]phenyl)-6-(4-methoxycarbonyl 
phenyl)pyrimidine, 23  
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4-(4-[3-Imidazol-1-ylpropylcarboxyamido]phenyl)-6-(4-methoxycarbonylphenyl) 
pyrimidine, 28,  (0.2 g, 0.45 mmol) and NaOH (0.18 g, 4.5 mmol) were heated in 
water (50 ml) to 50 °C until the solid had dissolved. The solution was acidified 
with HCl to pH 3 (4 M) and the resultant precipitate filtered and washed with 
water and ether to leave a waxy solid 23 (0.18 g, 73 %); m.p. decomp. >300 °C; 
1Η ΝΜR (DΜSΟ) δ 9.38 (d, J = 1.2 Hz, 1H, 2-H), 9.26 (s, 1H, NCHN), 8.95 (t,  
J = 5.5 Hz, 1H, NH), 8.79 (d, J = 1.2 Hz, 1H, 5-H), 8.50 and 8.48 (2 x ½ ΑΒ,  
J = 8.4 Ηz, 2Η, 2'-Η, 6'-Η and 2''-Η, 6''-Η), 8.11 and 8.09 (2 x ½ ΑΒ, J = 8.4 Ηz, 
2Η, 3'-Η, 5'-Η and 3''-Η, 5''-Η), 7.89 and 7.68 (2 x s, 1H, NCHCHN), 4.29 (t,  
J = 6.6 Hz, 2H CONHCH2CH2CH2), 3.31 (q, J = 6.6 Hz, 2H CONHCH2), 2.11 
(quint., J = 6.6 Hz, 2H CONHCH2CH2); 
13C ΝΜR (DΜSΟ) δ 166.7 (C=O), 166.6 
(C=O), 162.4 and 162.1 (C-4, C-6), 155.6 (C-2), 143.4 and 141.9 (C-4' or C-4''), 
139.3 (C-1' or C-1''), 137.9 (NCHN), 130.3 (C-3'', C-5''), 129.0 (C-3', C-5'), 128.4 
and 127.5 (C-2', C-6', C-2'', C-6''), 127.1 and 120.9 (NCH2CH2N or NCH2CH2N), 
119.9 (C-5), 44.4 (CONHCH2CH2CH2), 37.2 (CONHCH2), 31.4 (CONHCH2CH2); 
Either C-1' or C-1'' not observed. ΙR (ATR): 3230 (O-H), 3056m (Ar C-H), 1697s 
(C=O(OH)), 1650s (C=O(NH)), 1465m (C-Η2), 1226s (C-Ν) cm
-1; MS (ESI+): 
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m/z 428.1 (100 %) (M+H)+•, 214.2 (6 %) (M-PhCONH(CH2)3(CH)3N2)
+•, 179.1  
(2 %), 158.1 (3 %), 151.1 (5 %), 125.2 (3 %), 69.5 (7 %);  
Elemental analysis found C, 52.44; H, 3.96; N,12.74 %  
C24H21N5O3•3HCl•⅔CO2 requires: C, 52.34; H, 4.27; N, 12.38 %. 
 
2-(4-[3-Imidazol-1-ylpropylcarboxyamido]phenyl)-6-(4-carboxyphenyl) 
pyridine, 85  
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2-(4-[3-Imidazol-1-ylpropylcarboxyamido]phenyl)-6-(4-methoxycarbonylphenyl) 
pyridine, 84,  (0.5 g, 1.14 mmol) and NaOH (0.45 g, 11.35 mmol) were heated 
in water (50 ml) to 50 °C for 2 h. The solution was acidified with HCl (4 M) to pH 
3 and the resultant precipitate collected by filtration and washed with water and 
ether to leave a white solid (0.40 g, 63 %); m.p. decomp >300 °C; 1Η ΝΜR 
(DΜSΟ) δ 9.23 (s, 1H NCHN), 8.80 (t, J = 5.3 Hz, 1H, NH); 8.36 (½ ΑΒ,  
J = 9.1 Ηz, 2Η, 2''-Η, 6''-Η), 8.20 (½ ΑΒ, J = 9.1 Ηz, 2Η, 2'-Η, 6'-Η), 8.11-8.03 
(m, 7Η, 3'-Η, 5'-Η, 3''-Η, 5''-Η, 3-H, 4-H, 5-H), 7.86 and 7.70 (2 x s, 1H, 
NCHCHN), 7.70 (s, 1H, NCHCHN or NCHCHN), 4.32 (t , J = 6.7 Hz, 2Η, 
CONHCH2CH2CH2), 3.32 (q, J = 6.7 Hz, 2Η, CONHCH2), 2.14 (quint.,  
J = 6.7 Hz, 2Η, CONHCH2CH2); 
13C ΝΜR (DΜSΟ) δ 167.7 (COOH), 
166.7(CONH), 155.5 and 155.3 (C-2, C-6), 143.0 (C-4''), 141.5 (C-4'), 139.3  
(C-4), 136.1 (NCHN), 135.3 (C-1'), 131.8 (C-1''), 130.4 (C-3'', C-5''), 128.4 (C-3', 
C-5'), 127.4 (C-2'', C-6''), 127.1 (C-2', C-6'), 122.6 (NCHCHN or NCHCHN), 
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120.71 and 120.70 (C-3, C-5), 120.4 (NCHCHN or NCHCHN), 47.1 
(CONHCH2CH2CH2), 36.6 (CONHCH2), 30.3 (CONHCH2CH2); ΙR (ATR): 3000m 
(Ar C-H), 1679s (C=O(OH)), 1634s (C=O(NH)), 1610s (Ar C-C), 1587 (N-H), 
1449m (C-Η3), 1291 (C-Ν) cm
-1; MS (ESI+): m/z 427.1 (100%) (M+H)+•, 381.2 
(10%) (M-CO2H)
+•, 353.2 (7%), 214.1 (5%). 
Elemental analysis found C, 54.69; H, 3.93; N, 9.82 %  
C25H22N4O3•2½HCl•1½H2O requires: C, 54.54; H, 4.23; N, 9.6 %. 
 
 
6.2.5 EXPERIMENTAL DETAILS FOR SECTION 3.4 
 
N-Boc-1-Amino-3-[biotin-1-ylamido]carboxyamidopropane, 88 
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Biotin, 87, (2.00 g 8.19 mmol), PyBOP (4.69 g, 9.00 mmol) and Et3N (0.91 g,  
9.00 mmol) were stirred at room temperature in DMF (10 ml) for 1 h. N-Boc-1,3-
Diaminopropane, 71, (1.58 g, 9.00 mmol) was added to the solution and left to 
stir for 15 h. The resultant oil was washed with ethyl acetate and the residue 
filtered to leave a white solid 88 (2.66 g, 92 %); m.p. 120.6-121.3 °C; 1H NMR 
(DMSO, 400.13 MHz) δ 7.73 (t, J = 5.3 Hz, 1H, 6'-H), 6.74 (t, J = 5.3 Hz, 1H, 2'-
H), 6.41 (s, 1H, 6-H), 6.35 (s, 1H, 4-H), 4.31 (s, 1H, 7-H), 4.14 (s, 1H, 3-H), 3.10 
(m, 1H, 2-H), 3.01 (q, J = 6.1 Hz, 2H, 5'-H), 2.90 (q, J = 6.3 Hz, 2H, 3'-H), 2.82 
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(dd, 1H, J = 5.1, 12.4 Hz, 8-Ha), 2.58 (d, 1H, J = 12.4 Hz, 8-Hb), 2.05 (t, J = 7.3 
Hz, 2H, 8'-H), 1.60 (m, 1H, 11'-Ha), 1.52-1.45 (m, 5H, 4'-H, 9'-H, 11'-Hb), 1.38 (s, 
9H, tBu), 1.31 (m, 2H, 10'-H).  13C ΝΜR (DΜSΟ) δ 172.5 (C-7'), 163.2 (C-5), 
156.1 (C-1'), 78.0 (CCH3), 61.5 (C-3), 59.7 (C-7), 55.9 (C-2), 38.1 (C-3'), 36.7 
(C-5'), 35.8 (C-8'), 30.2 (C-4'), 28.8 (CCH3), 28.7 (C-10'), 28.6 (C-11'), 25.8  
(C-9') C-8''' under DMSO solvent peak; ΙR (ATR): 3261m (C-H), 1765s (C=O), 
1629 (C=O), 1525 (N-H), 1473m (C-Η2), 1450m (C-Η3) cm
-1; MS (ESI+): m/z 
401.2 (100 %) (M+H)+•, 345.1 (5%), 301.1 (20 %) (M-Boc)+•, 214.2 (10%); 
Elemental analysis found C, 51.27; H, 7.88; N, 13.77;  
C18H32N4O4S·H2O requires: C, 51.65; H, 8.19; N, 13.39 %.           
 
4-[4-(3-[Biotin-1-ylamido]carboxyamidopropyl)carboxyamidophenyl]-4-[4-
methoxycarbonylphenyl]pyrimidine, 90 
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4-(4-Methoxycarbonylphenyl)-6-(4-carboxyphenyl)pyrimidine, 30, (0.25 g, 0.75 
mmol),  PyBOP (0.43 g, 0.82 mmol) and Et3N (0.38 g, 3.74 mmol) were stirred 
in DMF (10 ml) at RT for 1 h. In parallel, N-Boc-1-amino-3-[biotin-1-ylamido] 
carboxyamidopropane, 88,  (0.29 g, 0.82 mmol) was taken up in HBr (1 ml) and 
the HBr was evaporated under reduced pressure The residue was added to the 
PyBOP reaction mixture and it was left to stir for 18 h at RT. The DMF was 
evaporated under reduced pressure and the residue triturated with ethyl acetate 
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to leave a white solid 90 (0.16 g, 46 %); m.p. 154.2-154.6 °C; 1Η ΝΜR (DΜSΟ) 
δ 9.26 (d, J = 1.2 Hz, 1H, 2-H), 8.68 (d, J = 1.2 Hz, 1H, 5-H), 8.55 (t, J = 5.5 Hz, 
1H, NHB), 8.43 (½ ΑΒ, J = 8.6 Hz, 2H, 2'-H, 6'-H), 8.37 (½ ΑΒ, J = 8.6 Hz, 2H, 
2''-H, 6''-H), 8.03 (½ ΑΒ, J = 8.6 Hz, 2H, 3''-H, 5''-H), 7.92 (½ ΑΒ, J = 8.6 Hz, 
2H, 3'-H, 5'-H), 7.75 (t, J = 5.7 Hz, 1H, NHF), 6.32 (s, 1H, 6'''-H), 6.24 (s, 1H,  
4'''-H), 4.17 (m, 1H, 7'''-H), 4.00 (m, 1H, 3'''-H), 3.79 (s, 3H, OMe), 3.22 (m, 1H, 
2'''-H), 3.18 (q, J = 6.2 Hz, 2H, HC), 3.00 (q, J = 6.2 Hz, 2H, HE), 2.68 (dd,  
J = 5.0 Hz, 12.5 Hz, 1H, 8'''-Ha), 2.44 (d, J = 12.5 Hz, 1H, 8'''-Hb), 1.95 (t,  
J = 6.2 Hz, 2H, HH), 1.55 (quint., J = 6.2 Hz, 2H, HD) 1.51-1.38 (m, 6H, HK, HJ, 
HL); 
13C ΝΜR (DΜSΟ) δ 172.7 (CG), 166.4 and 166.0 (COOH, CA), 163.8  
(C-5'''),163.30 (C-4, C-6), 159.6 (C-2), 141.0 (C-4'), 138.9 (C-4''), 137.4 and 
137.3 (C-1', C-1''), 130.3 and 128.32 (C-3', C-5', C-3'', C-5''), 128.29 and 127.9 
(C-2', C-6', C-2'', C-6''), 114.2 (C-5), 61.9 (C-3'''), 59.7 (C-7'''), 56.0 (C-2'''), 53.0 
(OMe), 40.6 (C-8'''), 37.6 (CC), 36.9 (CE) 35.8 (CH), 29.9 (CD), 28.8 (CK) 28.6 
(CL), 25.9 (CJ); ΙR (ATR): 3281m (Ar C-H), 1699s (C=O(OMe)), 1640 
(C=O(NH)), 1588 (N-H), 1467m (C-Η2) cm
-1; MS (ESI+): m/z 617.1 (100 %) 
(M+H)+•, 539.3 (5 %), 473.2 (10 %), 391.1 (10 %), 374.2 (10 %), 317.1 (8 %) 
(M-NH(CH2)3NH-Biotin)
+•, 284.1 (7 %), 227.1 (7 %) (Biotin)+•, 187.2 (6 %), 102.4 
(50 %), 83.3 (38 %), 58.5 (65 %) (COOMe)+•.    
Elemental analysis found C, 62.68; H, 5.67; N, 13.72 %  
C32H36N6O5S· requires: C, 62.32; H, 5.88; N, 13.63%. 
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2-[4-(3-[Biotin-1-ylamido]carboxyamidopropyl)carboxyamidophenyl]-4-[4-
methoxycarbonylphenyl] pyridine, 91 
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2-(4-Methoxycarbonylphenyl)-6-(4-carboxyphenyl)pyridine, 83, (0.3 g, 0.90 
mmol),  PyBOP (0.52 g, 1.00 mmol) and Et3N (0.45 g, 4.49 mmol) were stirred 
in DMF (10 ml) at RT for 1 h. In parallel, N-Boc-1-amino-3-[biotin-1-
ylamido]carboxyamidopropane, 88, (0.29 g, 0.82 mmol) was taken up in HBr  
(1 ml) and the HBr was evaporated under reduced pressure The residue was 
added to the PyBOP reaction mixture and it was left at RT for 18 h. The DMF 
was evaporated under reduced pressure and the residue triturated with ethyl 
acetate to leave a white solid 91 (0.54 g, 83 %); m.p. 187.5-187.7 °C; 1Η ΝΜR 
(DΜSΟ) δ 8.57 (t, J = 5.6 Hz, 1H, NHB), 8.38 (½ ΑΒ, J = 8.6 Hz, 2H, 2'-H, 6'-H), 
8.32 (½ ΑΒ, J = 8.6 Hz, 2H, 2''-H, 6''-H), 8.08 (½ ΑΒ, J = 8.6 Hz, 2H, 3''-H, 5''-
H), 8.09 (m, 3H, 3-H, 4-H, 5-H), 8.01 (½ ΑΒ, J = 8.6 Hz, 2H, 3'-H, 5'-H), 7.83 (t, 
J = 5.6 Hz, 1H, NHF), 6.42 (s, 1H, 6'''-H), 6.35 (s, 1H, 4'''-H), 4.29 (m, 1H, 7'''-H), 
4.13 (m, 1H, 3'''-H), 3.90 (s, 1H, OMe), 3.29 (q, J = 6.8 Hz,  2H, HC), 3.12 (m, 
3H, 2'''-H, HE), 2.80 (dd, J = 5.1 Hz, 12.4 Hz, 1H, 8'''-Ha), 2.57 (d, J = 1245 Hz, 
1H, 8'''-Hb), 2.09 (t, J = 7.3 Hz, 2H, HH), 1.70 (quint., J = 6.8 Hz, 2H, HD),  1.55-
1.44 (m, 4H, HJ, HL), 1.32 (m, 2H, HK); 
13C ΝΜR (DΜSΟ) δ 172.5 (CG), 166.6 
(COOH), 166.2 (CA), 163.4 (C-5'''), 155.4 and 155.0 (C-2, C-6), 143.3 and 141.2 
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(C-4' or C4''), 139.2 (C-4), 135.6 and 130.5 (C-1', C-1'), 130.2 (C-3'', C-5''), 
128.2 (C-3', C-5'), 127.4 (C-2'', C-6''), 127.0 (C-2', C-6'), 120.7 and 120.6 (C-3, 
C-5), 61.5 (C-3'''), 59.2 (C-7'''), 56.0 (C-2'''), 52.7 (OMe), 40.6 (C-8'''), 37.5 (CC), 
36.8 (CE) 35.9 (CH), 29.8 (CD), 28.9 (CK) 28.6 (CL), 25.7 (CJ); ΙR (ATR): 2928m 
(Ar C-H), 1693s (C=O(OMe)), 1631 (C=O(NH)), 1587 (N-H), 1434m (C-Η2) 
1270 (C-O) cm-1;  MS (ESI+): m/z 617.1 (100 %) (M+H)+•, 539.3 (5 %), 473.2 
(10 %), 391.1 (10 %), 374.2 (10 %), 317.1 (8 %) (M-NH(CH2)3NH-Biotin)
+•, 
284.1 (7 %), 227.1 (7 %) (Biotin)+•, 187.2 (6 %), 102.4 (50 %), 83.3 (38 %), 58.5 
(65 %) (COOMe)+•;  
Elemental analysis found C, 61.87; H, 5.55; N, 61.87 %  
C33H37N5O5S•⅓HBr requires: C, 61.70; H, 5.86; N, 10.90 %. 
 
 
2-[4-(3-[Biotin-1-ylamido]carboxyamidopropyl)carboxyamidophenyl]-4-[4-
carboxyphenyl]pyridine, 92 
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2-[4-(3-[Biotin-1-ylamido]carboxyamidopropyl)carboxyamidophenyl]-4-[4-
methoxycarbonylphenyl]pyridine, 90, (0.14 g, 0.22 mmol) and NaOH (0.18 g, 20 
mmol) were stirred in a solution of water (20 ml) at 50 °C for 2 h. The basic 
solution was acidified with HCl (4 M) and the precipitate was collected by 
filtration. The resultant solid was washed with water and ether to leave a white 
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waxy solid (0.12 g, 89 %). m.p.decomp >300 °C; 1Η ΝΜR (DΜSΟ) δ 8.77 (br t, 
1H, NHC), 8.33-8.30 (m, 4H, 2'-H, 6'-H, 2''-H, 6''-H), 8.08-8.05 (m, 8H, 3-H, 4-H, 
5-H, 3'-H, 5'-H, 3''-H, 5''-H, NHF), 6.44 (s, 1H, 6'''-H), 6.37 (s, 1H, 4'''-H), 4.27 (m, 
1H, 7'''-H), 4.11 (m, 1H, 3'''-H), 3.29 (q, J = 6.5 Hz, 2H, HC), 3.09 (m, 3H, 2'''-H, 
HE), 2.79 (dd, J = 5.0 Hz, 12.5 Hz, 1H, 8'''- Ha), 2.55 (d, J = 12.5 Hz, 1H,  
8'''- Hb), 2.07 (t, J = 7.4 Hz, 2H, HH), 1.65 (quint., J = 6.5 Hz, 2H, HD) 1.60 (m, 
1H, HLa),  1.49 (m, 2H, HJ), 1.44 (m, 1H, HLb), 1.30 (m, 2H, HK); 
13C ΝΜR 
(DΜSΟ) δ 172.6 (CG=O), 167.9 (COOH), 166.2 (CA=O), 163.2 (C-5'''), 155.5  
(C-2 or C-6), 155.4 (C-2 or C-6), 141.4 (C-4' or C-4''), 141.3 (C-4' or C-4''), 
139.3 (C-4), 135.7 (C-1' or C-1''), 135.5 (C-1' or C-1''), 130.4 (C-3', C-5' or C-3'', 
C-5''), 128.3 (C-3', C-5' or C-3'', C-5''), 127.3 (C-2', C-6' or C-2'', C-6''), 127.1  
(C-2', C-6' or C-2'', C-6''), 120.6 (C-3, C-5),  61.6 (C-3'''), 59.8 (C-7'''), 56.0  
(C-2'''), 37.5 (CC), 36.7 (CE), 35.8 (CH), 29.7 (CD), 28.9 (CK), 28.6 (CL), 25.9 (CJ), 
C-8''' under DMSO solvent peak; ΙR (ATR): 3282m (O-H), 2850m (Ar C-H), 
1690s (C=O(OH)), 1635 (C=O(NH)), 1539 (N-H), 1448m (C-Η2) 1266 (C-O) 
cm1;  MS (ESI+): m/z 602.2 (100 %) (M+H)+•, 464.6 (10 %), 442.7 (9 %), 376.1 
(8 %) (M-Biotin)+•, 320.0 (8 %), 301.1 (6 %) (M-NH(CH2)3NHBiotin)
+•, 227.1  
(7 %) (Biotin)+•, 179.1 (5 %), 151.1 (6 %), 141.1 (5 %), 105.2 (12 %), 81.4 (6 %), 
53.5 (11 %);  
Elemental analysis found C, 51.68; H, 4.92; N, 9.21 %  
C32H35N5O5S·3HCl·1½CO2 requires: C, 51.78; H, 4.93; N, 9.01 %. 
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2-[4-(3-[Biotin-1-ylamido]carboxyamidopropyl)carboxyamidophenyl]-4-[4-
(3-[imidazol-1-yl]carboxyamidophenyl]pyridine, 16  
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2-[4-(3-[Imidazol-1-ylamido]carboxyamidopropyl)phenyl]-6-[4-carboxyphenyl] 
pyridine, 85, (0.10 mg, 0.23 mmol), PyBOP (0.13 g, 0.26 mmol) and Et3N (0.26 
g, 2.6 mmol) were stirred in DMF (5 ml) for 1 h at room temperature. In parallel, 
N-Boc-1-amino-3-[biotin-1-ylamido]carboxyamidopropane, 88, (0.10 g, 0.26 
mmol) was taken up in HBr (1 ml) and the HBr was evaporated under reduced 
pressure The residue was added to the PyBOP mixture and left to stir for 18 h. 
The DMF was evaporated under reduced pressure and the residue washed with 
ethyl acetate and acetonitrile. Recrystallisation from methanol yielded 0.11 g of 
product 16 (62 %). m.p. decomp >138.4-138.7 °C; 1Η ΝΜR (DΜSΟ) δ 8.69 (t, J 
= 5.15 Hz, 1H, NHB or NHN), 8.64 (s, 1H NCHN), 8.58 (t, J = 5.15 Hz, 1H, NHB 
or NHN), 8.33 (m, 4H, 2'-H, 6'-H, 2''-H, 6''-H), 8.07-8.03 (m, 3H, 3-H, 4-H, 5-H), 
8.00 (m,42H, 3'-H, 5'-H, 3''-H, 5''-H), 7.86 (t, J = 5.15 Hz, 1H, NHF), 7.63 (s, 1H, 
and 7.42 (2 x s, 1H, NCHCHN), 6.43 (s, 1H, 6'''-H), 6.36 (s, 1H, 4'''-H), 4.28 (m, 
1H, 7'''-H), 4.19 (t, J = 6.8 Hz, 2H, HR), 4.11 (m, 1H, 3'''-H), 3.29 (m, 4H, HC, 
HP), 3.10 (m, 3H, 2'''-H, HE), 2.79 (dd, J = 5.0 Hz, 12.4 Hz, 1H, 8'''-Ha), 2.55 (d,  
J = 12.4 Hz, 1H, 8'''-Hb), 2.09 (m, 4H, HH, HQ), 1.64 (quint., J = 6.8 Hz, 2H, HD) 
1.61 (m, 1H, HLa),  1.52 (m, 2H, HJ), 1.47 (m, 1H, HLb), 1.31 (m, 2H, HK); 
13C 
ΝΜR (DΜSΟ)  δ 172.9 (CG), 166.7 (CA, C M), 163.3 (C-5'''), 155.5 (C-2, C-6), 
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141.5 and 141.4 (C-4', C4''), 139.2 (C-4), 135.6 (NCHN), 135.4 (C-1', C-1''), 
128.4 and 128.3 (C-3', C-5', C-3'', C-5''), 127.1 (C-2', C-6', C-2'', C-6''), 121.5 
and 120.5 (NCHCHN),  120.4 (C-3, C-5), 61.6 (C-3'''), 59.7 (C-7'''), 56.0 (C-2'''), 
46.4 (CR) 39.7 (CP), 37.7 (CC), 36.9 (CE), 35.8 (CH), 30.4 (CQ), 29.8 (CD), 28.8 
(CK), 28.6 (CL), 25.9 (CJ), C-8''' under DMSO solvent peak; ΙR (ATR): 2950m (Ar 
C-H), 1691s (C=O(OH)), 1630 (C=O(NH)), 1536 (N-H), 1448m (C-Η2) 1250  
(C-N) cm-1;  MS (ESI+) m/z 709.3 (100 %) (M+H)+•, 641.2 (25 %)  
(M-imidazole)+•, 584.1 (5 %) (M-NH(CH2)3imidazole)
+•, 483.1 (3 %), 415.1  
(10 %), 409.1 (18 %) (M- NH(CH2)3NHBiotin)
+•, 358.1 (15 %), 341.1 (47 %), 
313.0 (34 %), 283.1 (11 %), 228.2 (8 %) (Biotin)+•, 219.2 (14 %), 187.1 (3 %), 
177.2 (9 %), 151.2 (4 %) (CONH(CH2)3imidazole)
+•, 114.2 (22 %), 97.3 (8 %), 
70.5 (18 %) (CH5H10)
+•, 56.4 (45 %) (CH4H8)
+•. 
Elemental analysis found C, 59.44; H, 6.26; N, 14.11. 
C38H44N8O4S•⅔HBr•½H2O requires C, 59.11; H, 5.96; N, 14.51. 
 
 
 
 
 
 
 
 
 
 
Experimental 
193 
 
2-[4-(3-[biotin-1-ylamido]carboxyamidopropyl)carboxyamidophenyl]-4-[4-
(3-[pyrrolidin-1-yl]carboxyamidophenyl]pyridine, 17  
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2-[4-(3-[Biotin-1-ylamido]carboxyamidopropyl)phenyl]-6-[4-carboxyphenyl] 
pyridine, 92, (0.10 mg, 0.17 mmol), PyBOP (0.95 g, 0.18 mmol) and Et3N (0.50 
g, 0.50 mmol) were stirred in DMF (5 ml) for 1 h at RT. 1-(3-Aminopropyl) 
pyrrolidine, 94, (0.23 g, 0.18 mmol) was added and the solution stirred for  
18 h at RT. The DMF was evaporated under reduced pressure and the residue 
washed with ethyl acetate. Recrystallisation from methanol yielded product 17 
(0.089 g, 52 %). m.p. decomp >300 °C; 1Η ΝΜR (DΜSΟ) δ 8.69 and 8.64 (2 x t, 
J = 5.5 Hz, 1H, NHB, NHN), 8.31 (m, 4H, 2'-H, 6'-H, 2''-H, 6''-H),  8.07-7.99 (m, 
7H, 3-H, 4-H, 5-H, 3'-H, 5'-H, 3''-H, 5''-H,), 7.90 (q, J = 5.50 Hz, 1H, NHF), 6.42 
(s, 1H, 6'''-H), 6.35 (s, 1H, 4'''-H), 4.28 (m, 1H, 7'''-H), 4.11 (m, 1H, 3'''-H), 3.38 
(q, J = 6.5 Hz, 2H, HR), 3.34 (q, J = 6.5 Hz, 2H, HD), 3.30 (m, 6H, Hc, 
HNCH2(CH2)2CH2), 3.10 (m, 3H, 2'''-H, HE), 2.79 (dd, J = 5.2 Hz, 12.5 Hz, 1H, 
8'''-Ha), 2.55 (d, J = 12.5 Hz, 1H, 8'''-Hb), 2.07 (m, 4H, HH, HQ), 1.93-1.89 (m, 
4H, HNCH2(CH2)2CH2) 1.64 (q, J = 6.9 Hz, 2H, HD) 1.59 (m, 1H, HLa),  1.50 (m, 
2H, HJ), 1.44 (m, 1H, HLb), 1.32 (m, 2H, HK); 
13C ΝΜR (DΜSΟ) δ 172.6 (CG), 
166.5 and 166.2 (CA, CM), 163.4 (C-5'''), 155.5 (C-2, C-6), 141.4 (C-4', C-4''), 
139.4 (C-4), 135.6 (C-1', C-1''), 128.4 and 128.2 (C-3', C-5', C-3'', C-5''), 127.1 
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(C-2', C-6', C-2'', C-6''), 120.6 (C-3, C-5),  61.6 (C-3'''), 59.7 (C-7'''), 55.8 (C-2'''), 
53.4 (NCH2(CH2)2CH2, CR), 37.5 (CC), 37.2 (CP), 37.0 (CE), 35.9 (CH), 31.3 
(CQ)29.7 (CD), 28.8 (CK), 28.6 (CL), 25.9 (CJ), 23.0 (NCH2(CH2)2CH2), C-8''' 
under DMSO solvent peak; ΙR (ATR): 2929m (Ar C-H), 1691s (C=O(OH)), 1633 
(C=O(NH)), 1536 (N-H), 1448m (C-Η2) 1305 (C-N) cm
-1;  MS (ESI+) m/z 712.3 
(100 %) (M+H)+•, 679.2 (18 %), 641.2 (10 %) (M-pyrrolidine)+•, 584.1 (5 %)  
(M-NH(CH2)3pyrrolidine)
+•, 415.1 (4 %), 412.1 (7 %) (M- NH(CH2)3NHBiotin)
+•, 
358.1 (12 %), 341.1 (35 %), 313.0 (20 %), 286.0 (10 %), 283.1 (5 %), 114.2  
(2 %), 84.4 (13 %), 56.4 (45 %) (CH4H8)
+•.  
Elemental analysis found C, 45.88; H, 5.13; N, 9.71.  
C39Η49Ν7Ο4S·7⅔ ΗCl·1⅓ CO2Ο required C, 46.13; Η, 5.44; Ν, 9.34 % 
 
 
6.1.5 EXPERIMENTAL DETAILS FOR SECTION 3.5 
 
2-Chloro-4,6-bis-(4-methoxycarbonylphenyl)pyrimidine, 37 
2,4,6-Trichloropyrimidne, 38, (2.00 g, 10.9 mmol), 4-methoxycarbonylphenyl 
boronic acid, 27, (3.92 g, 21.80 mmol) and aqueous sodium carbonate (3.47 g, 
32.71 mmol) were stirred in glyme (150 ml) with thorough degassing with N2 for 
30 min. Pd(OAc)2 (0.06 g, 2.50 mol%) and PPh3 (0.14 g, 5.00 mol%) were 
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added and the reaction heated at 100 °C for 15 h. The reaction mixture was 
cooled and the precipitate collected by filtration. The solid was recrystallised 
from ethanol and washed with petroleum ether to leave a white powder 37 (3.62 
g, 87%); m.p. 282.9 – 283.9°C;  1H NMR (CDCl3) δ 8.21 (½ AB, J = 8.6 Hz, 4H,  
2'-H, 4'-H), 8.18 (½ AB, J = 8.6 Hz,4H, 3'-H, 5'-H), 8.08 (s, 1H, 5-H), 3.96 (s, 6H, 
CH3); 
13C NMR (CDCl3) δ 166.9 (C=O), 166.4 (C-4, C-6), 139.4 (C-4'), 133.0  
(C-1'), 130.4 (C-3', C-5'), 127.6 (C-2', C-6'), 111.9 (C-5), 52.6 (OCH3); IR (KBr): 
2350m, 1750s (C=O), 1575s (Ar C-C), 1460m (Ar C-C), 1450s (C-H3), 1375m 
(C-H3), 1115 (C-O), 750s (C-Cl) cm
-1. MS (ESI+): m/z 383.2 (8 %)(M+H)+•(37Cl),  
381.2 (30 %) (M+H)+•(35Cl), 352.2 (20 %) (M-OMe)+• (37Cl), 349.1 (100 %)  
(M-OMe)+• (35Cl), 301.0 (5 %), 279.1 (6 %), 249.2 (5 %), 196.2 (2 %), 183.1  
(5 %), 151.1 (28 %), 119.2 (20 %), 105.2 (10 %), 94.4 (7 %);  
Elemental analysis found C, 62.63; H, 3.72; N,6.99.  
C20H15N2O4Cl requires: C, 62.75; H, 3.95; N, 7.32 %. 
 
General Method 3: Attachment of a linker to the 2-pyrimidine position 
 
2-Benzylamino-4,6-bis-(4-methoxycarbonylphenyl)pyrimidine, 103  
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2-Chloro-4,6-bis-(4-methoxycarbonylphenyl)pyrimidine, 37, (0.20 g, 0.52 mmol), 
benzylamine, 102, (0.08 g, 0.78 mmol), potassium carbonate (0.14 g, 1.04 
mmol), copper iodide (0.01 g, 0.05 mmol) and L-proline (0.01 g, 0.10 mmol) 
were stirred in DMSO (2 ml) at 80 °C for 5 h. Water (20 ml) was added and the 
mixture extracted with ethyl acetate (3 x 15 ml). The organic layers were 
combined and dried over MgSO4. The solids were removed by filtration through 
a celite pad. The solvent was evaporated and the residue was recrystallised 
from ethanol to leave a fine solid 103 (0.15 g, 64 %); m.p. 194.1-194.8 °C; 1H 
NMR (CDCl3) δ 8.37 (½ AB, J = 8.3 Hz, 4H, 2'-H, 6'-H), 8.09 (½ AB, J = 8.3 Hz, 
4H, 3'-H, 5'-H), 7.90 (s, 1H, 5-H), 7.43 (d, 2H, J = 7.4 Hz, 2''-H, 6''-H), 7.31 (t,  
J = 7.4 Hz, 2H, 3''-H, 5''-H), 7.20 (t, J = 7.4 Hz, 1H, 4''-H), 4.66 (d, J = 6.2 Hz, 
2H, CH2), 3.89 (s, 6H, CH3), 3.33 (s, 1H, NH); 
13C NMR (DMSO) δ 166.4 (C=O), 
163.2 (C-4, C-6), 142.0 (C-2), 141.1 (C-4'), 131.8 (C-1'), 130.0 (C-3', C-5'), 
128.8 (C-2'', C-6''), 127.91 and 127.90 (C-2', C-6', C-3''', C-5'''), 127.1 (C-4''), 
103.4 (C-5), 52.9 (OCH3), 44.9 (CH2), C-1''' not observed; IR (KBr): 3400s  
(N-H), 3025w (Ar C-H), 2950w (C-H), 2350w, 1700s (C=O), 1600s (Ar C-C) 
1550s (N-H), 1475m (Ar C-C), 1460m (C-H3), 1450m (C-H2), 1275s (C-N), 
1100s (C-O) cm-1; MS (ESI+): m/z 454 (100 %) (M+H)+•, 381 (8 %)  
(M-MeCOOMe) +•, 353 (5 %), 301 (4 %), 241 (18 %), 236 (7 %), 213 (5 %), 196 
(13 %), 170 (2 %), 165 (15 %), 151 (6 %), 133 (18 %), 117 (7 %), 101 (23 %), 
91 (29 %) (PhCH2)
+•, 79 (28 %) (Ph+H)+•, 74 (4 %) (MeCOOMe)+•.  
Elemental analysis found C, 69.66; H, 5.27; N, 9.03 %  
C27H23N3O4•
2/3 H2O requires: C, 69.71; H, 5.26; N, 9.03 %. 
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2-(N-Boc-1,3-diaminopropane)-4,6-bis-(4-methoxycarbonylphenyl) 
pyrimidine, 104 
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Prepared according to general method 3, from 2-chloro-4,6-bis-(4-methoxy 
carbonylphenyl)pyrimidine, 37, (1.00 g, 2.60 mmol) and N-Boc-1,3-
diaminopropane, 71, (0.68 g, 3.90 mmol). Recrystallisation from ethanol yielded 
a white solid (0.65 g, 48 %); m.p. 163.5-164.5 °C; 1H NMR (DMSO) δ 8.38 (½ 
AB, J = 8.3 Hz, 4H, 2'-H, 6'-H), 8.08 (½ AB, J = 8.3 Hz, 4H, 3'-H, 5'-H), 7.87 (s, 
1H, 5-H), 7.44 (t, J = 5.6 Hz, 1H, NHCH2), 6.85 (t, J = 5.6 Hz, 1H, NHCO), 3.90 
(s, 6H, OCH3), 3.44 (q, J = 6.5 Hz, 2H, CH2NHAr), 3.03 (q, J = 6.5 Hz, 2H, 
CH2NHCO), 1.72 (quint., J = 6.5 Hz, 2H, CH2CH2CH2), 1.35 (s, 9H, 
tBu); 13C 
NMR (DMSO) δ 166.4 (COOCH3), 163.3 (COOBu
t), 156.2 (C-2), 142.0 (C-4'), 
131.7 (C-1'), 130.0 (C-3', C-5'), 127.9 (C-2', C-6'), 103.0 (C-5), 78.0 (CMe3), 
52.9 (OCH3), 39.1 (ArNHCH2), 38.3 (CH2NHBoc), 30.0 (NHCH2CH2CH2NH), 
28.8 (C(CH3)3); IR (KBr): 3400s (N-H), 3025w (Ar C-H), 2950m (C-H), 2350m, 
1750s (C=O), 1580s (Ar C-C) 1550s (N-H), 1450m (C-H3), 1450m (C=C), 1275s 
(C-N), 1100s (C-O) cm-1; MS (ESI+): m/z 521 (100 %) (M+H)+•, 241 (18 %), 197 
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(7 %), 165 (34 %), 151 (10 %), 133 (31 %), 119 (10 %), 101 (10 %) (Boc)+•, 79 
(6 %) (Ph+H)+•, 61 (4 %) (CH3COOH+H)
+•.  
Elemental analysis found C, 64.66; H, 5.83; N, 10.59 %  
C28H32N4O6 requires: C, 64.60; H, 6.20; N, 10.76 %. 
 
2-Benzylamine-4,6-bis-(4-carboxyphenyl)pyrimidine, 105  
2-Benzylamino-4,6-bis-(4-methoxycarbonylphenyl)pyrimidine, 104, (82 mg, 0.18 
mmol) was heated at 100°C in a solution of sodium hydroxide (2 M, 10 ml) for 
18 h. The solution was acidified with HCl (4 M) and the precipitate collected by 
filtration and washed with water and chloroform to leave a fine powder (76 mg, 
75 %); m.p. decomp. > 250°C;1Η ΝΜR (DΜSΟ) δ 8.11 (½ ΑΒ, J = 8.1 Ηz, 4Η, 
2'-Η, 6'-Η), 7.93 (½ ΑΒ, J = 8.1 Ηz, 4Η, 3'-Η, 5'-Η), 7.82 (t, J = 6.4 Hz, 1Η, ΝΗ), 
7.01 (s, 1Η, 5-Η), 7.43 (d, J = 7.6 Hz, 2-Η, 2''-Η, 6''-Η), 7.30 (t, J = 7.6 Hz, 2-Η, 
3''-Η, 5''-Η), 7.19 (t, J = 7.4 Hz, 1Η, 4''-H), 4.64 (d, J = 6.36 Hz, 2Η, CΗ2 ); 
13C 
ΝΜR (DΜSΟ) δ 169.6 (C=Ο), 163.2 (C-4, C-6), 143.3 (C-2), 141.5 (C-4'), 137.7 
(C-1'), 129.7 (C-3', C-5'), 128.7 (C-2'', C-6''), 127.9 (C-3'', C-5''), 127.0 (C-2',  
C-6'), 126.5 (C-4''), 102.4 (C-5), 44.9 (CΗ2); ΙR (ΚΒr): 3400s (Ν-Η), 3350br  
(Ο-Η) 2975w (Αr C-Η), 2350m (C-Η), 1600s (Αr C-C), 1575s (C=Ο), 1550s  
N N
HO
O
OH
O
1
2
3
4
5
6
1'
2'
3'
4'
5'
6'
NH
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(Ν-Η), 1500m (C-Η2), 1425m (C=C), 1400s (C-Ν), 1050m (C-Ο); ΜS (ΕSΙ+): 
m/z 448 (12%) (Μ+Η+Νa)+•, 426 (100 %) (Μ+Η)+•, 381 (4 %) (Μ-CΟ2)
+•, 117 (2 
%), 91 (5 %) (PhCH2)
+•, 85 (10 %).  
Elemental analysis found C, 53.77; Η, 4.18; Ν, 7.61 % 
C25Η19Ν3Ο4•1.5Η2Ο•3HCl requires: C, 54.81; Η, 4.24; Ν, 7.59 %.  
 
2-Chloro-4,6-bis-(4-carboxyphenyl)pyrimidine, 36  
N N
HO
O
OH
O
1
2
3
4
5
6
1'
2'
3'
4'
5'
6'
Cl
 
2,4,6-Trichloropyrimidne, 38, (0.50 g, 2.73 mmol), 4-carboxyphenylboronic acid 
pinacol ester, 81, (1.35 g, 5.44 mmol) and aqueous sodium carbonate (0.87 g, 
8.21 mmol) were stirred in glyme (50 ml) with thorough degassing with N2 for 1 
h. Pd(OAc)2 (0.02 g, 2.50 mol%) and PPh3 (0.04 g, 5.00 mol %) were added and 
the mixture was heated at 100 °C for 18 h. The reaction mixture was cooled and 
the precipitate collected by filtration. The solid was washed with petroleum ether 
and the solid triturated with hot methanol to leave a solid (0.69 g, 72%); m.p. 
decomp. > 250 °C;  1H NMR (DMSO) δ 8.81 (s, 1H, 5-H), 8.47 (½ AB,  
J = 8.4 Hz, 4H, 2'-H, 6'-H), 8.11 (½ AB, J = 8.4 Hz, 4H, 3'-H, 5'-H); 13C NMR 
(DMSO) δ 167.3 (C=O), 166.9 (C-4, C-6), 161.4 (C-2), 139.1 (C-4'), 134.2  
(C-1'), 130.5 (C-3', C-5'), 128.4 (C-2', C-6'), 113.7 (C-5); IR (KBr): 3400br (O-H), 
3100s (Ar C-H) 1700s (C=O), 1600s (Ar C-C), 1460m (Ar C-C), 1235 (C-O), 
750s (C-Cl) cm-1. MS (ESI-): m/z 355.0 (22 %) (M-H)-• (37Cl),  , 353.0 (55 %)  
M-H)-• (35Cl), 335.1 (3 %), 311.0 (2 %) (M-COOH)-•(37Cl), 309.0 (5 %)  
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(M-COOH)-• (35Cl), 251.1 (7 %), 249.1 (18 %), 241.2 (20 %), 212.3 (18 %), 
198.0 (12 %), 163.0 (5 %), 145.2 (100 %), 137.2 (16 %), 121.2 (8 %) 
(PhCOOH)-•, 93.3 (10 %).  
 
 
EXPERIMENTAL DETAILS FOR CHAPTER 4: BIOLOGICAL 
EVALUATION AND PROTEOMICS 
 
MATERIALS 
 
Acrylamide (30%), Dodeca silver stain kit, and trishydroxymethyl 
aminomethane were purchased from Bio-Rad. Peptide calibrant standard II 
(ACTH clip 1-17, ACTH clip 18-39, angiotensin I, angiotensin II, bombesin, 
bradykinin 1-7, renin substrate, somatostatin 28, substance P) was purchased 
from Bruker Daltonics (Bremen, Germany). Complete mini EDTA-free protease 
inhibitor cocktail tablets and trypsin were purchased from Roche Diagnostics 
(Mannheim, Germany). NAP-5 columns were purchased from GE Healthcare. 
All other materials, including streptavidin beads and HPLC solvents were 
purchased from Sigma-Aldrich, Gillingham, UK or Lancaster, Morecambe, UK. 
The Human ovarian carcinoma A2780 (#93112520) and human colon 
adenocarcinoma HT29 (#91072201) were obtained from the ECACC.   
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CELL MAINTENANCE 
 
Cell lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 
medium supplemented with fetal bovine serum (10 %), L-glutamine (2 mM) and 
sodium pyruvate (1 mM).  Cells lines were maintained at 37˚ C in a 5 % CO2 
humidified atmosphere.  
 
Cells were maintained in exponential growth by subculturing every 3-4 days at 
approximately 75 % confluence. Adhered cells were washed with HBSS (2 x 10 
ml) and trypsinisation was carried out using trypsin-EDTA solution (0.25 %,  
3 ml). Upon the cells detachment from the flask, the trypsin solution was diluted 
with medium (10 ml). The cell suspension was centrifuged (200 g, 5 mins) and 
the supernatant discarded. The cell pellet was either re-suspended in fresh 
culture medium (10 ml) and transferred (1 ml) to a new flask containing fresh 
medium (19 ml), or frozen at -80 °C for proteomics.        
 
MTT ASSAY 
 
Cells at approximately 75 % confluence were washed with HBSS (2 x 10 ml), 
trypsinised and resuspended in fresh medium (10 ml). The cell concentration 
was determined by counting the cells with a haemocytometer and the cells were 
plated at 2000 cells per well in 200 µl of medium (the first lane was left blank) 
and incubated at 37 °C for 24 h. 
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The medium was removed and fresh medium (180 µl) was added to the wells 
(fresh medium was also added to lane 1 (200 µl)). DMSO solution (0.1 %, 20 µl) 
was added to wells in lane 2. Serial dilutions of drugs ranging from 1 mM –  
2 µM, were prepared in culture medium and added (20 µl) to cells in lanes 3-12, 
giving a drug concentration of 100 µM – 0.2 µM. Cells were left to incubate for 
96 h at 37 °C.  
 
MTT solution was made by diluting a stock MTT solution (0.5 mg/ml, 2 ml) with 
culture medium (18 ml). Medium was removed from all wells and replaced with 
MTT solution and the plate was left to incubate for 4 h at 37 °C. The MTT 
solution was removed and the resultant formazan crystals were dissolved in 
DMSO (150 µl). The absorbance of each lane was measured at 540 nm. 
 
Analysis of Chemosensitivity Data 
 
The percentage of cell survival was calculated using the following equation from 
the mean absorbance for all eight wells in each lane: 
 
 
 
Equation 6.1. Where blank is lane 1 containing culture medium and control is lane 2 
containing cells treated with DMSO (0.1 %).    
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Percentage cell survival was plotted against drug concentration and IC50 values 
obtained from the concentration of drug when cell survival was equal to 50 % of 
the control. 
 
NAP-5 COLUMN 
 
A NAP-5 column was equilibrated with PBS or ambic (~10 ml). The sample was 
loaded on the column (500 µl, diluted with buffer if necessary). The sample was 
eluted using the same buffer used for equilibration (1 ml). Desalted samples 
were lyophilised and stored at -20 °C.    
 
AFFINITY CHROMATOGRAPHY 
 
Method 1 
 
A2780 cell pellets (3) were thawed and washed with PBS (3 x 1 ml, 15 min). 
They were resuspended in Tris HCl (pH 7.5, 100 µl) containing CHAPs (4%) 
and complete protease inhibitor cocktail (14 µl). The cell suspensions were 
combined and sonicated using a SH70A sonicator (2 x 20 s). The suspensions 
were centrifuged (4 °C, 13000 g, 10 min). The DNA was extruded from cell 
pellets with a fine pipette needle (10 x) and centrifuged (4 °C, 13000 g, 10 min). 
The supernatant was collected and split in two. An affinity probe (16 or 17,  
10 µl, 400 µM in Tris-HCl) was added to the supernatant (190 µl), to give a final 
affinity probe concentration of 20 µM, and incubated for 2 h at room 
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temperature on a carousel. Protein samples were desalted with a NAP-5 
column using PBS. 
 
Streptavidin beads (2 x 100 µl) were washed with PBS (3 x 1 ml). The desalted 
protein solutions were added to the streptavidin beads and incubated at RT for 
4 h on a carousel. The bead suspensions were centrifuged (13000 g, 1 min) 
and the supernatant removed and stored. The streptavidin beads were washed 
with PBS (3 x 1 ml, 15 mins) and Urea (15 mins, 300 µl, 8M in ambic (25 mM)). 
The urea elutions were desalted with a NAP-5 column using ambic (25 mM).      
 
Method 2 
 
Carried out according to method 1 (Section 6.1.3.1) using A2780 cell pellets (6) 
and incubating protein suspensions (290 µl) with affinity probes (16 or 17, 10 µl, 
3 mM in Tris-HCl), to give a final drug concentration of 100 µM, for 24 h.  
 
Method 3 
 
Streptavidin beads (6 x 100 µl) were washed with PBS (3 x 1 ml, 15 min), 
resuspended in PBS (290 µl) and incubated with either 16 (10 µl, 3 mM), 17 (10 
µl, 3 mM) or no compound for 2 h. In parallel, Cell pellets (9) from A2780 and 
HT29 cell lines were thawed and washed with PBS (3 x 1 ml, 15 min). They 
were resuspended in Tris HCl (pH 7.5, 100 µl) containing CHAPs (4 %) and 
complete protease inhibitor cocktail (14 µl). The cell suspensions were 
combined and sonicated using a SH70A sonicator (2 x 20 s). The suspensions 
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were centrifuged (4 °C, 13000 g, 10 min). The DNA was extruded from cell 
pellets with a fine pipette needle (10 x) and centrifuged (4 °C, 13000 g, 10 min). 
The supernatant was collected.  
 
The streptavidin beads suspensions were centrifuged (13000 g, 1 min) and the 
supernatant removed. The protein suspensions (300 µl) were added to the 
streptavidin beads and left to incubate at room temperature for 24 h on a 
carousel.  The bead suspensions were centrifuged (13000 g, 1 min) and the 
supernatant removed and stored. The streptavidin beads were washed with 
PBS (3 x 1 ml, 15 min) and Urea (15 min, 300 µl, 8 M in ambic (25 mM)). The 
urea elutions were desalted with a NAP-5 column using ambic (25 mM).      
  
Method 4 
 
Streptavidin beads (12 x 100 µl) were washed with PBS (3 x 1 ml, 15 min), 
resuspended in PBS (100 µl) and incubated with either 16 (100 µl, 1 mM), 17 
(100 µl, 1 mM) or no compound for 24 h at 4 °C. In parallel, Cell pellets (9) from 
A2780 and HT29 cell lines were thawed and washed with PBS (3 x 1 ml, 15 
min). They were resuspended in PBS (500 µl) containing Triton X (1 %), and 
complete protease inhibitor cocktail (14 µl). The cell suspensions were 
sonicated using a SH70A sonicator (2 x 20 s). The suspensions were 
centrifuged (4 °C, 13000 g, 10 min). The supernatant was collected and the cell 
pellets were suspended in PBS (500 µl) containing C7BzO (1 %), CHAPs (4%) 
and complete protease inhibitor cocktail (14 µl). The cell suspensions sonicated 
using a SH70A sonicator (2 x 20 s). The suspensions were centrifuged (4 °C, 
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13000 g, 10 min). The DNA was extruded from cell pellets with a fine pipette 
needle (10 x) and centrifuged (4 °C, 13000 g, 10 min). The supernatant was 
collected.  
 
The streptavidin bead suspensions were centrifuged (13000 g, 1 min) and the 
supernatant removed. The protein suspensions (300 µl) were added to the 
streptavidin beads and left to incubate at room temperature for 24 h on a 
carousel.  The bead suspensions were centrifuged (13000 g, 1 min) and the 
supernatant removed and stored. The streptavidin beads were washed with 
PBS (3 x 1 ml, 15 min) and Compound 2 (3 x 100 µl, 2 mM) in PBS. The 
competition elutions were desalted with a NAP-5 column using ambic (25 mM).      
 
SDS-PAGE 
 
Resolving gel [HPLC water (750 µl), acrylamide (30 %, 2 ml), Tris HCl (1.5 M, 
pH 8.8, 1.95 ml), SDS (10 %, 50 µl), APS (10%, 50 µl), TEMED (2 µl)] was 
transferred to mini-PROTEAN casting plates attached to a casting frame on a 
casting stand. Isopropanol (1 ml) was added and the gel was left to set for 45 
min. The isoproponol was removed and the top of the gel washed with water (3 
x 1 ml). Stacking gel [HPLC water (3.4 ml), acrylamide (30 %, 830 µl), Tris HCl 
(0.5 M, pH 6.8, 630 µl), SDS (10 %, 50 µl), APS (10%, 50 µl), TEMED (5 µl)] 
was added on top of the set resolving gel and a comb inserted to create the 
wells. The gel was left to set for 20 min. The gels were removed from the 
casting frame and inserted into a mini-PROTEAN electrophoresis system and 
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filled with SDS running buffer [Tris HCl (5 mM), Glycine (38.4 mM), SDS 
(0.02%)].   
 
Samples were prepared by heating equal volumes of SDS buffer [water (3.55 ml 
water, Tris-HCl (0.5 M, 1.25 ml), Glycerol (2.5 ml), SDS (10 %, 2.0 ml), (0.5 %, 
0.2 ml)] and protein sample to 70 °C for 20 min. The comb was removed and 
the samples (10-15 µl) loaded into the wells. The gels were run at 80 V for 15 
min and then 150 V for 90 min.Gels were stained by immersion in Instant Blue 
stain for 30 min and then stored in water at 4 °C.      
 
Silver staining 
 
Pre-prepared solutions from the Bio-Rad Dodeca silver staining kit were used. 
Gels were destained for 24 h by immersing in a solution of water (40 ml), 
ethanol (32 ml) and acetic acid (8 ml). The gel was sensitised using a solution 
of Bio-Rad sensitising concentrate (8 ml), ethanol (24 ml), Bio-Rad background 
reducer concentrate (800 µl) and water (47.2 ml) for 30 min, washed with water 
(3 x 80 ml, 5 min), stained with a solution of Bio-Rad silver reagent concentrate 
(1.6 ml) in water (78.4 ml) for 20 min in the dark and rinsed with water (80 ml, 1 
min). The gel was developed by immersing in a solution of Bio-Rad 
development buffer concentrate (8 ml), Bio-Rad image development 
concentrate (16 µl), Bio-Rad background reducing concentrate  
(4 µl) and water (72 ml) until the bands were visible (5 – 15 min) and stopped 
using a solution of acetic acid (4 ml) in water (76 ml) for 10 min. The gels were 
stored in water at 4 °C.      
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TRYPSIN DIGESTION 
 
Samples were dissolved in MeCN (5 %, 5 µl or 50 µl for beads). DTT (50 mM,  
1 µl or 5 µl for beads) was added and the solutions heated to 70 °C for 20 min. 
Samples were alkylated with iodoacetamide (100 mM, 1 µl or 5 µl for beads) in 
the dark at room temperature for 20 min. Trypsin (10 µg/ml in ambic, l µl or  
5 µl for beads) was added and incubated at 37 °C for 18 h. Samples were 
desalted using C18 cartridges, lyophilised and stored at -20 °C.       
 
IN-GEL TRYPSIN DIGESTION 
 
Protein bands were excised using a scalpel and the gel pieces were dehydrated 
by incubating in MeCN (200 µl, 15 min). The solvent was removed and the gel 
pieces rehydrated by incubating in ambic (20 µl, 15 min). The process was 
repeated three times and a final dehydration with MeCN (200 µl, 15 min) was 
carried out. The solvent was removed and fragments left to dry (30 min, 37 °C). 
The gel was incubated in a solution of trypsin (20 µl, 10 ng/µl in ambic (25 
mmol), 18 h, 28 °C). The supernatants were desalted using C18 cartridges, 
lyophilised and stored at -20 °C.  
 
C18 CARTRIGES 
 
Isolute C18 cartridges (Kinesis Ltd., Cambridgeshire, England) were wetted with 
methanol (1 ml) and equilibrated with acetonitrile (2 %, 2 x 1 ml). The trypsin 
digested sample was loaded and made up to a total volume of 500 µl with 
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acetonitrile (2 %). The column was washed with acetonitrile (2 %, 2 x 1 ml) and 
eluted with acetonitrile (80%, 1 ml). Samples were lyophilised and stored at  
-20 °C.   
 
MASS SPECTROMETRY 
 
Mass spectra were generated for desalted, trypsin-digested peptides using a 
MALDI-TOF/TOF UltraFlex II Instrument (Bruker Daltonics, Bremen, Germany). 
α-CHCA (1 µl) was applied onto a MTP 384 „massive‟ target T plate (Bruker 
Daltonics, Bremen, Germany), followed by peptides (0.5 µl) and then α-CHCA 
(0.5 µl). Mass spectrometry was carried out in reflector positive mode using a 
mass range of 700-4000 Da and a total of 500 cumulative shots. MS/MS  was 
carried out using LIFT mode and peak list and a total of 1500 cumulative shots. 
Peak lists for MS and MS/MS data were generated using FlexAnalysis version 
3.0 software.   
 
Proteins were identified by their peptide fragmentation fingerprints or MS/MS 
fragments. Peaklists were compiled into a batch using Bruker BioTools version 
3.2 (BrukerDaltonics, Bremen, Germany) and searched using Mascot software 
version 2.2 (Matrix Science, USA) against a Swiss-Prot database. 
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APPENDIX 2: MASS SPECTROMETRY DATA FOR PEPTIDES IDENTIFIED 
AS hnRNP A2/B1 
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